https://www.astrazeneca-us.com/ 2026-08-05T18:48:21.744Z https://www.astrazeneca-us.com/whatsciencecando.html 2026-06-02T19:32:19.937Z https://www.astrazeneca-us.com/whatsciencecando/campaign-films.html 2026-07-20T15:33:23.486Z https://www.astrazeneca-us.com/whatsciencecando/thank-you-science.html 2025-12-03T19:19:35.964Z https://www.astrazeneca-us.com/whatsciencecando/our-impact-our-people.html 2026-07-22T18:32:28.622Z https://www.astrazeneca-us.com/az-in-us.html 2026-06-04T17:08:07.755Z https://www.astrazeneca-us.com/az-in-us/arun-krishna.html 2025-05-27T15:41:28.558Z https://www.astrazeneca-us.com/az-in-us/rick-suarez.html 2026-02-18T17:23:49.292Z https://www.astrazeneca-us.com/az-in-us/Contact-us.html 2026-08-04T19:53:41.560Z https://www.astrazeneca-us.com/az-in-us/ruud-dobber.html 2024-06-20T19:24:41.059Z https://www.astrazeneca-us.com/az-in-us/mariam-koohdary.html 2024-06-20T20:39:17.396Z https://www.astrazeneca-us.com/az-in-us/tarek-rabah.html 2024-06-20T20:45:36.509Z https://www.astrazeneca-us.com/az-in-us/thomaz-bonato.html 2024-06-20T20:47:29.214Z https://www.astrazeneca-us.com/az-in-us/mina-makar.html 2024-06-20T20:55:21.120Z https://www.astrazeneca-us.com/az-in-us/rachele-berria.html 2024-06-20T21:26:29.824Z https://www.astrazeneca-us.com/az-in-us/kiersten-combs.html 2024-06-20T21:27:05.900Z https://www.astrazeneca-us.com/az-in-us/monica-marsh.html 2024-06-20T21:30:12.805Z https://www.astrazeneca-us.com/az-in-us/don-sawyer.html 2024-06-20T21:31:34.132Z https://www.astrazeneca-us.com/az-in-us/sarah-walters.html 2024-06-20T21:40:42.375Z https://www.astrazeneca-us.com/az-in-us/liz-bodin.html 2026-03-17T22:18:12Z https://www.astrazeneca-us.com/az-in-us/kevin-durning.html 2026-05-19T19:44:26.430Z https://www.astrazeneca-us.com/az-in-us/mohit-manrao.html 2024-06-20T21:45:43.565Z https://www.astrazeneca-us.com/az-in-us/carlos-doti.html 2026-08-07T14:52:43.207Z https://www.astrazeneca-us.com/az-in-us/shubh-goel.html 2024-06-20T21:50:03.074Z https://www.astrazeneca-us.com/az-in-us/eder-martins.html 2026-04-14T16:19:10Z https://www.astrazeneca-us.com/az-in-us/bruce-wilson.html 2024-06-20T21:51:43.616Z https://www.astrazeneca-us.com/az-in-us/dan-wygal.html 2025-10-23T15:52:45.425Z https://www.astrazeneca-us.com/az-in-us/nancy-ghattas.html 2026-02-11T18:33:01.226Z https://www.astrazeneca-us.com/az-in-us/nilsa-sanchez.html 2024-06-20T21:54:01.629Z https://www.astrazeneca-us.com/az-in-us/miroslav-sokolov.html 2024-06-20T21:55:00.031Z https://www.astrazeneca-us.com/az-in-us/chris-mancill.html 2024-10-17T19:32:29.922Z https://www.astrazeneca-us.com/az-in-us/alison-dziarmaga.html 2025-05-27T15:43:14.553Z https://www.astrazeneca-us.com/az-in-us/daniele-paone.html 2024-12-19T20:28:41.654Z https://www.astrazeneca-us.com/az-in-us/colleen-kempf.html 2025-06-11T19:55:10.228Z https://www.astrazeneca-us.com/az-in-us/tiffany-davis.html 2025-06-06T21:26:52.466Z https://www.astrazeneca-us.com/az-in-us/Cesar-Cerezo.html 2026-07-24T15:45:27.721Z https://www.astrazeneca-us.com/az-in-us/James-Teague.html 2026-06-18T15:24:47.709Z https://www.astrazeneca-us.com/az-in-us/jim-fox.html 2026-07-24T15:43:26.957Z https://www.astrazeneca-us.com/az-in-us/roula-qaqish.html 2026-08-07T15:22:21.025Z https://www.astrazeneca-us.com/sustainability.html 2024-06-21T13:55:37.860Z https://www.astrazeneca-us.com/sustainability/patient-programs.html 2024-06-21T14:09:53.826Z https://www.astrazeneca-us.com/sustainability/Corporate-transparency.html 2024-10-07T19:42:47.717Z https://www.astrazeneca-us.com/sustainability/Corporate-transparency/contributions-disclosure.html 2026-02-18T16:37:58.776Z https://www.astrazeneca-us.com/sustainability/Corporate-transparency/physician-engagement.html 2024-06-24T18:12:55.362Z https://www.astrazeneca-us.com/sustainability/Corporate-transparency/political-contributions.html 2026-01-21T22:47:48.115Z https://www.astrazeneca-us.com/sustainability/Corporate-transparency/postmarketing-study-commitments.html 2024-06-25T20:18:35.535Z https://www.astrazeneca-us.com/sustainability/Corporate-transparency/us-compliance-program.html 2026-06-16T20:42:10.661Z https://www.astrazeneca-us.com/sustainability/Corporate-transparency/financial-conflict-of-interest.html 2024-06-24T18:14:01.058Z https://www.astrazeneca-us.com/sustainability/healthcare-foundation.html 2026-04-13T18:17:08Z https://www.astrazeneca-us.com/sustainability/healthcare-foundation/connections-for-cardiovascular-health.html 2024-06-24T18:14:50.400Z https://www.astrazeneca-us.com/sustainability/healthcare-foundation/faqs.html 2026-05-05T20:46:51.920Z https://www.astrazeneca-us.com/sustainability/healthcare-foundation/latest-news.html 2024-06-24T18:15:34.203Z https://www.astrazeneca-us.com/sustainability/healthcare-foundation/latest-news/2017.html 2017-02-06T16:28:20.794Z https://www.astrazeneca-us.com/sustainability/healthcare-foundation/latest-news/2017/astrazeneca-healthcare-foundation-awards-more-than-1-million-to-10-grassroots-innovative-heart-health-programs-02082017.html 2017-02-06T18:58:08.234Z https://www.astrazeneca-us.com/sustainability/healthcare-foundation/latest-news/2017/astrazeneca-healthcare-foundation-awards-nearly-1-million-to-10-innovative-heart-health-programs-announces-open-call-for-applications-09192017.html 2017-09-18T20:38:58.908Z https://www.astrazeneca-us.com/sustainability/healthcare-foundation/past-programs.html 2025-04-09T19:59:55.102Z https://www.astrazeneca-us.com/sustainability/healthcare-foundation/change.html 2026-05-05T20:45:45.414Z https://www.astrazeneca-us.com/sustainability/healthcare-foundation/who-we-are.html 2026-03-20T19:33:00Z https://www.astrazeneca-us.com/sustainability/community-investments.html 2026-07-06T20:43:21.002Z https://www.astrazeneca-us.com/sustainability/Request-Support.html 2025-07-14T20:37:37.076Z https://www.astrazeneca-us.com/sustainability/Request-Support/faqs.html 2025-10-01T14:56:43.754Z https://www.astrazeneca-us.com/sustainability/Request-Support/medical-education-office.html 2025-01-08T17:42:41.989Z https://www.astrazeneca-us.com/sustainability/Request-Support/medical-education-office/educational-areas-call-for-grants.html 2026-07-31T22:31:02.389Z https://www.astrazeneca-us.com/sustainability/Request-Support/medical-education-office/grant-reporting.html 2024-06-21T19:27:45.316Z https://www.astrazeneca-us.com/sustainability/Request-Support/medical-education-office/contact-us.html 2021-04-27T08:08:51.728Z https://www.astrazeneca-us.com/sustainability/Responsible-business.html 2026-06-03T21:06:57.200Z https://www.astrazeneca-us.com/sustainability/employee-volunteerism-giving.html 2025-04-21T18:53:38.014Z https://www.astrazeneca-us.com/sustainability/actonhealthequity.html 2026-07-07T17:07:46.682Z https://www.astrazeneca-us.com/careers.html 2024-06-24T15:37:14.913Z https://www.astrazeneca-us.com/careers/military-careers.html 2024-06-24T15:36:08.311Z https://www.astrazeneca-us.com/media.html 2024-06-07T10:02:37.714Z https://www.astrazeneca-us.com/media/articles.html 2024-08-09T21:41:31.980Z https://www.astrazeneca-us.com/media/articles/2022.html 2022-01-25T14:49:08.360Z https://www.astrazeneca-us.com/media/articles/2022/eplontersen-granted-orphan-drug-designation-in-the-us-for-transthyretin-amyloidosis.html 2022-01-25T14:53:51.266Z https://www.astrazeneca-us.com/media/articles/2022/supporting-our-people-to-deliver-growth-through-innovation.html 2022-02-08T19:54:46.512Z https://www.astrazeneca-us.com/media/articles/2022/going-green-blazing-a-trail-in-sustainability.html 2022-03-01T19:31:12.433Z https://www.astrazeneca-us.com/media/articles/2022/advancing-health-equity-through-community-based-contributions-announcing-the-act-on-health-equity-community-solutions-challenge-recipients.html 2022-03-01T20:11:35.476Z https://www.astrazeneca-us.com/media/articles/2022/a-sense-of-comfort-providing-housing-to-patients-and-their-families-during-treatment-09222021.html 2022-03-01T20:12:02.662Z https://www.astrazeneca-us.com/media/articles/2022/womens-history-month-celebrating-pioneers-and-future-trailblazers-03092022.html 2022-03-25T15:32:30.513Z https://www.astrazeneca-us.com/media/articles/2022/learning-undefeated-prepares-over-3000-delaware-students-for-stem-careers-this-school-year-05102022.html 2022-05-10T20:49:42.829Z https://www.astrazeneca-us.com/media/articles/2022/building-for-the-future-of-cancer-care-06082022.html 2022-06-13T15:24:17.711Z https://www.astrazeneca-us.com/media/articles/2023.html 2023-01-19T19:42:49.775Z https://www.astrazeneca-us.com/media/articles/2023/announcing-the-2022-power-of-us-award-winners-01192023.html 2025-05-28T19:18:30.138Z https://www.astrazeneca-us.com/media/articles/2023/harnessing-science-for-a-positive-impact-on-people-society-and-the-planet-06072023.html 2025-05-28T19:18:56.273Z https://www.astrazeneca-us.com/media/articles/2023/how-astrazeneca-is-shrinking-its-carbon-footprint.html 2025-05-28T19:19:17.387Z https://www.astrazeneca-us.com/media/articles/2023/precision-medicine-in-oncology-accelerating-biomarker-testing-to-help-advance-patient-outcomes-09282023.html 2025-05-28T19:19:37.288Z https://www.astrazeneca-us.com/media/articles/2024.html 2024-01-02T20:48:48.078Z https://www.astrazeneca-us.com/media/articles/2024/addressing-barriers-to-optimal-cancer-care-to-help-improve-access-and-outcomes-01032024.html 2025-05-28T19:14:05.672Z https://www.astrazeneca-us.com/media/articles/2024/announcing-the-2023-Power-of-Us-Award-winners-01242024.html 2025-05-28T19:14:48.373Z https://www.astrazeneca-us.com/media/articles/2024/survey-finds-knowledge-gaps-in-cancer-screening-and-access-to-care-01312024.html 2025-05-28T19:15:13.548Z https://www.astrazeneca-us.com/media/articles/2024/astrazenecas-aradhana-sarin-named-to-cnbcs-2024-changemakers-women-transforming-business-list.html 2025-05-28T19:15:36.784Z https://www.astrazeneca-us.com/media/articles/2024/the-next-horizon-in-connected-healthcare-patient-empowered-virtual-care.html 2025-05-28T19:15:54.845Z https://www.astrazeneca-us.com/media/articles/2024/green-patients-healthy-planet.html 2025-05-28T19:16:22.372Z https://www.astrazeneca-us.com/media/articles/2024/investing-in-health-investing-in-nature.html 2025-05-28T19:16:47.875Z https://www.astrazeneca-us.com/media/articles/2024/lung-health-in-a-changing-climate-astrazenecas-commitment-to-equity-and-action.html 2025-05-28T19:44:08.165Z https://www.astrazeneca-us.com/media/articles/2024/oncology-trailblazers-risk-and-hope-driving-improvements-in-cancer-care.html 2025-05-28T19:17:31.517Z https://www.astrazeneca-us.com/media/articles/2025.html 2024-12-24T13:00:30.179Z https://www.astrazeneca-us.com/media/articles/2025/employee-volunteerism-inspiring-positive-change-in-our-communities.html 2025-08-19T21:23:00.535Z https://www.astrazeneca-us.com/media/articles/2025/employee-volunteerism-inspiring-positive-change-in-our-communities1.html 2025-05-28T19:12:53.979Z https://www.astrazeneca-us.com/media/articles/2025/developing-tomorrows-workforce-astrazenecas-apprenticeship-journey.html 2025-05-28T19:12:15.253Z https://www.astrazeneca-us.com/media/articles/2025/Partnerships-in-Motion-How-Cross-Sector-Collaboration-is-Powering-Broader-Clinical-Trial-Representation.html 2025-05-28T19:11:53.600Z https://www.astrazeneca-us.com/media/articles/2025/rooted-in-legacy-leading-into-the-future.html 2025-08-14T18:10:12.248Z https://www.astrazeneca-us.com/media/articles/2025/advancing-flu-protection-the-need-to-increase-access-and-impact.html 2025-08-14T18:11:21.782Z https://www.astrazeneca-us.com/media/articles/2025/lung-health-breaking-silos-advancing-state-level-solutions.html 2025-11-18T20:21:59.259Z https://www.astrazeneca-us.com/media/articles/2025/Governor-Glenn-Youngkin-Announces-Industry-Partnership-with-AstraZeneca-Lilly-and-Merck-to-Create-the-Nations-Largest-Workforce-Development-Center-for-Advanced-Pharmaceutical-Manufacturing-in-Virginia.html 2025-11-18T20:23:07.007Z https://www.astrazeneca-us.com/media/articles/2026.html 2026-03-31T10:58:19Z https://www.astrazeneca-us.com/media/articles/2026/Advancing-Our-US-R-I-and-V-I-Ambition-Transforming-Care-for-Millions-of-People.html 2026-03-31T23:34:31Z https://www.astrazeneca-us.com/media/articles/2026/FASENRA-approved-in-US-for-hypereosinophilic-syndrome.html 2026-05-15T13:55:40.857Z https://www.astrazeneca-us.com/media/articles/2026/From-Ambition-to-Momentum-Advancing-Care-for-Millions-of-Patients-in-the-US.html 2026-06-24T14:51:12.889Z https://www.astrazeneca-us.com/media/articles/2026/BREZTRI-is-now-available-in-the-US-as-the-first-and-only-fixed-dose-triple-therapy-for-asthma-patients-12-years-of-age-and-older.html 2026-07-20T13:34:12.090Z https://www.astrazeneca-us.com/media/statements.html 2022-02-04T10:34:37.235Z https://www.astrazeneca-us.com/media/statements/2026.html 2026-02-05T21:18:16.269Z https://www.astrazeneca-us.com/media/statements/2026/Statement-on-availability-of-AstraZeneca-medicines-through-TrumpRx.html 2026-02-06T00:28:10.622Z https://www.astrazeneca-us.com/media/press-releases.html 2024-08-06T15:15:10.804Z https://www.astrazeneca-us.com/media/press-releases/2016.html 2016-04-18T16:28:16.815Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazeneca-diabetes-hands-foundation-partner-to-help-adults-with-type-2-diabetes-walk-their-way-to-better-health04052016.html 2016-09-28T13:59:34.529Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazeneca-partners-with-dr-phil-to-launch-20160310.html 2016-09-28T13:59:08.077Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazeneca-patient-assistance-programs-provided-20160303.html 2016-09-28T13:58:43.501Z https://www.astrazeneca-us.com/media/press-releases/2016/fda-approves-new-indication-for-faslodex-fulvestrant-20160302.html 2016-09-28T13:57:40.778Z https://www.astrazeneca-us.com/media/press-releases/2016/durvalumab-granted-breakthrough-therapy-designation-20160217.html 2016-09-28T13:57:14.071Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazeneca-plc-fourth-quarter-and-full-year-results-20160204.html 2016-09-28T13:55:06.709Z https://www.astrazeneca-us.com/media/press-releases/2016/brilinta-preferred-over-clopidogrel-in-updated-american-20160331.html 2017-02-28T17:39:09.683Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazeneca-enters-into-us-licensing-agreement-04262016.html 2017-02-28T17:40:21.257Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazeneca-plc-first-quarter-results2016-04292016.html 2016-11-09T18:34:41.615Z https://www.astrazeneca-us.com/media/press-releases/2016/bevespi-aerosphere-approved-by-the-us-fda-for-patients-with-copd-04252016.html 2026-07-20T19:02:04.681Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazeneca-confirms-north-america-commercial-headquarters-05032016.html 2017-02-28T17:42:15.498Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazeneca-to-highlight-the-breadth-of-its-respiratory-medicines-05122016.html 2026-07-20T18:30:06.280Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazeneca-announces-positive-results-from-benralizumab-phase-iii-programme-in-severe-asthma-17052016.html 2017-02-28T17:47:20.782Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazeneca-highlights-continued-progress-of-oncology-18052016.html 2017-02-28T17:49:30.596Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazenecas-fulvestrant-met-its-primary-endpoint-as-first-line-treatment-in-a-phase-iii-trial-for-hr-advanced-breast-cancer-27052016.html 2017-02-28T17:51:29.639Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazeneca-to-highlight-scientific-advancements-across-its-diabetes-association-76th-scientific-sessions-08062016.html 2017-02-28T17:56:05.679Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazeneca-introduces-azhelps-an-innovative-savings-and-support-program-to-help-patients-with-their-medicines-14062016.html 2017-02-28T18:00:28.008Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazeneca-provides-update-on-flumist-quadrivalent-vaccine-in-the-us-for-the-2016-17-influenza-season-23060216.html 2017-02-28T17:35:41.570Z https://www.astrazeneca-us.com/media/press-releases/2016/TAGRISSO-osimertinib-met-primary-endpoint-in-phase-III-2nd-line-lung-cancer-trial-18072016.html 2017-02-28T17:34:03.309Z https://www.astrazeneca-us.com/media/press-releases/2016/AstraZeneca-diabetes-diet-and-lifestyle-support-program-Fit2Me-extends-to-include-cardiovascular-health-08082016.html 2017-02-28T18:01:38.117Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazeneca-announces-positive-top-line-data-from-two-phase-III-sympicort-studies-10082016.html 2017-02-28T18:03:12.861Z https://www.astrazeneca-us.com/media/press-releases/2016/AstraZeneca-announces-SYMBICORT-demonstrated-comparable-risk-of-serious-asthma-related-events-and-lower-risk-of-asthma-exacerbations-compared-to-budesonide-alone-31082016.html 2016-10-25T13:48:14.977Z https://www.astrazeneca-us.com/media/press-releases/2016/Benralizumab-PhaseIII-trials-show-positive-results-in-severe-asthma-5092016.html 2016-10-21T18:35:01.902Z https://www.astrazeneca-us.com/media/press-releases/2016/phase-iii-combination-trial-of-bydureon-and-farxiga-shows-significant-blood-sugar-reduction-in-patients-with-type-2-diabetes.html 2017-02-28T17:32:29.825Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazeneca-to-strengthen-presence-in-california-with-new-south-san-francisco-location-09272016.html 2016-09-27T14:36:19.701Z https://www.astrazeneca-us.com/media/press-releases/2016/us-fda-approves-tagrisso-osimertinib-blood-based-t790m-companion-diagnostic-test-09292016.html 2016-10-21T18:31:49.896Z https://www.astrazeneca-us.com/media/press-releases/2016/new-study-shows-increases-in-rsv-hospitalization-among-high-risk-preterm-infants-10052016.html 2016-10-04T20:16:45.625Z https://www.astrazeneca-us.com/media/press-releases/2016/fulvestrant-demonstrates-progression-free-survival-advantage-in-1st-line-advanced-breast-cancer-10082016.html 2016-10-08T12:13:08.876Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazeneca-purchases-us-manufacturing-facility-to-support-biologics-manufacturing-capabilities-10102016.html 2016-10-10T15:34:00.219Z https://www.astrazeneca-us.com/media/press-releases/2016/lynparza-olaparib-phase-III-solo-2-trial-shows-significant-progression-free-survival-benefit-10262016.html 2017-02-28T17:29:22.955Z https://www.astrazeneca-us.com/media/press-releases/2016/new-data-shows-frequent-icu-admissions-from-severe-rsv-disease-among-preterm-infants-in-the-first-three-months-of-life-10282016.html 2016-10-27T23:46:54.608Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazeneca-plc-third-quarter-results-2016-11102016.html 2016-11-09T18:34:32.971Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazeneca-announces-study-results-show-symbicort-improves-lung-function-in-pediatric-asthma-patients-11112016.html 2016-11-09T18:48:59.060Z https://www.astrazeneca-us.com/media/press-releases/2016/early-data-demonstrate-clinical-activity-of-acalabrutinib-in-difficult-to-treat-chronic-lymphocytic-leukemia-12052016.html 2016-12-05T16:38:20.261Z https://www.astrazeneca-us.com/media/press-releases/2016/tagrisso-osimertinib-demonstrates-superiority-over-chemotherapy-in-egfr-t790m-mutation-positive-non-small-cell-lung-cancer-12062016.html 2017-01-17T19:45:25.270Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazeneca-announces-subgroup-analysis-from-falcon-trial-comparing-faslodex-fulvestrant-to-arimidex-anastrozole-12082016.html 2017-02-28T17:27:06.204Z https://www.astrazeneca-us.com/media/press-releases/2016/astrazeneca-announces-update-to-us-commercial-business-12082016.html 2016-12-08T16:15:47.346Z https://www.astrazeneca-us.com/media/press-releases/2015.html 2016-04-19T09:20:10.903Z https://www.astrazeneca-us.com/media/press-releases/2014.html 2016-04-19T09:20:10.958Z https://www.astrazeneca-us.com/media/press-releases/2013.html 2016-04-19T09:20:11.028Z https://www.astrazeneca-us.com/media/press-releases/2011.html 2016-05-04T15:31:34.606Z https://www.astrazeneca-us.com/media/press-releases/2012.html 2016-05-04T12:00:54.589Z https://www.astrazeneca-us.com/media/press-releases/2009.html 2016-05-04T12:21:17.169Z https://www.astrazeneca-us.com/media/press-releases/2008.html 2016-05-04T12:21:27.193Z https://www.astrazeneca-us.com/media/press-releases/2007.html 2016-05-04T12:22:18.130Z https://www.astrazeneca-us.com/media/press-releases/2017.html 2017-01-17T19:43:14.736Z https://www.astrazeneca-us.com/media/press-releases/2017/us-fda-approves-symbicort-for-the-treatment-of-asthma-in-pediatric-patients-01302017.html 2017-01-30T13:01:16.673Z https://www.astrazeneca-us.com/media/press-releases/2017/lynparza-olaparib-meets-primary-endpoint-in-phase-iii-trial-in-brca-mutated-metastatic-breast-cancer-02172017.html 2017-02-28T17:24:06.495Z https://www.astrazeneca-us.com/media/press-releases/2017/fda-approves-once-daily-qtern-dapagliflozin-and-saxagliptin-tablets-for-adults-with-type-2-diabetes-02282017.html 2017-03-03T00:39:03.126Z https://www.astrazeneca-us.com/media/press-releases/2017/lynparza-olaparib-phase-iii-solo-2-data-demonstrated-progression-free-survival-benefit-in-brca-mutated-ovarian-cancer-as-maintenance-therapy-03142017.html 2017-03-14T20:25:22.451Z https://www.astrazeneca-us.com/media/press-releases/2017/astrazenecas-cvd-real-study-shows-sglt-2-inhibitors-significantly-reduced-hospitalizations-for-heart-failure-and-death-versus-other-type-2-diabetes-medicines-03192017.html 2017-03-19T14:16:15.827Z https://www.astrazeneca-us.com/media/press-releases/2017/new-data-demonstrate-rsv-immunoprophylaxis-with-synagis-palivizumab-may-result-in-reduced-overall-costs-03282017.html 2017-03-28T11:43:02.391Z https://www.astrazeneca-us.com/media/press-releases/2017/astrazeneca-shares-progress-on-lynparza-olaparib-tablets-in-the-us-03282017.html 2017-03-28T11:35:03.232Z https://www.astrazeneca-us.com/media/press-releases/2017/tagrisso-osimertinib-receives-us-fda-full-approval-03312017.html 2017-03-31T00:57:30.339Z https://www.astrazeneca-us.com/media/press-releases/2017/astrazenecas-imfinzi-durvalumab-receives-us-fda-accelerated-approval-for-previously-treated-patients-with-advanced-bladder-cancer-05012017.html 2017-05-01T22:13:57.908Z https://www.astrazeneca-us.com/media/press-releases/2017/imfinzi-durvalumab-significantly-reduces-the-risk-of-disease-worsening-or-death-in-the-phase-iii-pacific-trial-for-stage-iii-unresectable-lung-cancer-05152017.html 2017-05-16T14:39:17.436Z https://www.astrazeneca-us.com/media/press-releases/2017/phase-iii-zonda-trial-for-benralizumab-shows-ability-to-reduce-oral-steroid-use-in-severe-asthma-patients-05222017.html 2017-05-22T18:46:22.469Z https://www.astrazeneca-us.com/media/press-releases/2017/bydureon-exscel-trial-meets-primary-safety-objective-in-type-2-diabetes-patients-at-wide-range-of-cardiovascular-risk-05232017.html 2017-05-23T11:12:21.916Z https://www.astrazeneca-us.com/media/press-releases/2017/astrazeneca-initiates-voluntary-nationwide-recall-of-one-lot-of-brilinta-90-mg-professional-sample-bottles-due-to-report-of-another-medicine-in-one-bottle-from-that-lot-052517.html 2017-05-25T22:17:27.821Z https://www.astrazeneca-us.com/media/press-releases/2017/astrazeneca-delivers-new-data-on-expanding-portfolio-of-cancer-medicines-at-2017-american-society-of-clinical-oncology-asco-annual-meeting-052617.html 2017-05-26T14:49:56.875Z https://www.astrazeneca-us.com/media/press-releases/2017/lynparza-olaparib-significantly-reduces-the-risk-of-disease-worsening-or-death-in-patients-with-brca-mutated-metastatic-breast-cancer-06042017.html 2017-06-04T11:41:30.015Z https://www.astrazeneca-us.com/media/press-releases/2017/astrazeneca-presents-tagrisso-osimertinib-data-in-patients-with-egfr-t790m-mutation-positive-lung-cancer-and-central-nervous-system-metastases-06062017.html 2017-06-26T12:46:52.842Z https://www.astrazeneca-us.com/media/press-releases/2017/astrazeneca-to-present-scientific-advances-in-cardiovascular-and-metabolic-diseases-at-2017-ada-scientific-sessions-06082017.html 2017-06-08T00:38:54.783Z https://www.astrazeneca-us.com/media/press-releases/2017/astrazeneca-presents-new-data-underpinning-safety-profile-and-real-world-cv-outcomes-of-farxiga-at-ada-2017-06122017.html 2017-06-12T01:30:53.200Z https://www.astrazeneca-us.com/media/press-releases/2017/astrazeneca-accepting-applications-for-charitable-funding-to-support-innovative-health-and-science-programs-06282017.html 2017-06-28T13:27:37.950Z https://www.astrazeneca-us.com/media/press-releases/2017/tagrisso-osimertinib-significantly-improves-progression-free-survival-in-the-phase-iii-flaura-trial-for-lung-cancer-07272017.html 2017-11-28T01:17:11.096Z https://www.astrazeneca-us.com/media/press-releases/2017/astrazeneca-reports-initial-results-from-the-ongoing-mystic-trial-in-stage-iv-lung-cancer-07272017.html 2017-07-27T10:26:01.723Z https://www.astrazeneca-us.com/media/press-releases/2017/imfinzi-durvalumab-granted-breakthrough-therapy-designation-by-us-fda-for-patients-with-locally-advanced-unresectable-non-small-cell-lung-cancer-07312017.html 2017-08-08T18:56:42.681Z https://www.astrazeneca-us.com/media/press-releases/2017/acalabrutinib-granted-breakthrough-therapy-designation-by-us-fda-for-the-treatment-of-patients-with-mantle-cell-lymphoma-08012017.html 2017-08-01T10:35:18.272Z https://www.astrazeneca-us.com/media/press-releases/2017/us-fda-accepts-regulatory-submission-for-acalabrutinib-and-grants-priority-review-08022017.html 2017-08-02T08:10:38.632Z https://www.astrazeneca-us.com/media/press-releases/2017/lynparza-olaparib-receives-additional-fda-approval-in-the-us-for-ovarian-cancer-08172017.html 2017-08-17T20:22:23.626Z https://www.astrazeneca-us.com/media/press-releases/2017/faslodex-fulvestrant-receives-us-fda-approval-as-monotherapy-for-expanded-use-in-hr-her2-advanced-breast-cancer-08282017.html 2017-08-28T10:54:18.902Z https://www.astrazeneca-us.com/media/press-releases/2017/astrazeneca-highlights-latest-advances-in-lung-cancer-at-the-esmo-2017-congress-08312017.html 2017-08-31T00:40:54.126Z https://www.astrazeneca-us.com/media/press-releases/2017/astrazeneca-presents-superior-progression-free-survival-for-imfinzi-durvalumab-in-the-pacific-trial-of-patients-with-locally-advanced-unresectable-lung-cancer-at-esmo-2017-congress-09082017.html 2017-09-11T12:57:27.055Z https://www.astrazeneca-us.com/media/press-releases/2017/astrazenecas-tagrisso-osimertinib-shows-potential-as-a-new-standard-of-care-in-1st-line-egfr-mutated-non-small-cell-lung-cancer-at-esmo-2017-congress-09082017.html 2017-09-11T12:57:58.873Z https://www.astrazeneca-us.com/media/press-releases/2017/bydureon-exscel-trial-demonstrates-favorable-cardiovascular-cv-safety-profile-and-fewer-cv-events-in-patients-with-type-2-diabetes-at-wide-range-of-cv-risk-09142017.html 2017-09-14T16:15:06.982Z https://www.astrazeneca-us.com/media/press-releases/2017/tagrisso-osimertinib-granted-breakthrough-therapy-designation-by-us-fda-for-the-1st-line-treatment-of-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer-10092017.html 2017-10-09T11:43:08.900Z https://www.astrazeneca-us.com/media/press-releases/2017/us-fda-accepts-supplemental-biologics-license-application-for-imfinzi-durvalumab-in-locally-advanced-unresectable-non-small-cell-lung-cancer-10172017.html 2017-10-18T00:21:43.202Z https://www.astrazeneca-us.com/media/press-releases/2017/us-fda-accepts-regulatory-submission-for-lynparza-olaparib-in-metastatic-breast-cancer-and-grants-priority-review-10182017.html 2017-10-18T14:56:32.381Z https://www.astrazeneca-us.com/media/press-releases/2017/astrazeneca-announces-new-data-showing-us-preterm-infants-at-significantly-greater-risk-of-rsv-hospitalizations-following-2014-guidance-change-10182017.html 2017-10-19T20:01:01.076Z https://www.astrazeneca-us.com/media/press-releases/2017/us-fda-approves-new-easy-to-use-once-weekly-bydureon-bcise-injectable-medicine-for-patients-with-type-2-diabetes-10232017.html 2017-10-23T10:57:42.306Z https://www.astrazeneca-us.com/media/press-releases/2017/us-fda-approves-astrazenecas-calquence-acalabrutinib-for-adult-patients-with-previously-treated-mantle-cell-lymphoma-10312017.html 2017-10-31T17:57:33.907Z https://www.astrazeneca-us.com/media/press-releases/2017/astrazeneca-shares-scientific-updates-from-its-extensive-cardiovascular-renal-and-metabolic-diseases-cvmd-portfolio-at-aha-2017-11082017.html 2017-11-08T11:48:38.728Z https://www.astrazeneca-us.com/media/press-releases/2017/faslodex-fulvestrant-receives-us-fda-approval-for-the-treatment-of-advanced-breast-cancer-in-combination-with-abemaciclib-11152017.html 2017-11-15T12:02:32.006Z https://www.astrazeneca-us.com/media/press-releases/2017/fasenra-benralizumab-receives-us-fda-approval-for-severe-eosinophilic-asthma-11142017.html 2017-11-15T00:46:55.620Z https://www.astrazeneca-us.com/media/press-releases/2017/celebrity-trainer-and-author-bob-harper-teams-up-with-astrazeneca-to-connect-with-fellow-heart-attack-survivors-11302017.html 2017-11-30T15:01:15.210Z https://www.astrazeneca-us.com/media/press-releases/2017/astrazeneca-to-highlight-its-commitment-to-blood-cancers-at-the-2017-american-society-of-hematology-annual-meeting-12062017.html 2017-12-06T00:44:10.387Z https://www.astrazeneca-us.com/media/press-releases/2017/astrazenecas-calquence-acalabrutinib-demonstrates-activity-in-relapsed-or-refractory-mantle-cell-lymphoma-trial-12092017.html 2017-12-09T16:10:43.419Z https://www.astrazeneca-us.com/media/press-releases/2017/astrazenecas-calquence-acalabrutinib-shows-potential-in-chronic-lymphocytic-leukemia-trials-12102017.html 2017-12-10T21:16:51.394Z https://www.astrazeneca-us.com/media/press-releases/2017/us-fda-accepts-regulatory-submission-for-tagrisso-osimertinib-in-1st-line-egfr-mutated-non-small-cell-lung-cancer-12182017.html 2017-12-18T11:01:50.493Z https://www.astrazeneca-us.com/media/press-releases/2017/us-fda-updates-symbicort-label-with-laba-safety-class-revisions-and-removes-boxed-warning-for-serious-asthma-related-outcomes-12212017.html 2017-12-21T16:20:20.229Z https://www.astrazeneca-us.com/media/press-releases/2018.html 2018-01-10T12:29:58.764Z https://www.astrazeneca-us.com/media/press-releases/2018/bydureon-bcise-injectable-medicine-now-available-in-the-us-for-patients-with-type-2-diabetes-01102018.html 2018-01-10T12:42:56.767Z https://www.astrazeneca-us.com/media/press-releases/2018/lynparza-olaparib-approved-by-us-fda-in-germline-brca-mutated-metastatic-breast-cancer-01122018.html 2018-01-12T17:06:19.254Z https://www.astrazeneca-us.com/media/press-releases/2018/daliresp-receives-us-fda-approval-for-250-mcg-starting-dose-for-patients-with-severe-copd-01242018.html 2018-01-24T20:43:55.885Z https://www.astrazeneca-us.com/media/press-releases/2018/us-fda-approves-imfinzi-durvalumab-for-unresectable-stage-iii-non-small-cell-lung-cancer-02162018.html 2018-02-17T03:55:12.512Z https://www.astrazeneca-us.com/media/press-releases/2018/astrazeneca-announces-renewed-recommendation-and-availability-of-flumist-quadrivalent-vaccine-in-the-us-02212018.html 2018-02-22T21:16:15.342Z https://www.astrazeneca-us.com/media/press-releases/2018/astrazeneca-presents-new-data-evaluating-safety-and-efficacy-of-farxiga-in-patients-with-type-2-diabetes-and-moderate-renal-impairment-03192018.html 2018-03-19T15:12:42.517Z https://www.astrazeneca-us.com/media/press-releases/2018/us-fda-accepts-biologics-license-application-for-moxetumomab-pasudotox-in-hairy-cell-leukemia-04032018.html 2018-04-03T13:10:13.089Z https://www.astrazeneca-us.com/media/press-releases/2018/us-fda-approves-bydureon-for-use-with-basal-insulin-in-patients-with-type-2-diabetes-with-inadequate-glycemic-control-04032018.html 2018-04-03T11:57:13.362Z https://www.astrazeneca-us.com/media/press-releases/2018/updated-overall-survival-data-for-lynparza-olaparib-in-gbrca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr-04152018.html 2018-04-15T20:50:48.863Z https://www.astrazeneca-us.com/media/press-releases/2018/us-fda-approves-tagrisso-osimertinib-as-1st-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer-04182018.html 2018-04-19T14:21:04.730Z https://www.astrazeneca-us.com/media/press-releases/2018/lokelma-approved-in-the-us-for-the-treatment-of-adults-with-hyperkalemia-05182018.html 2019-01-11T14:00:36.298Z https://www.astrazeneca-us.com/media/press-releases/2018/astrazeneca-announces-opening-of-new-south-san-francisco-site-05222018.html 2018-05-22T16:47:48.729Z https://www.astrazeneca-us.com/media/press-releases/2018/astrazeneca-announces-opening-of-new-south-san-francisco-site-05223018-test.html 2018-05-29T19:00:57.150Z https://www.astrazeneca-us.com/media/press-releases/2018/astrazeneca-heads-to-2018-asco-annual-meeting-with-its-diversified-oncology-portfolio-and-next-generation-pipeline-05242018.html 2018-05-31T19:59:00.505Z https://www.astrazeneca-us.com/media/press-releases/2018/imfinzi-durvalumab-significantly-improves-overall-survival-in-the-phase-iii-pacific-trial-for-unresectable-stage iii-non-small-cell-lung-cancer-05252018.html 2018-05-25T11:04:28.108Z https://www.astrazeneca-us.com/media/press-releases/2018/moxetumomab-pasudotox-pivotal-data-in-patients-with-previously-treated-hairy-cell-leukemia-presented-at-the-2018-asco-meeting-06022018.html 2018-06-02T17:30:33.359Z https://www.astrazeneca-us.com/media/press-releases/2018/lynparza-olaparib-in-combination-with-abiraterone-delayed-disease-progression-in-metastatic-castration-resistant-prostate-cancer-06042018.html 2018-06-04T21:23:17.490Z https://www.astrazeneca-us.com/media/press-releases/2018/astrazeneca-to-share-latest-data-from-an-industry-leading-portfolio-that-aims-to-advance-clinical-understanding-of-diabetes-and-cv-risk-management-at-ada-2018-06192018.html 2018-06-19T10:57:52.383Z https://www.astrazeneca-us.com/media/press-releases/2018/farxiga-in-combination-with-onglyza-demonstrates-similar-glycemic-control-with-additional-benefits-vs-insulin-glargine-in-patients-with-type-2-diabetes-06252018.html 2018-06-24T20:44:39.970Z https://www.astrazeneca-us.com/media/press-releases/2018/lynparza-olaparib-significantly-delays-disease-progression-in-phase-iii-1st-line-solo-1-trial-for-ovarian-cancer-06272018.html 2018-06-27T10:56:19.369Z https://www.astrazeneca-us.com/media/press-releases/2018/us-fda-approves-lumoxiti-moxetumomab-pasudotox-tdfk-for-certain-patients-with-relapsed-or-refractory-hairy-cell-leukemia-09132018.html 2018-09-13T19:52:35.659Z https://www.astrazeneca-us.com/media/press-releases/2018/fasenra-benralizumab-shows-consistent-safety-and-sustained-efficacy-in-long-term-phase-iii-bora-trial-in-severe-eosinophilic-asthma-09182018.html 2018-09-25T22:58:56.787Z https://www.astrazeneca-us.com/media/press-releases/2018/astrazeneca-ships-flumist-quadrivalent-vaccine-in-the-us-for-2018-2019-flu-season-09252018.html 2018-09-24T20:38:27.775Z https://www.astrazeneca-us.com/media/press-releases/2018/farxiga-achieved-a-positive-result-in-the-phase-iii-declare-timi-58-trial-a-large-cardiovascular-outcomes-trial-in-17000-patients-with-type-2-diabetes-09242018.html 2018-09-23T23:11:24.795Z https://www.astrazeneca-us.com/media/press-releases/2018/imfinzi-durvalumab-is-the-first-immunotherapy-to-demonstrate-significant-overall-survival-benefit-in-unresectable-stage-iii-lung-cancer-09252018.html 2018-09-25T12:25:41.214Z https://www.astrazeneca-us.com/media/press-releases/2018/solo-1-phase-iii-trial-demonstrates-lynparza-maintenance-therapy-cut-the-risk-of-disease-progression-or-death-by-70-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovarian-cancer-10212018.html 2018-10-21T14:38:18.689Z https://www.astrazeneca-us.com/media/press-releases/2018/astrazeneca-to-present-new-data-demonstrating-breadth-of-research-portfolio-in-renal-disease-at-asn-kidney-week-2018-10222018.html 2019-01-11T13:47:05.825Z https://www.astrazeneca-us.com/media/press-releases/2018/the-landmark-declare-timi-58-cardiovascular-outcomes-trial-of-farxiga-in-patients-with-type-2-diabetes-to-be-featured-at-aha-2018-11012018.html 2018-11-01T11:03:36.945Z https://www.astrazeneca-us.com/media/press-releases/2018/farxiga-significantly-reduced-hospitalization-for-heart-failure-or-cv-death-in-a-broad-patient-population-with-type-2-diabetes-in-the-landmark-declare-timi-58-trial-11102018.html 2018-11-10T20:14:01.319Z https://www.astrazeneca-us.com/media/press-releases/2018/us-fda-accepts-regulatory-submission-for-lynparza-olaparib-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review-11122018.html 2018-11-12T01:41:10.752Z https://www.astrazeneca-us.com/media/press-releases/2018/astrazeneca-presents-clinical-research-advances-for-blood-cancer-patients-at-2018-american-society-of-hematology-annual-meeting-11272018.html 2018-11-27T12:01:32.318Z https://www.astrazeneca-us.com/media/press-releases/2018/new-long-term-data-on-calquence-presented-at-ash-2018-12032018.html 2018-12-03T18:52:24.786Z https://www.astrazeneca-us.com/media/press-releases/2018/lynparza-olaparib-approved-by-us-fda-for-first-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer-12192018.html 2018-12-19T23:40:52.743Z https://www.astrazeneca-us.com/media/press-releases/2018/phase-iii-olympus-and-rockies-trials-for-roxadustat-met-their-primary-endpoints-in-chronic-kidney-disease-patients-with-anemia-12202018.html 2019-02-25T01:38:23.395Z https://www.astrazeneca-us.com/media/press-releases/2019.html 2018-12-10T18:27:47.314Z https://www.astrazeneca-us.com/media/press-releases/2019/brilintas-phase-iii-themis-trial-met-primary-endpoint-in-patients-with-established-coronary-artery-disease-and-type-2-diabetes-02252019.html 2019-02-25T11:51:34.853Z https://www.astrazeneca-us.com/media/press-releases/2019/lynparza-olaparib-reduced-the-risk-of-disease-progression-or-death-as-1st-line-maintenance-treatment-in-germline-brca-mutated-metastatic-pancreatic-cancer-02262019.html 2019-02-26T11:44:07.592Z https://www.astrazeneca-us.com/media/press-releases/2019/us-fda-approves-expanded-farxiga-and-xigduo-xr-labels-for-use-in-patients-with-type-2-diabetes-and-moderate-renal-impairment-02272019.html 2019-02-27T01:32:40.703Z https://www.astrazeneca-us.com/media/press-releases/2019/astrazeneca-to-present-new-cardiovascular-data-on-farxiga-in-type-2-diabetes-at-acc-2019-03112019.html 2019-03-08T21:50:08.463Z https://www.astrazeneca-us.com/media/press-releases/2019/first-sub-analyses-from-the-declare-timi-58-trial-further-support-the-cardiovascular-effects-of-farxiga-in-type-2-diabetes-03182019.html 2019-03-18T12:32:22.239Z https://www.astrazeneca-us.com/media/press-releases/2019/new-updates-to-2019-american-diabetes-association-standards-of-medical-care-in-diabetes-incorporate-findings-from-recent-astrazeneca-clinical-trials-03282019.html 2019-03-28T00:42:22.193Z https://www.astrazeneca-us.com/media/press-releases/2019/selumetinib-granted-us-breakthrough-therapy-designation-in-neurofibromatosis-type-1-04012019.html 2019-04-01T10:45:11.382Z https://www.astrazeneca-us.com/media/press-releases/2019/change-makers-across-the-oncology-community-recognized-at-2019-cancer-community-c2-awards-05032019.html 2019-05-03T12:53:18.727Z https://www.astrazeneca-us.com/media/press-releases/2019/astrazeneca-teams-up-with-pga-golf-champion-jason-day-to-raise-awareness-about-the-importance-of-biomarker-testing-in-lung-cancer-05082019.html 2019-05-07T21:04:24.197Z https://www.astrazeneca-us.com/media/press-releases/2019/fam-trastuzumab-deruxtecan-demonstrated-clinically-meaningful-response-in-patients-with-refractory-her2-positive-metastatic-breast-cancer-a-population-with-high-unmet-need-05082019.html 2019-05-08T10:38:20.139Z https://www.astrazeneca-us.com/media/press-releases/2019/astrazeneca-continues-to-redefine-cancer-treatment-at-the-2019-asco-annual-meeting-05162019.html 2019-05-16T11:00:24.705Z https://www.astrazeneca-us.com/media/press-releases/2019/fasenra-benralizumab-reduces-oral-corticosteroid-use-and-maintains-long-term-efficacy-and-safety-profile-in-severe-eosinophilic-asthma-05202019.html 2019-05-17T18:31:19.703Z https://www.astrazeneca-us.com/media/press-releases/2019/bob-harper-and-astrazeneca-expand-survivors-have-heart-initiative-to-empower-and-unite-heart-attack-survivors-nationwide-05222019.html 2019-05-22T11:15:05.291Z https://www.astrazeneca-us.com/media/press-releases/2019/imfinzi-durvalumab-is-the-only-immunotherapy-to-demonstrate-overall-survival-at-three-years-in-unresectable-stage-iii-non-small-cell-lung-cancer-06012019.html 2019-06-02T11:52:13.647Z https://www.astrazeneca-us.com/media/press-releases/2019/lynparza-olaparib-1st-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-iii-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreatic-cancer-06022019.html 2019-06-02T20:51:25.264Z https://www.astrazeneca-us.com/media/press-releases/2019/lynparza-olaparib-achieved-a-72-objective-response-rate-in-patients-with-relapsed-germline-brca-mutated-advanced-ovarian-cancer-06032019.html 2019-06-03T18:29:21.095Z https://www.astrazeneca-us.com/media/press-releases/2019/farxiga-study-showed-reduced-progression-of-kidney-disease-or-renal-death-in-patients-with-type-2-diabetes-06102019.html 2019-06-10T11:38:13.827Z https://www.astrazeneca-us.com/media/press-releases/2019/lokelma-demonstrated-efficacy-in-treating-hyperkalemia-in-patients-with-end-stage-renal-disease-on-hemodialysis-06142019.html 2019-06-14T11:01:04.105Z https://www.astrazeneca-us.com/media/press-releases/2019/calquence-acalabrutinib-significantly-prolonged-the-time-patients-lived-without-disease-progression-in-relapsed-or-refractory-chronic-lymphocytic-leukemia-06152019.html 2019-06-15T12:57:11.285Z https://www.astrazeneca-us.com/media/press-releases/2019/imfinzi-durvalumab-improves-overall-survival-at-interim-analysis-in-the-phase-iii-caspian-trial-in-1st-line-extensive-stage-small-cell-lung-cancer-06272019.html 2019-06-27T12:43:01.679Z https://www.astrazeneca-us.com/media/press-releases/2019/imfinzi-durvalumab-us-label-updated-with-overall-survival-data-in-unresectable-stage-iii-non-small-cell-lung-cancer-07222019.html 2019-07-22T11:06:25.329Z https://www.astrazeneca-us.com/media/press-releases/2019/lynparza-olaparib-phase-iii-profound-trial-in-hrr-mutation-selected-metastatic-castration-resistant-prostate-cancer-met-primary-endpoint-08072019.html 2019-08-07T03:15:23.995Z https://www.astrazeneca-us.com/media/press-releases/2019/tagrisso-osimertinib-significantly-improves-overall-survival-in-the-phase-iii-flaura-trial-for-1st-line-egfr-mutated-non-small-cell-lung-cancer-08092019.html 2019-08-29T15:37:53.576Z https://www.astrazeneca-us.com/media/press-releases/2019/lynparza-olaparib-phase-iii-paola-1-trial-met-primary-endpoint-as-1st-line-maintenance-treatment-with-bevacizumab-for-advanced-ovarian-cancer-08142019.html 2019-08-14T01:40:52.741Z https://www.astrazeneca-us.com/media/press-releases/2019/calquence-acalabrutinib-granted-us-breakthrough-therapy-designation-for-chronic-lymphocytic-leukemia-08142019.html 2019-08-14T12:01:03.431Z https://www.astrazeneca-us.com/media/press-releases/2019/farxiga-met-primary-endpoint-in-landmark-phase-iii-dapa-hf-trial-for-the-treatment-of-patients-with-heart-failure-08202019.html 2019-08-20T00:49:45.456Z https://www.astrazeneca-us.com/media/press-releases/2019/fda-grants-fast-track-designation-for-farxiga-in-chronic-kidney-disease-08272019.html 2019-08-27T10:46:08.138Z https://www.astrazeneca-us.com/media/press-releases/2019/pt010-phase-iii-ethos-trial-met-its-primary-endpoint-in-chronic-obstructive-pulmonary-disease-08282019.html 2019-08-28T11:36:21.044Z https://www.astrazeneca-us.com/media/press-releases/2019/brilinta-reduced-the-risk-of-cardiovascular-events-in-patients-with-coronary-artery-disease-and-type-2-diabetes-in-phase-iii-themis-trial-09012019.html 2019-09-01T13:15:28.957Z https://www.astrazeneca-us.com/media/press-releases/2019/detailed-results-from-phase-iii-dapa-hf-trial-showed-farxiga-significantly-reduced-both-the-incidence-of-cardiovascular-death-and-the-worsening-of-heart-failure-09012019.html 2019-09-01T12:58:18.562Z https://www.astrazeneca-us.com/media/press-releases/2019/imfinzi-is-first-immunotherapy-to-show-both-significant-survival-benefit-and-improved-durable-responses-in-extensive-stage-small-cell-lung-cancer-09092019.html 2019-11-07T13:53:51.995Z https://www.astrazeneca-us.com/media/press-releases/2019/fda-grants-fast track-designation-for-farxiga-in-heart-failure-091519.html 2019-09-15T23:57:17.174Z https://www.astrazeneca-us.com/media/press-releases/2019/brilinta-monotherapy-in-high-bleeding-risk-patients-who-underwent-pci-had-reduced-risk-of-clinically-relevant-bleeding-than-with-dual-antiplatelet-therapy-in-the-twilight trial-09262019.html 2019-09-26T18:21:35.422Z https://www.astrazeneca-us.com/media/press-releases/2019/lynparza-olaparib-improved-the-time-women-lived-without-disease-progression-to-22-months-in-the-broad-population-and-to-37-months-in-hrd-positive-patients-as-1st-line-maintenance-treatment-with-bevacizumab-for-newly-diagnosed-advanced-ovarian-cancer-092820191.html 2019-09-28T16:09:32.839Z https://www.astrazeneca-us.com/media/press-releases/2019/tagrisso-is-the-only-1st-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer-to-deliver-a-median-overall-survival-of-more-than-three-years-09282019.html 2019-09-29T21:44:46.615Z https://www.astrazeneca-us.com/media/press-releases/2019/lynparza-olaparib-more-than-doubled-the-time-without-radiographic-disease-progression-in-patients-with-brca12-or-atm-mutated-metastatic-castration-resistant-prostate-cancer-09302019.html 2019-09-30T15:10:58.717Z https://www.astrazeneca-us.com/media/press-releases/2019/fasenra-benralizumab-approved-in-the-us-for-self-administration-in-a-new-pre-filled-auto-injector-the-fasenra-pen-10042019.html 2019-10-04T12:06:06.132Z https://www.astrazeneca-us.com/media/press-releases/2019/astrazeneca-launches-signature-STEM-program-to-empower-students-to-live-healthier-lives-and-inspire-future-scientists-10072019.html 2019-10-07T02:39:48.768Z https://www.astrazeneca-us.com/media/press-releases/2019/fam-trastuzumab-deruxtecan-ds-8201-granted-fda-priority-review-for-treatment-of-patients-with-her2-positive-metastatic-breast-cancer-10172019.html 2019-10-17T11:21:03.746Z https://www.astrazeneca-us.com/media/press-releases/2019/farxiga-approved-in-the-US-to-reduce-the-risk-of-hospitalization-for-heart-failure-in-patients-with-type-2-diabetes-10212019.html 2019-10-21T00:00:27.046Z https://www.astrazeneca-us.com/media/press-releases/2019/imfinzi-durvalumab-and-imfinzi-plus-tremelimumab-delayed-disease-progression-in-phase-iii-poseidon-trial-for-1st-line-treatment-of-stage-iv-non-small-cell-lung-cancer-10282019.html 2019-10-28T20:29:33.614Z https://www.astrazeneca-us.com/media/press-releases/2019/astrazeneca-to-present-pivotal-roxadustat-phase-iii-data-at-the-american-society-of-nephrology-kidney-week-2019-10302019.html 2019-10-30T11:24:07.797Z https://www.astrazeneca-us.com/media/press-releases/2019/calquence-data-to-show-improved-progression-free-survival-in-phase-iii-front-line-chronic-lymphocytic-leukemia-at-ash-2019-annual-meeting-11062019.html 2019-11-06T19:27:37.847Z https://www.astrazeneca-us.com/media/press-releases/2019/roxadustat-significantly-increased-hemoglobin-levels-for-chronic-kidney-disease-patients-with-anemia-in-phase-iii-olympus-and-rockies-trials-11072019.html 2019-11-07T22:06:14.559Z https://www.astrazeneca-us.com/media/press-releases/2019/new-data-from-the-phase-iii-dapa-hf-trial-showed-farxiga-reduced-the-worsening-of-heart-failure-or-cardiovascular-death-in-hfref-patients-with-and-without-chronic-kidney-disease-11082019.html 2019-11-08T19:23:03.777Z https://www.astrazeneca-us.com/media/press-releases/2019/roxadustat-phase-iii-program-pooled-analyses-showed-positive-efficacy and-no-increased-cardiovascular-risk-in-patients-with-anemia-from-chronic-kidney-disease-versus-comparators-11082019.html 2019-11-08T19:24:33.811Z https://www.astrazeneca-us.com/media/press-releases/2019/us-fda-accepts-regulatory-submission-for-selumetinib-in-neurofibromatosis-type-1-and-grants-priority-review-11142019.html 2019-11-14T02:33:12.868Z https://www.astrazeneca-us.com/media/press-releases/2019/astrazeneca-launches-diabetes-can-break-your-heart-11142019.html 2019-11-14T13:25:21.272Z https://www.astrazeneca-us.com/media/press-releases/2019/subgroup-analysis-of-twilight-trial-patients-with-non-st-elevation-acute-coronary-syndrome-nste-acs-who-underwent-pci-showed-brilinta-monotherapy-reduced-the-risk-of-clinically-relevant-bleeding-compared-with-dual-antiplatelet-therapy-dapt-11172019.html 2019-11-17T16:51:40.498Z https://www.astrazeneca-us.com/media/press-releases/2019/consistent-effects-of-farxiga-in-heart-failure-patients-with-reduced-ejection-fraction-shown-in-new-analyses-from-landmark-phase-iii-dapa-hf-trial-11172019.html 2019-11-16T23:20:10.724Z https://www.astrazeneca-us.com/media/press-releases/2019/calquence-approved-in the-us-for-adult-patients-with-chronic-lymphocytic-leukemia-11212019.html 2019-11-21T20:50:33.946Z https://www.astrazeneca-us.com/media/press-releases/2019/imfinzi-durvalumab-granted-fda-priority-review-for-the-treatment-of-patients-with-extensive-stage-small-cell-lung-cancer-12022019.html 2019-12-02T21:24:41.546Z https://www.astrazeneca-us.com/media/press-releases/2019/calquence-significantly-prolonged-the-time-patients-lived-without-disease-progression-or-death-in-previously-untreated-chronic-lymphocytic-leukemia-12072019.html 2019-12-07T14:11:55.043Z https://www.astrazeneca-us.com/media/press-releases/2019/fam-trastuzumab-deruxtecan-achieved-a-tumor-response-of-609-in-pivotal-phase-ii-her2-positive-metastatic-breast-cancer-trial-12112019.html 2019-12-11T12:59:12.420Z https://www.astrazeneca-us.com/media/press-releases/2019/lynparza-olaparib-recommended-by-fda-advisory-committee-for-1st-line-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-cancer-that-has-not-progressed-on-platinum-based-chemotherapy-12172019.html 2019-12-18T22:09:46.769Z https://www.astrazeneca-us.com/media/press-releases/2019/enhertu-fam-trastuzumab-deruxtecan-nxki-approved-in-the-us-for-her2-positive-unresectable-or-metastatic-breast-cancer-following-two-or-more-prior-anti-her2-based-regimens-12202019.html 2019-12-20T22:31:54.944Z https://www.astrazeneca-us.com/media/press-releases/2019/lynparza-olaparib-approved-in-the-us-as-a-1st-line-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-cancer-12302019.html 2019-12-30T12:20:15.861Z https://www.astrazeneca-us.com/media/press-releases/2020.html 2020-01-22T16:07:09.570Z https://www.astrazeneca-us.com/media/press-releases/2020/covid-19-information-hub0.html 2020-03-26T15:06:05.230Z https://www.astrazeneca-us.com/media/press-releases/2020/farxiga-granted-fda-priority-review-for-patients-with-heart-failure-with-reduced-ejection-fraction-01062020.html 2021-08-17T08:42:06.746Z https://www.astrazeneca-us.com/media/press-releases/2020/lynparza-olaparib-regulatory-submission-granted-priority-review-in-us-for-1st-line-maintenance-treatment-with-bevacizumab-in-advanced-ovarian-cancer-01132020.html 2021-08-17T08:42:30.986Z https://www.astrazeneca-us.com/media/press-releases/2020/lynparza-olaparib-regulatory-submission-granted-priority-review-in-us-for-hrr-mutated-metastatic-castration-resistant-prostate-cancer-012020.html 2021-08-17T08:51:48.507Z https://www.astrazeneca-us.com/media/press-releases/2020/imfinzi-durvalumab-and-tremelimumab-granted-orphan-drug-designation-in-us-for-liver-cancer-01212020.html 2021-08-17T09:02:53.106Z https://www.astrazeneca-us.com/media/press-releases/2020/brilinta-met-primary-endpoint-in-the-phase-iii-thales-trial-in-stroke-01272020.html 2021-08-17T09:08:34.861Z https://www.astrazeneca-us.com/media/press-releases/2020/imfinzi-durvalumab-confirmed-a-sustained-overall-survival-benefit-in-final-analysis-of-the-phase-iii-caspian-trial-in-1st-line-extensive-stage-small-cell-lung-cancer-03172020.html 2021-08-17T09:09:40.303Z https://www.astrazeneca-us.com/media/press-releases/2020/our-update-on-covid-19.html 2021-08-17T09:14:56.664Z https://www.astrazeneca-us.com/media/press-releases/2020/astrazeneca-to-donate-9-million-face-masks-to-support-healthcare-workers-around-the-world-in-the-fight-against-covid-19.html 2021-08-17T11:26:43.946Z https://www.astrazeneca-us.com/media/press-releases/2020/covid-19-information-hub.html 2020-04-09T16:02:41.658Z https://www.astrazeneca-us.com/media/press-releases/2020/farxiga-reduced-the-incidence-of-heart-failure-worsening-or-cardiovascular-death-in-a-sub-analysis-from-landmark-phase-iii-dapa-hf-trial-03282020.html 2021-08-17T09:18:49.098Z https://www.astrazeneca-us.com/media/press-releases/2020/imfinzi-durvalumab-approved-in-the-us for-extensive-stage-small-cell-lung-cancer-03302020.html 2021-08-17T09:20:15.514Z https://www.astrazeneca-us.com/media/press-releases/2020/farxiga-phase-iii-dapa-ckd-trial-will-be-stopped-early-after-overwhelming-efficacy-in-patients-with-chronic-kidney-disease-03302020.html 2021-08-17T09:23:18.960Z https://www.astrazeneca-us.com/media/press-releases/2020/brilinta-reduced-bleeding-vs-dual-therapy-in-high-risk-coronary-patients-in-sub-analyses-from-phase-iv-twilight-trial-03302020.html 2021-08-17T09:26:52.533Z https://www.astrazeneca-us.com/media/press-releases/2020/astrazeneca-gsk-university-of-cambridge-collaborate-to-support-uk-national-effort-to-boost-covid-19-testing.html 2021-08-17T09:27:40.289Z https://www.astrazeneca-us.com/media/press-releases/2020/researching-antibodies-to-target-covid-19.html 2021-08-17T09:28:31.724Z https://www.astrazeneca-us.com/media/press-releases/2020/tagrisso-phase-iii-adaura-trial-will-be-unblinded-early-after-overwhelming-efficacy-in-the-adjuvant-treatment-of-patients-with-egfr-mutated-lung-cancer-04102020.html 2021-08-17T09:29:53.328Z https://www.astrazeneca-us.com/media/press-releases/2020/koselugo-selumetinib-approved-in-us-for-pediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas-04132020.html 2021-08-17T09:31:02.273Z https://www.astrazeneca-us.com/media/press-releases/2020/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19-04142020.html 2021-08-17T09:32:36.840Z https://www.astrazeneca-us.com/media/press-releases/2020/lynparza-olaparib-demonstrated-overall-survival-benefit-in-phase-iii-profound-trial-for-brca-1-2-or-atm-mutated-metastatic-castration-resistant-prostate-cancer-04242020.html 2021-08-17T09:34:32.547Z https://www.astrazeneca-us.com/media/press-releases/2020/lokelma-us-label-updated-to-include-dosing-guidance-for-the-treatment-of-hyperkalemia-in-patients-with-end-stage-renal-disease-on-hemodialysis-04272020.html 2021-08-17T09:39:04.153Z https://www.astrazeneca-us.com/media/press-releases/2020/farxiga-approved-in-the-us-for-the-treatment-of-heart-failure-in-patients-with-heart-failure-with-reduced-ejection-fraction-05062020.html 2021-08-17T09:39:57.850Z https://www.astrazeneca-us.com/media/press-releases/2020/lynparza-olaparib-approved-in-us-as-1st-line-maintenance-treatment-with-bevacizumab-for-hrd-positive-advanced-ovarian-cancer-05112020.html 2021-08-17T09:55:40.717Z https://www.astrazeneca-us.com/media/press-releases/2020/enhertu-granted-breakthrough-therapy-designation-in-the-us-for-her2-positive-metastatic-gastric-cancer-05112020.html 2021-08-17T10:00:46.798Z https://www.astrazeneca-us.com/media/press-releases/2020/astrazeneca-advances-the-science-of-cancer-medicine-with-practice-changing-data-at-the-asco20-virtual-scientific-program-05132020.html 2021-08-17T09:56:10.005Z https://www.astrazeneca-us.com/media/press-releases/2020/enhertu-granted-breakthrough-therapy-designation-in-the-us-for-her2-mutant-metastatic-non-small-cell-lung-cancer-05182020.html 2021-08-17T09:57:45.647Z https://www.astrazeneca-us.com/media/press-releases/2020/lynparza-olaparib-approved-in-the-us-for-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer-05202020.html 2021-08-17T09:58:44.513Z https://www.astrazeneca-us.com/media/press-releases/2020/astrazeneca-to-use-personalized-cancer-assays-to-detect-minimal-residual-disease-in-lung-cancer-trials-in-collaboration-with-archerdx-05272020.html 2021-08-17T10:02:01.405Z https://www.astrazeneca-us.com/media/press-releases/2020/tagrisso-demonstrated-unprecedented-patient-benefit-in-the-adjuvant-treatment-of-egfr-mutated-lung-cancer-05282020.html 2021-08-17T10:08:39.733Z https://www.astrazeneca-us.com/media/press-releases/2020/enhertu-fam-trastuzumab-deruxtecan-nxki-demonstrated-meaningful-clinical-activity-in-patients-with-her2-mutant-non-small-cell-lung-cancer-in-interim-analysis-of-phase-ii-destiny-lung01-trial-052920201.html 2021-08-17T10:09:38.999Z https://www.astrazeneca-us.com/media/press-releases/2020/enhertu-fam-trastuzumab-deruxtecan-nxki-significantly-improved-tumor-response-rate-and-overall-survival-in-her2-positive-metastatic-gastric-cancer-in-phase-ii-destiny-gastric01-trial-05292020.html 2021-08-17T10:18:08.831Z https://www.astrazeneca-us.com/media/press-releases/2020/enhertu-fam-trastuzumab-deruxtecan-nxki-achieved-a-tumor-response-rate-of-453-in-patients-with-her2-positive-metastatic-colorectal-cancer-in-phase-ii-destiny-crc01-05292020.html 2021-08-17T10:25:49.045Z https://www.astrazeneca-us.com/media/press-releases/2020/imfinzi-durvalumab-showed-a-sustained-overall-survival-benefit-in-1st-line-extensive-stage-small-cell-lung-cancer-in-the-phase-iii-caspian-trial-05292020.html 2021-08-17T10:29:47.540Z https://www.astrazeneca-us.com/media/press-releases/2020/imfinzi-plus-tremelimumab-demonstrated-promising-clinical-activity-and-tolerability-in-patients-with-advanced-liver-cancer-05292020.html 2021-08-17T10:30:25.712Z https://www.astrazeneca-us.com/media/press-releases/2020/brilinta-approved-in-the-us-to-reduce-the-risk-of-a-first-heart-attack-or-stroke-in-high-risk-patients-with-coronary-artery-disease-06012020.html 2021-08-17T10:31:23.403Z https://www.astrazeneca-us.com/media/press-releases/2020/astrazeneca-to-showcase-leadership-in-treating-type-2-diabetes-and-cardiorenal-complications-at-ada-2020-06112020.html 2021-08-17T10:31:55.896Z https://www.astrazeneca-us.com/media/press-releases/2020/pt010-significantly-reduced-rate-of-moderate-or-severe-copd-exacerbations-in-phase-iii-ethos-trial-06242020.html 2021-08-17T10:34:06.662Z https://www.astrazeneca-us.com/media/press-releases/2020/brilinta-granted-fda-priority-review-for-the-reduction-of-subsequent-stroke-in-patients-who-had-an-acute-ischemic-stroke-or-transient-ischemic-attack-07082020.html 2021-08-17T10:34:38.365Z https://www.astrazeneca-us.com/media/press-releases/2020/bob-harper-and-astrazeneca-bring-virtual-series-to-heart-attack-survivors-to-inspire-others-with-stories-about-second-chances-07152020.html 2021-08-17T10:35:04.030Z https://www.astrazeneca-us.com/media/press-releases/2020/brilinta-significantly-reduced-the-rate-of-the-composite-of-stroke-and-death-in-patients-who-had-an-acute-ischemic-stroke-or-transient-ischemic-attack-in-the-phase-iii-thales-trial-07162020.html 2021-08-17T10:35:35.628Z https://www.astrazeneca-us.com/media/press-releases/2020/farxiga-granted-fast-track-designation-in-the-us-for-heart-failure-following-acute-myocardial-infarction-leveraging-an-innovative-registry-based-trial-design-07162020.html 2021-08-17T10:36:01.252Z https://www.astrazeneca-us.com/media/press-releases/2020/breztri-aerosphere-approved-in-the-us-for-the-maintenance-treatment-of-copd-07242020.html 2021-08-17T10:37:50.501Z https://www.astrazeneca-us.com/media/press-releases/2020/farxiga-met-all-primary-and-secondary-endpoints-in-groundbreaking-phase-iii-dapa-ckd-trial-for-the-treatment-of-patients-with-chronic-kidney-disease-07282020.html 2021-08-17T10:38:19.690Z https://www.astrazeneca-us.com/media/press-releases/2020/tagrisso-granted-breakthrough-therapy-designation-in-the-us-for-the-adjuvant-treatment-of-patients-with-stage-ib-iiia-egfr-mutated-lung-cancer-07302020.html 2021-08-17T10:38:45.680Z https://www.astrazeneca-us.com/media/press-releases/2020/astrazeneca-partners-with-actor-and-author-tony-hale-to-build-awareness-of-eosinophilic-asthma-and-how-not-all-asthma-is-the-same-08062020.html 2021-08-17T10:48:04.218Z https://www.astrazeneca-us.com/media/press-releases/2020/astrazeneca-ships-flumist-quadrivalent-vaccine-in-the-us-for-2020-2021-flu-season-08132020.html 2021-08-17T12:18:18.304Z https://www.astrazeneca-us.com/media/press-releases/2020/imfinzi-durvalumab-granted-fda-priority-review-for-less-frequent-fixed-dose-use-08182020.html 2021-08-17T10:49:13.536Z https://www.astrazeneca-us.com/media/press-releases/2020/farxiga-demonstrated-unprecedented-reduction-in-the-risk-of-kidney-failure-and-cardiovascular-or-renal-death-in-patients-with-chronic-kidney-disease-in-the-phase-iii-dapa-ckd-trial-08302020.html 2021-08-17T10:52:07.477Z https://www.astrazeneca-us.com/media/press-releases/2020/development-of-covid-19-vaccine-azd1222-expands-into-us-phase-iii-clinical-trial-across-all-adult-age-groups-08312020.html 2021-08-17T10:51:22.691Z https://www.astrazeneca-us.com/media/press-releases/2020/biopharma-leaders-unite-to-stand-with-science-09082020.html 2021-08-17T12:18:55.649Z https://www.astrazeneca-us.com/media/press-releases/2020/astrazeneca-aims-to-transform-cancer-treatment-and-advance-clinical-practice-with-data-presented-at-esmo-2020-09092020.html 2021-08-17T11:06:21.956Z https://www.astrazeneca-us.com/media/press-releases/2020/imfinzi-demonstrated-unprecedented-survival-in-unresectable-stage-iii-non-small-cell-lung-cancer-with-an-estimated-50-of-patients-surviving-four-years-09182020.html 2021-08-17T11:07:59.974Z https://www.astrazeneca-us.com/media/press-releases/2020/lynparza-olaparib-improved-median-time-patients-lived-without-disease-progression-to-over-four-and-half-years-in-brca-mutated-advanced-ovarian-cancer-vs-just-over-one-year-with-placebo-09182020.html 2021-08-17T11:07:15.128Z https://www.astrazeneca-us.com/media/press-releases/2020/lynparza-olaparib-reduced-the-risk-of-death-by-31-in-brca1-2-or-atm-mutated-metastatic-castration-resistant-prostate-cancer-in-phase-iii-profound-trial-09202020.html 2021-08-17T11:09:17.887Z https://www.astrazeneca-us.com/media/press-releases/2020/tagrisso-reduced-the-risk-of-disease-recurrence-in-the-brain-by-82-in-the-adjuvant-treatment-of-early-stage-egfr-mutated-lung-cancer-09192020.html 2021-08-17T11:08:44.435Z https://www.astrazeneca-us.com/media/press-releases/2020/farxiga-granted-breakthrough-therapy-designation-in-us-for-chronic-kidney-disease-10022020.html 2021-08-17T11:09:49.092Z https://www.astrazeneca-us.com/media/press-releases/2020/tagrisso-granted-priority-review-in-the-us-for-the-adjuvant-treatment-of-patients-with-early-stage-egfr-mutated-lung-cancer-10202020.html 2021-08-17T11:10:21.872Z https://www.astrazeneca-us.com/media/press-releases/2020/astrazeneca-announces-winners-and-recognizes-unsung-heroes-of-oncology-in-2020-cancer-community-c2-awards-10222020.html 2021-08-17T11:10:53.571Z https://www.astrazeneca-us.com/media/press-releases/2020/farxiga-dapa-ckd-phase-iii-trial-reduced-worsening-of-kidney-function-risk-of-cardiovascular-or-renal-death-in-patients-with-chronic-kidney-disease-irrespective-of-underlying-cause-10232020.html 2021-08-17T11:11:24.344Z https://www.astrazeneca-us.com/media/press-releases/2020/enhertu-fam-trastuzumab-deruxtecan-nxki-granted-priority-review-in-the-us-for-the-treatment-of-her2-positive-metastatic-gastric-cancer-10282020.html 2021-08-17T11:11:51.193Z https://www.astrazeneca-us.com/media/press-releases/2020/fasenra-eliminated-oral-corticosteroid-use-in-a-majority-of-ocs-dependent-patients-with-asthma-in-ponente-phase-iiib-trial-10292020.html 2021-08-17T11:12:24.013Z https://www.astrazeneca-us.com/media/press-releases/2020/brilinta-approved-in-the-us-to-reduce-the-risk-of-stroke-in-patients-with-an-acute-ischemic-stroke-or-high-risk-transient-ischemic-attack-11062020.html 2021-08-17T11:16:30.419Z https://www.astrazeneca-us.com/media/press-releases/2020/tezepelumab-navigator-phase-iii-trial-met-primary-endpoint-of-a-statistically-significant-and-clinically-meaningful-reduction-in-exacerbations-in-a-broad-population-of-patients-with-severe-asthma-11102020.html 2021-08-17T11:17:00.106Z https://www.astrazeneca-us.com/media/press-releases/2020/data-from-contemporary-registry-confirms-that-four-out-of-five-patients-with-heart-failure-with-reduced-ejection-fraction-eligible-for-treatment-with-farxiga-11132020.html 2021-08-17T11:19:39.671Z https://www.astrazeneca-us.com/media/press-releases/2020/astrazeneca-demonstrates-strength-in-hematology-with-robust-data-at-ash-2020-11192020.html 2021-08-17T11:20:09.135Z https://www.astrazeneca-us.com/media/press-releases/2020/imfinzi-durvalumab-approved-in-the-us-for-less-frequent-fixed-dose-use-11202020.html 2021-08-17T11:20:38.194Z https://www.astrazeneca-us.com/media/press-releases/2020/astrazeneca-demonstrates-growing-leadership-in-breast-cancer-at-sabcs-with-data-from-its-innovative-medicines-and-robust-pipeline-12032020.html 2021-08-17T11:21:09.602Z https://www.astrazeneca-us.com/media/press-releases/2020/calquence-shows-long-term-efficacy-and-tolerability-at-three-years-for-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-12062020.html 2021-08-17T11:21:49.686Z https://www.astrazeneca-us.com/media/press-releases/2020/calquence-data-across-four-trials-reinforces-cardiovascular-safety-profile-in-patients-with-chronic-lymphocytic-leukemia-12072020.html 2021-08-17T11:22:24.475Z https://www.astrazeneca-us.com/media/press-releases/2020/enhertu-fam-trastuzumab-deruxtecan-nxki-continues-to-demonstrate-durable-responses-with-new-data-from-destiny-breast01-in-her2-positive-metastatic-breast-cancer-12102020.html 2021-08-17T11:22:51.213Z https://www.astrazeneca-us.com/media/press-releases/2020/imfinzi-durvalumab-granted-orphan-drug-designation-in-the-us-for-advanced-biliary-tract-cancer-12162020.html 2021-08-17T11:23:12.173Z https://www.astrazeneca-us.com/media/press-releases/2020/tagrisso-approved-in-the-us-for-the-adjuvant-treatment-of-patients-with-early-stage-egfr-mutated-lung-cancer-12212020.html 2021-08-17T11:23:41.969Z https://www.astrazeneca-us.com/media/press-releases/2021.html 2020-12-03T11:04:06.889Z https://www.astrazeneca-us.com/media/press-releases/2021/farxiga-granted-priority-review-in-the-us-for-the-treatment-of-patients-with-chronic-kidney-disease-01062021.html 2021-08-17T11:35:01.583Z https://www.astrazeneca-us.com/media/press-releases/2021/astrazeneca-to-showcase-transformative-data-across-diverse-pipeline-at-world-conference-on-lung-cancer-01132021.html 2021-08-17T11:36:13.395Z https://www.astrazeneca-us.com/media/press-releases/2021/enhertu-fam-trastuzumab-deruxtecan-nxki-approved-in-the-us-for-the-treatment-of-patients-with-previously-treated-her2-positive-advanced-gastric-cancer-01182021.html 2021-08-17T11:37:19.663Z https://www.astrazeneca-us.com/media/press-releases/2021/calquence-met-primary-efficacy-endpoint-in-head-to-head-trial-against-ibrutinib-in-chronic-lymphocytic-leukemia-01252021.html 2021-08-17T11:37:49.536Z https://www.astrazeneca-us.com/media/press-releases/2021/tagrisso-extended-disease-free-survival-regardless-of-prior-adjuvant-chemotherapy-in-early-stage-egfr-mutated-lung-cancer-01292021.html 2021-08-17T11:58:18.972Z https://www.astrazeneca-us.com/media/press-releases/2021/idmc-has-concluded-that-olympia-trial-of-lynparza-olaparib-crossed-superiority-boundary-for-invasive-disease-free-survival-vs-placebo-at-planned-interim-analysis-02172021.html 2021-08-17T12:03:38.238Z https://www.astrazeneca-us.com/media/press-releases/2021/voluntary-withdrawal-of-imfinzi-indication-in-advanced-bladder-cancer-in-the-us-02222021.html 2021-08-17T12:05:37.410Z https://www.astrazeneca-us.com/media/press-releases/2021/tezepelumab-is-the-first-biologic-to-consistently-and-significantly-reduce-exacerbations-in-broad-population-of-severe-asthma-patients-02262021.html 2021-08-17T12:06:00.825Z https://www.astrazeneca-us.com/media/press-releases/2021/azd1222-us-phase-iii-trial-met-primary-efficacy-endpoint-in-preventing-covid-19-at-interim-analysis-03222021.html 2021-08-17T12:16:00.134Z https://www.astrazeneca-us.com/media/press-releases/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy-03242021.html 2021-08-17T12:16:20.150Z https://www.astrazeneca-us.com/media/press-releases/2021/statement-on-azd1222-us-government-drug-substance-production-04032021.html 2021-08-17T12:16:40.884Z https://www.astrazeneca-us.com/media/press-releases/2021/astrazeneca-announces-collaboration-with-massachusetts-general-hospital-to-accelerate-digital-health-solutions-04062021.html 2021-08-17T12:17:03.666Z https://www.astrazeneca-us.com/media/press-releases/2021/farxiga-approved-in-the-us-for-the-treatment-of-chronic-kidney-disease-in-patients-at-risk-of-progression-with-and-without-type-2-diabetes-04302021.html 2021-08-17T12:06:48.208Z https://www.astrazeneca-us.com/media/press-releases/2021/imfinzi-and-tremelimumab-with-chemotherapy-demonstrated-overall-survival-benefit-in-poseidon-trial-for-1st-line-stage-iv-non-small-cell-lung-cancer-05072021.html 2021-08-17T12:07:11.595Z https://www.astrazeneca-us.com/media/press-releases/2021/new-tezepelumab-data-continue-to-strengthen-profile-for-a-broad-05132021.html 2021-08-17T12:08:03.725Z https://www.astrazeneca-us.com/media/press-releases/2021/new-fasnera-data-from-the-meltemi-extension-trial-confirm-long-term-safety-05192021.html 2021-08-17T12:09:54.553Z https://www.astrazeneca-us.com/media/press-releases/2021/astrazeneca-asco-2021-data-support-ambition-to-revolutionize-cancer-outcomes-by-treating-earlier-and-transforming-the-patient-experience-05192021.html 2021-08-17T12:09:05.401Z https://www.astrazeneca-us.com/media/press-releases/2021/lynparza-olaparib-reduced-the-risk-of-cancer-recurrence-by-42-percent-in-the-adjuvant-treatment-of-patients-with-germline-brca-mutated-high-risk-early-breast-cancer-in-olympia-phase-iii-trial-06032021.html 2021-08-17T12:10:13.995Z https://www.astrazeneca-us.com/media/press-releases/2021/imfinzi-demonstrated-unprecedented-survival-in-unresectable-stage-iii-lung-cancer-06042021.html 2021-08-17T12:10:51.618Z https://www.astrazeneca-us.com/media/press-releases/2021/calquence-demonstrated-fewer-incidences-of-atrial-fibrillation-06072021.html 2021-08-17T12:11:44.302Z https://www.astrazeneca-us.com/media/press-releases/2021/phase-iii-pivotal-trial-of-once-weekly-exenatide-in-adolescents-aged-10-17-shows-benefit-for-the-treatment-of-type-2-diabetes.html 2021-08-17T12:12:13.500Z https://www.astrazeneca-us.com/media/press-releases/2021/tezepelumab-regulatory-submission-accepted-and-granted-fda-07082021.html 2021-08-17T12:12:40.479Z https://www.astrazeneca-us.com/media/press-releases/2021/bydureon-bcise-exenatide-extended-release-approved-in-the-us-for-the-treatment-of-type-2-diabetes.html 2021-08-17T12:13:17.407Z https://www.astrazeneca-us.com/media/press-releases/2021/saphnelo--anifrolumab--approved-in-the-us-for-moderate-to-severe.html 2021-08-17T12:13:47.332Z https://www.astrazeneca-us.com/media/press-releases/2021/enhertu-fam-trastuzumab-deruxtecan-nxki-significantly-improved-progression-08092021.html 2021-08-17T12:14:54.388Z https://www.astrazeneca-us.com/media/press-releases/2021/azd7442-provent-phase-iii-prophylaxis-trial-met-primary-endpoint-in-preventing-covid-19-08202021.html 2021-08-26T05:55:41.377Z https://www.astrazeneca-us.com/media/press-releases/2021/flumistr-quadrivalent-influenza-vaccine-live-intranasal-vaccine-now-available-in-the-us-for-annual-flu-season.html 2021-08-31T13:13:41.396Z https://www.astrazeneca-us.com/media/press-releases/2021/fixed-dose-combination-of-albuterol-and-budesonide-pt027-demonstrated-significant-benefits-for-asthma-patients-in-mandala-and-denali-phase-iii-trials.html 2021-09-09T10:49:42.129Z https://www.astrazeneca-us.com/media/press-releases/2021/imfinzi-and-tremelimumab-with-chemotherapy-improved-progression-free-survival-by-28-and-overall-survival-by-23-in-1st-line-stage-iv-non-small-cell-lung-cancer-vs-chemotherapy-09092021.html 2021-09-09T16:07:07.339Z https://www.astrazeneca-us.com/media/press-releases/2021/imfinzi-combined-with-novel-immunotherapies-improved-clinical-outcomes-for-patients-with-unresectable-stage-iii-non-small-cell-lung-cancer-09172021.html 2021-09-17T11:31:26.060Z https://www.astrazeneca-us.com/media/press-releases/2021/enhertu-fam-trastuzumab-deruxtecan-nxki-demonstrated-clinically-meaningful-and-durable-response-in-patients-with-her2-positive-advanced-gastric-cancer-in-destiny-gastric02-phase-ii-trial-09172021.html 2021-09-17T14:59:37.480Z https://www.astrazeneca-us.com/media/press-releases/2021/enhertu-fam-trastuzumab-deruxtecan-nxki-demonstrated-robust-and-durable-tumor-response-of-549-in-patients-with-her2-mutant-metastatic-non-small-cell-lung-cancer-09182021.html 2021-09-18T01:19:26.151Z https://www.astrazeneca-us.com/media/press-releases/2021/enhertu-fam-trastuzumab-deruxtecan-nxki-reduced-the-risk-of-disease-progression-or-death-by-72-vs-trastuzumab-emtansine-t-dm1-in-patients-with-her2-positive-metastatic-breast-cancer-09182021.html 2021-10-01T15:42:00.466Z https://www.astrazeneca-us.com/media/press-releases/2021/imfinzi-plus-chemotherapy-tripled-patient-survival-at-three-years-in-the-caspian-phase-iii-trial-in-extensive-stage-small-cell-lung-cancer-09182021.html 2021-09-18T11:56:49.860Z https://www.astrazeneca-us.com/media/press-releases/2021/lynparza-olaparib-in-combination-with-abiraterone-significantly-delayed-disease-progression-in-all-comers-in-propel-phase-iii-trial-in-1st-line-metastatic-castration-resistant-prostate-cancer-09242021.html 2021-09-24T02:35:44.242Z https://www.astrazeneca-us.com/media/press-releases/2021/astrazeneca-covid-19-and-rsv-presentations-at-idweek-2021-will-showcase-scientific-progress-in-infectious-diseases.html 2021-09-27T11:50:05.382Z https://www.astrazeneca-us.com/media/press-releases/2021/astrazeneca-healthcare-foundation-awards-seven-us-nonprofits-more-than-900k-to-improve-heart-health-and-advance-health-equity-09282021.html 2021-09-28T22:11:08.869Z https://www.astrazeneca-us.com/media/press-releases/2021/enhertu-fam-trastuzumab-deruxtecan-nxki-granted-breakthrough-therapy-designation-in-us-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-one-or-more-prior-anti-her2-based-regimens-10042021.html 2021-10-03T23:14:41.299Z https://www.astrazeneca-us.com/media/press-releases/2021/azd7442-request-for-emergency-use-authorization-for-covid-19-prophylaxis-filed-in-us-10052021.html 2021-10-08T16:10:16.278Z https://www.astrazeneca-us.com/media/press-releases/2021/astrazeneca-covid-19-and-rsv-presentations-at-idweek-2021-will-showcase-scientific-progress-in-infectious-diseases1.html 2021-10-07T14:46:26.730Z https://www.astrazeneca-us.com/media/press-releases/2021/tezepelumab-granted-orphan-drug-designation-in-the-us-for-eosinophilic-esophagitis.html 2021-10-08T16:13:25.299Z https://www.astrazeneca-us.com/media/press-releases/2021/imfinzi-plus-tremelimumab-significantly-improved-overall-survival-in-himalaya-phase-iii-trial-in-1st-line-unresectable-liver-cancer-10152021.html 2021-10-15T01:28:44.059Z https://www.astrazeneca-us.com/media/press-releases/2021/astrazeneca-announces-winners-and-recognizes-oncology-change-makers-in-third-annual-cancer-community-awards-10202021.html 2021-10-19T18:05:16.670Z https://www.astrazeneca-us.com/media/press-releases/2021/astrazeneca-and-bob-harper-unveil-the-survivors-old.html 2021-10-21T15:54:23.449Z https://www.astrazeneca-us.com/media/press-releases/2021/astrazeneca-and-bob-harper-unveil-the-survivors.html 2021-10-22T11:07:05.255Z https://www.astrazeneca-us.com/media/press-releases/2021/imfinzi-plus-chemotherapy-significantly-improved-overall-survival-in-1st-line-advanced-biliary-tract-cancer-in-topaz-1-phase-iii-trial-at-interim-analysis-10252021.html 2021-10-27T13:59:43.273Z https://www.astrazeneca-us.com/media/press-releases/2021/astrazeneca-awards-through-the-act-on-health-equity-community-solutions-challenge-11012021.html 2026-07-20T18:15:30.763Z https://www.astrazeneca-us.com/media/press-releases/2021/saphnelo-consistently-reduces-systemic-lupus-erythematosus-disease-11012021.html 2021-11-01T15:13:51.156Z https://www.astrazeneca-us.com/media/press-releases/2021/astrazeneca-advances-ambition-to-redefine-care-for-blood-cancer-at-ash-2021-11052021.html 2021-11-05T01:25:48.539Z https://www.astrazeneca-us.com/media/press-releases/2021/lokelma-granted-fast-track-designation-in-the-us-to-reduce-cardiovascular-outcomes-in-patients-on-chronic-hemodialysis-with-hyperkalemia-11172021.html 2021-11-17T15:12:40.056Z https://www.astrazeneca-us.com/media/press-releases/2021/new-analyses-of-two-AZD7442-COVID-19-Phase-III-trials-in-high-risk-populations-confirm-robust-efficacy-and-long-term-prevention.html 2021-11-18T11:56:11.667Z https://www.astrazeneca-us.com/media/press-releases/2021/evusheld-formerly-AZD7442-long-acting-antibody-combination-authorized-for-emergency-use-in-the-US-for-pre-exposure-prophylaxis-prevention-of-COVID-19.html 2021-12-09T00:41:18.525Z https://www.astrazeneca-us.com/media/press-releases/2021/lynparza-olaparib-granted-priority-review-in-the-us-for-brca-mutated-her2-negative-high-risk-early-breast-cancer-11302021.html 2021-11-30T13:00:02.623Z https://www.astrazeneca-us.com/media/press-releases/2021/astrazeneca-reinforces-leadership-in-breast-cancer-at-sabcs-2021-with-new-data-underscoring-ambition-to-redefine-cancer-care-12032021.html 2021-12-03T02:10:14.949Z https://www.astrazeneca-us.com/media/press-releases/2021/evusheld-formerly-AZD7442-long-acting-antibody-combination-authorized-for-emergency-use-in-the-US-for-pre-exposure-prophylaxis-prevention-of-COVID-191.html 2021-12-09T01:06:44.405Z https://www.astrazeneca-us.com/media/press-releases/2021/evusheld-long-acting-antibody-combination-authorized-for-emergency-use-in-the-us-12082021.html 2021-12-09T06:55:07.682Z https://www.astrazeneca-us.com/media/press-releases/2021/enhertu-fam-trastuzumab-deruxtecan-nxki-additional-analyses-further-reinforce-ground-breaking-efficacy-in-patients-with-her2-positive-metastatic-breast-cancer-120920212.html 2021-12-09T14:59:30.696Z https://www.astrazeneca-us.com/media/press-releases/2021/calquence-reduced-the-risk-of-disease-progression-or-death-by-71-vs-standard-of-care-combinations-at-three-years-in-the-ascend-phase-iii-trial-12122021.html 2021-12-10T20:43:12.686Z https://www.astrazeneca-us.com/media/press-releases/2021/evusheld-long-acting-antibody-combination-retains-neutralizing-activity-against-omicron-variant-in-independent-fda-study.html 2021-12-16T14:23:07.281Z https://www.astrazeneca-us.com/media/press-releases/2021/tezspire-approved-in-the-US-for-severe-asthma.html 2021-12-17T22:38:39.433Z https://www.astrazeneca-us.com/media/press-releases/2021/evusheld-long-acting-antibody-combination-retains-neutralizing-activity-against-omicron-variant-in-studies-from-oxford-and-washington-universities.html 2021-12-23T00:43:58.980Z https://www.astrazeneca-us.com/media/press-releases/2022.html 2022-01-05T06:54:20.578Z https://www.astrazeneca-us.com/media/press-releases/2022/tezspire-now-available-in-the-united-states-for-the-treatment-of-severe-asthma.html 2022-09-13T17:45:14.892Z https://www.astrazeneca-us.com/media/press-releases/2022/astrazeneca-aims-to-redefine-liver-biliary-tract-and-prostate-cancer-treatment-with-practice-changing-imfinzi-durvalumab-and-lynparza-olaparib-data-at-asco-gi-and-gu-01132021.html 2022-01-13T02:22:41.775Z https://www.astrazeneca-us.com/media/press-releases/2022/enhertu-granted-priority-review-in-the-us-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-a-prior-anti-her2-based-regimen-01172022.html 2022-01-18T02:21:42.252Z https://www.astrazeneca-us.com/media/press-releases/2022/imfinzi-durvalumab-plus-tremelimumab-demonstrated-unprecedented-survival-in-1st-line-unresectable-liver-cancer-with-31-percent-of-patients-alive-at-three-years-01182022.html 2022-01-18T21:54:13.201Z https://www.astrazeneca-us.com/media/press-releases/2022/imfinzi-durvalumab-plus-chemotherapy-reduced-risk-of-death-by-20-percent-in-1st-line-advanced-biliary-tract-cancer-01182022.html 2022-01-18T22:01:38.537Z https://www.astrazeneca-us.com/media/press-releases/2022/eplontersen-granted-orphan-drug-designation-in-the-us-for-transthyretin-amyloidosis.html 2022-09-13T17:44:58.762Z https://www.astrazeneca-us.com/media/press-releases/2022/lynparza-olaparib-plus-abiraterone-reduced-risk-of-disease-progression-by-34-vs-standard-of-care-in-1st-line-metastatic-castration-resistant-prostate-cancer-02142022.html 2022-02-14T22:18:58.950Z https://www.astrazeneca-us.com/media/press-releases/2022/enhertu-fam-trastuzumab-deruxtecan-nxki-significantly-improved-both-progression-free-and-overall-survival-in-destiny-breast04-trial-in-patients-with-her2-low-metastatic-breast-cancer-02212022.html 2022-02-21T17:28:33.347Z https://www.astrazeneca-us.com/media/press-releases/2022/lynparza-olaparib-approved-in-the-us-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer-03112022.html 2022-03-12T00:00:19.086Z https://www.astrazeneca-us.com/media/press-releases/2022/lynparza-olaparib-reduced-risk-of-death-by-32-in-the-adjuvant-treatment-of-patients-with-germline-brca-mutated-high-risk-early-breast-cancer-031622.html 2022-03-16T15:34:06.990Z https://www.astrazeneca-us.com/media/press-releases/2022/evusheld-long-acting-antibody-combination-retains-neutralizing-activity-against-omicron-variants-including-ba2-in-new-independent-studies.html 2022-09-13T17:44:35.506Z https://www.astrazeneca-us.com/media/press-releases/2022/astrazeneca-announces-sale-of-its-amazetm-disease-management-platform-to-huma-032322.html 2022-03-23T11:04:11.591Z https://www.astrazeneca-us.com/media/press-releases/2022/astrazeneca-announces-new-partnership-with-the-national-fish-and-wildlife-foundation-to-plant-one-million-trees.html 2022-09-13T17:43:53.866Z https://www.astrazeneca-us.com/media/press-releases/2022/ultomiris-demonstrated-sustained-improvements-in-functional-activities-and-quality-of-life-in-adults-with-generalized-myasthenia-gravis-through-60-weeks.html 2022-09-13T17:43:21.456Z https://www.astrazeneca-us.com/media/press-releases/2022/enhertu-granted-priority-review-in-the-us-for-patients-with-previously-treated-her2-mutant-metastatic-non-small-cell-lung-cancer.html 2022-09-13T17:54:00.516Z https://www.astrazeneca-us.com/media/press-releases/2022/evusheld-significantly-protected-against-symptomatic-covid-19-for-at-least-six-months-in-provent-phase-3-trial-in-high-risk-populations.html 2022-09-13T17:42:58.704Z https://www.astrazeneca-us.com/media/press-releases/2022/tremelimumab-accepted-under-priority-review-in-the-us-for-patients-with-unresectable-liver-cancer-in-combination-with-imfinzi-04252022.html 2022-04-25T01:23:12.765Z https://www.astrazeneca-us.com/media/press-releases/2022/enhertu-fam-trastuzumab-deruxtecan-nxki-granted-breakthrough-therapy-designation-in-the-us-for-patients-with-her2-low-metastatic-breast-cancer-04272022.html 2022-04-27T01:16:58.131Z https://www.astrazeneca-us.com/media/press-releases/2022/ultomiris-approved-in-the-us-for-adults-with-generalized-myasthenia-gravis.html 2022-09-13T17:42:31.546Z https://www.astrazeneca-us.com/media/press-releases/2022/imfinzi-plus-chemotherapy-granted-priority-review-in-the-us-for-patients-with-locally-advanced-or-metastatic-biliary-tract-cancer-based-on-topaz-1-phase-iii-trial-05042022.html 2022-05-04T12:19:49.005Z https://www.astrazeneca-us.com/media/press-releases/2022/farxiga-met-primary-endpoint-in-deliver-phase-III-trial.html 2022-09-13T17:42:01.480Z https://www.astrazeneca-us.com/media/press-releases/2022/ultomiris-met-primary-endpoint-in-champion-nmosd-phase-III-trial.html 2022-09-13T17:41:16.466Z https://www.astrazeneca-us.com/media/press-releases/2022/enhertu-fam-trastuzumab-deruxtecan-nxki-approved-in-the-us-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-a-prior-anti-her2-based-regimen-05052022.html 2022-05-05T11:03:51.850Z https://www.astrazeneca-us.com/media/press-releases/2022/pt027-significantly-reduced-the-risk-of-a-severe-exacerbation-compared-to-albuterol-in-patients-with-asthma.html 2025-05-14T22:04:52.238Z https://www.astrazeneca-us.com/media/press-releases/2022/astrazeneca-aims-to-transform-cancer-care-with-practice-changing-data-at-asco-2022-05232022.html 2022-05-23T01:33:35.426Z https://www.astrazeneca-us.com/media/press-releases/2022/evusheld-long-acting-antibody-combination-retains-neutralizing-activity-against-omicron-variants-BA4-and-BA5.html 2022-09-13T17:34:46.986Z https://www.astrazeneca-us.com/media/press-releases/2022/first-patients-dosed-in-iris-phase-iii-trial-evaluating-anifrolumab-in-lupus-nephritis.html 2022-09-13T17:30:46.677Z https://www.astrazeneca-us.com/media/press-releases/2022/calquence-plus-obinutuzumab-demonstrated-sustained-survival-benefit-in-1st-line-chronic-lymphocytic-leukemia-with-90-of-patients-surviving-five-years-in-elevate-tn-trial-06052022.html 2022-06-04T12:30:06.974Z https://www.astrazeneca-us.com/media/press-releases/2022/enhertu-fam-trastuzumab-deruxtecan-nxki-reduced-the-risk-of-disease-progression-or-death-by-50-vs-chemotherapy-in-patients-with-her2-low-metastatic-breast-cancer-with-hr-positive-and-hr-negative-disease-06052022.html 2022-06-13T17:27:05.019Z https://www.astrazeneca-us.com/media/press-releases/2022/astrazeneca-awards-4m-to-nonprofit-organizations-to-advance-health-equity1.html 2025-05-14T22:23:43.469Z https://www.astrazeneca-us.com/media/press-releases/2022/eplontersen-met-co-primary-and-secondary-endpoints-in-interim-analysis-of-the-neuro-ttransform-phase-III-trial-for-hereditary-transthyretin-mediated-amyloid-polyneuropathy.html 2022-09-13T17:28:35.208Z https://www.astrazeneca-us.com/media/press-releases/2022/propel-phase-iii-trial-positive-results-of-lynparza-olaparib-plus-abiraterone-in-1st-line-metastatic-castration-resistant-prostate-cancer-published-in-new-england-journal-of-medicine-evidence-02212022.html 2022-06-21T01:46:05.505Z https://www.astrazeneca-us.com/media/press-releases/2022/alxn1840-shows-rapid-and-sustained-improvement-in-copper-mobilization-from-tissues-potentially-closing-treatment-gaps-for-wilson-disease-community.html 2022-09-13T17:27:43.297Z https://www.astrazeneca-us.com/media/press-releases/2022/imfinzi-plus-chemotherapy-significantly-improved-pathologic-complete-response-in-aegean-phaseIII-trial-in-resectable-non-small-cell-lung-cancer.html 2022-09-13T17:26:40.706Z https://www.astrazeneca-us.com/media/press-releases/2022/astrazeneca-shares-data-at-easl-and-esmo-world-gi-for-imfinzi-combinations-in-patients-with-liver-and-biliary-tract-cancers.html 2022-09-13T17:25:59.368Z https://www.astrazeneca-us.com/media/press-releases/2022/astrazenecas-survivors-have-heart-and-the-philadelphia-phillies-partner-to-raise-heart-health-awareness.html 2022-09-13T17:25:04.700Z https://www.astrazeneca-us.com/media/press-releases/2022/enhertu-fam-trastuzumab-deruxtecan-nxki-granted-priority-review-in-the-us-for-patients-with-her2-low-metastatic-breast-cancer-07252022.html 2022-07-25T02:21:51.842Z https://www.astrazeneca-us.com/media/press-releases/2022/calquence-acalabrutinib-tablet-formulation-approved-in-the-us-across-current-indications-08052022.html 2022-08-05T16:57:18.769Z https://www.astrazeneca-us.com/media/press-releases/2022/tagrisso-plus-savolitinib-demonstrated-49-objective-response-rate-in-lung-cancer-patients-with-high-levels-of-met-overexpression-and-or-amplification-in-savannah-phase-ii-trial-08082022.html 2022-08-08T11:01:01.208Z https://www.astrazeneca-us.com/media/press-releases/2022/enhertu-fam-trastuzumab-deruxtecan-nxki-approved-in-the-us-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer-08052022.html 2022-08-05T21:40:31.588Z https://www.astrazeneca-us.com/media/press-releases/2022/poseidon-phase-iii-post-hoc-exploratory-analyses-presented-at-wclc-2022-08092022.html 2022-08-09T14:55:37.382Z https://www.astrazeneca-us.com/media/press-releases/2022/enhertu-fam-trastuzumab-deruxtecan-nxki-approved-in-the-us-as-the-first-her2-directed-therapy-for-patients-with-previously-treated-her2-mutant-metastatic-non-small-cell-lung-cancer-08122022.html 2022-08-12T02:24:31.344Z https://www.astrazeneca-us.com/media/press-releases/2022/lynparza-olaparib-in-combination-with-abiraterone-granted-priority-review-in-the-us-for-patients-with-metastatic-castration-resistant-prostate-cancer-08162022.html 2022-08-15T23:14:51.353Z https://www.astrazeneca-us.com/media/press-releases/2022/astrazeneca-aims-to-transform-cancer-outcomes-with-new-data-across-industry-leading-portfolio-at-esmo-2022-08242022.html 2022-08-24T01:40:42.412Z https://www.astrazeneca-us.com/media/press-releases/2022/farxiga-significantly-reduced-the-risk-of-cardiovascular-death-or-worsening-of-heart-failure-in-patients-with-mildly-reduced-or-preserved-ejection-fraction-in-deliver-phase-III-trial.html 2022-08-26T19:09:11.598Z https://www.astrazeneca-us.com/media/press-releases/2022/new-data-show-farxiga-significantly-lowers-the-risk-of-cardiovascular-death-in-patients-with-heart-failure.html 2022-08-25T20:04:50.803Z https://www.astrazeneca-us.com/media/press-releases/2022/flumist-quadrivalent-vaccine-now-available-in-the-us-for-2022-2023-flu-season.html 2025-05-14T21:57:57.833Z https://www.astrazeneca-us.com/media/press-releases/2022/imfinzi-durvalumab-plus-chemotherapy-approved-in-the-us-as-the-first-immunotherapy-regimen-for-patients-with-advanced-biliary-tract-cancer-09052022.html 2022-09-05T00:43:48.506Z https://www.astrazeneca-us.com/media/press-releases/2022/lynparza-olaparib-in-combination-with-bevacizumab-and-as-a-monotherapy-demonstrates-clinically-meaningful-survival-benefit-in-1st-line-advanced-ovarian-cancer-across-two-phase-iii-trials-09092022.html 2022-09-09T01:27:07.619Z https://www.astrazeneca-us.com/media/press-releases/2022/tagrisso-osimertinib-demonstrated-5-5-year-median-disease-free-survival-in-the-adjuvant-treatment-of-patients-with-egfr-mutated-lung-cancer-09112022.html 2022-09-11T03:01:02.535Z https://www.astrazeneca-us.com/media/press-releases/2022/imfinzi-durvalumab-and-tremelimumab-with-chemotherapy-demonstrated-sustained-survival-benefit-in-metastatic-non-small-cell-lung-cancer-nearly-doubling-the-number-of-patients-alive-after-three-years-vs-chemotherapy-09112022.html 2022-09-11T03:15:42.086Z https://www.astrazeneca-us.com/media/press-releases/2022/enhertu-fam-trastuzumab-deruxtecan-nxki-continues-to-demonstrate-clinically-meaningful-tumor-response-in-patients-with-her2-mutant-metastatic-non-small-cell-lung-cancer-09112022.html 2022-09-11T12:24:51.773Z https://www.astrazeneca-us.com/media/press-releases/2022/imfinzi-durvalumab-plus-chemotherapy-further-improved-overall-survival-benefit-in-advanced-biliary-tract-cancer-in-the-topaz-1-phase-iii-trial-reducing-the-risk-of-death-by-24-in-additional-follow-up-09122022.html 2022-09-12T14:08:00.134Z https://www.astrazeneca-us.com/media/press-releases/2022/astrazeneca-partners-with-jeff-bridges-kumail-nanjiani-and-emily-gordon-to-educate-the-immunocompromised-community-about-added-protection-against-covid-19.html 2025-05-14T19:58:43.495Z https://www.astrazeneca-us.com/media/press-releases/2022/danicopan-add-on-to-ultomiris-or-soliris-met-primary-endpoint-in-alpha-phase-III-trial-for-patients-with-paroxysmal-nocturnal-hemoglobinuria-who-experience-clinically-significant-extravascular-hemolysis.html 2022-09-16T10:19:39.458Z https://www.astrazeneca-us.com/media/press-releases/2022/alexion-astrazeneca-rare-disease-to-acquire-logicbio-therapeutics-to-accelerate-growth-in-genomic-medicine.html 2022-10-03T11:14:45.890Z https://www.astrazeneca-us.com/media/press-releases/2022/alexion-aims-to-advance-nmosd-treatment-landscape-with-exceptional-ultomiris-efficacy-data-at-ectrims-2022.html 2022-10-12T11:23:22.131Z https://www.astrazeneca-us.com/media/press-releases/2022/astrazeneca-announces-winners-of-fourth-annual-cancer-community-awards.html 2022-10-19T22:37:13.915Z https://www.astrazeneca-us.com/media/press-releases/2022/imjudo-tremelimumab-in-combination-with-imfinzi-durvalumab-approved-in-the-us-for-patients-with-unresectable-liver-cancer.html 2022-10-23T22:36:56.771Z https://www.astrazeneca-us.com/media/press-releases/2022/ultomiris-showed-zero-relapses-in-adults-with-neuromyelitis-optica-spectrum-disorder-with-median-treatment-duration-of-73-weeks.html 2022-10-27T10:35:24.830Z https://www.astrazeneca-us.com/media/press-releases/2022/capivasertib-plus-faslodex-significantly-improved-progression-free-survival-vs-faslodex-in-capitello-291-phase-III-trial-in-advanced-hr-positive-breast-cancer-102622.html 2022-11-16T01:59:32.239Z https://www.astrazeneca-us.com/media/press-releases/2022/camizestrant-significantly-improved-progression-free-survival-vs-faslodex-in-serena-2-phase-II-trial-in-advanced-er-positive-breast-cancer.html 2022-11-16T01:58:32.002Z https://www.astrazeneca-us.com/media/press-releases/2022/astrazeneca-advances-scientific-leadership-in-cardiovascular-and-renal-diseases-with-over-60-abstracts-collectively-at-asn-kidney-week-2022-and-aha-scientific-sessions-2022.html 2022-10-31T02:27:42.736Z https://www.astrazeneca-us.com/media/press-releases/2022/astrazeneca-presents-data-at-asn-kidney-week-2022-reinforcing-urgent-need-for-early-screening-of-chronic-kidney-disease-and-the-benefits-of-earlier-treatment-initiation-for-patients-and-healthcare-systems1.html 2022-11-04T15:25:27.901Z https://www.astrazeneca-us.com/media/press-releases/2022/farxiga-improved-symptom-burden-and-health-related-quality-of-life-in-patients-with-mildly-reduced-or-preserved-ejection-fraction-in-deliver-phase-iii-trial.html 2022-11-04T15:42:33.465Z https://www.astrazeneca-us.com/media/press-releases/2022/pt027-recommended-by-fda-advisory-committee-as-new-rescue-treatment-for-asthma.html 2025-05-14T22:07:53.741Z https://www.astrazeneca-us.com/media/press-releases/2022/astrazeneca-evusheld-named-on-times-list-of-the-best-inventions-of-2022.html 2025-05-14T22:13:28.991Z https://www.astrazeneca-us.com/media/press-releases/2022/imfinzi-and-imjudo-with-chemotherapy-approved-in-the-us-for-patients-with-metastatic-non-small-cell-lung-cancer-11112022.html 2022-11-11T11:50:52.598Z https://www.astrazeneca-us.com/media/press-releases/2022/alexion-astrazeneca-rare-disease-completes-acquisition-of-logicbio-therapeutics.html 2025-05-14T22:16:48.114Z https://www.astrazeneca-us.com/media/press-releases/2022/astrazeneca-aims-to-redefine-breast-cancer-care-with-new-data-across-the-treatment-spectrum-at-sabcs-2022-11232022.html 2022-11-22T12:19:29.775Z https://www.astrazeneca-us.com/media/press-releases/2022/astrazeneca-showcases-strength-of-hematology-portfolio-and-pipeline-across-multiple-hard-to-treat-conditions-at-ASH-2022-11302022.html 2022-11-30T02:48:20.262Z https://www.astrazeneca-us.com/media/press-releases/2022/enhertu-fam-trastuzumab-deruxtecan-nxki-achieved-statistically-significant-overall-survival-reducing-the-risk-of-death-by-36-vs-trastuzumab-emtansine-t-dm1-in-patients-with-her2-positive-metastatic-breast-cancer-in-destiny-breast03-12072022.html 2022-12-07T02:07:00.369Z https://www.astrazeneca-us.com/media/press-releases/2022/camizestrant-significantly-delayed-disease-progression-in-advanced-er-positive-breast-cancer-adding-at-least-3-5-months-benefit-versus-faslodex-fulvestrant-12082022.html 2022-12-08T01:45:41.035Z https://www.astrazeneca-us.com/media/press-releases/2022/capivasertib-plus-faslodex-fulvestrant-reduced-the-risk-of-disease-progression-or-death-by-40-versus-faslodex-in-advanced-hr-positive-breast-cancer-12082022.html 2023-01-06T16:24:26.766Z https://www.astrazeneca-us.com/media/press-releases/2023.html 2023-01-11T12:51:14.753Z https://www.astrazeneca-us.com/media/press-releases/2023/airsupra-pt027-approved-in-the-us-for-asthma.html 2025-05-14T22:27:06.070Z https://www.astrazeneca-us.com/media/press-releases/2023/astrazeneca-begins-tender-offer-to-acquire-cincor-pharma-inc.html 2025-05-14T22:29:16.152Z https://www.astrazeneca-us.com/media/press-releases/2023/update-on-us-food-and-drug-administration-emergency-use-authorization-of-evusheld.html 2025-05-14T22:30:56.859Z https://www.astrazeneca-us.com/media/press-releases/2023/tezspire_approved_for_self_administration_in_the_us_with_a_new_pre_filled_pen.html 2025-05-14T22:32:14.788Z https://www.astrazeneca-us.com/media/press-releases/2023/astrazeneca-and-merck-present-final-results-of-key-secondary-overall-survival-endpoint-from-phase-III-propel-trial-at-asco-gu-cancers-symposium.html 2025-05-14T22:33:54.183Z https://www.astrazeneca-us.com/media/press-releases/2023/alexion-advances-commitment-to-transform-patient-outcomes-in-rare-neurological-diseases-at-aan-2023.html 2025-05-14T22:37:25.131Z https://www.astrazeneca-us.com/media/press-releases/2023/enhertu-fam-trastuzumab-deruxtecan-nxki-showed-clinically-meaningful-and-durable-responses-across-multiple-her2-expressing-tumor-types-in-destiny-pantumor02-phase-ii-trial-03062023.html 2024-06-21T20:20:17.125Z https://www.astrazeneca-us.com/media/press-releases/2023/imfinzi-significantly-improved-event-free-survival-in-aegean-phase-iii-trial-for-patients-with-resectable-non-small-cell-lung-cancer-03092023.html 2024-06-21T20:20:57.099Z https://www.astrazeneca-us.com/media/press-releases/2023/tagrisso-osimertinib-demonstrated-strong-overall-survival-benefit-in-the-adaura-phase-iii-trial-for-adjuvant-treatment-of-patients-with-early-stage-egfr-mutated-lung-cancer-03092023.html 2024-06-21T20:21:51.635Z https://www.astrazeneca-us.com/media/press-releases/2023/eplontersen-demonstrated-sustained-benefit-in-phase-iii-trial-for-hereditary-transthyretin-mediated-amyloid-polyneuropathy-attrv-pn-through-66-weeks.html 2024-06-21T20:23:50.164Z https://www.astrazeneca-us.com/media/press-releases/2023/lynparza-and-imfinzi-combination-improved-progression-free-survival-in-newly-diagnosed-patients-with-advanced-ovarian-cancer-without-tumor-brca-mutations-in-duo-phase-iii-trial.html 2024-06-21T20:25:00.380Z https://www.astrazeneca-us.com/media/press-releases/2023/astrazeneca-reinforces-commitment-to-advancing-science-for-patients-with-chronic-kidney-disease-and-hyperkalemia-at-nkf-spring-clinical-meeting-2023.html 2024-06-21T20:26:06.490Z https://www.astrazeneca-us.com/media/press-releases/2023/imfinzi-based-treatment-before-and-after-surgery-reduced-the-risk-of-disease-recurrence-progression-events-or-death-by-32-percent-in-resectable-non-small-cell-lung-cancer-in-the-aegean-phase-iii-trial-04162023.html 2024-06-21T20:26:43.304Z https://www.astrazeneca-us.com/media/press-releases/2023/neuro-ttransform-phase-iii-results-presented-at-aan-showed-eplontersen-demonstrated-consistent-and-sustained-improvement-in-all-measures-of-disease-and-quality-of-life-through-66-weeks.html 2024-06-21T20:27:15.226Z https://www.astrazeneca-us.com/media/press-releases/2023/farxiga-extended-in-the-us-to-reduce-risk-of-cardiovascular-death-and-hospitalization-for-heart-failure-to-a-broader-range-of-patients-05092023.html 2024-06-21T20:27:43.971Z https://www.astrazeneca-us.com/media/press-releases/2023/tagrisso-osimertinib-plus-chemotherapy-demonstrated-strong-improvement-in-progression-free-survival-for-patients-with-egfr-mutated-advanced-lung-cancer-in-flaura2-phase-iii-trial-05172023.html 2024-06-21T20:28:21.039Z https://www.astrazeneca-us.com/media/press-releases/2023/new-astrazeneca-data-presented-at-ats-2023-strengthen-the-body-of-evidence-supporting-early-intervention-with-breztri-in-copd.html 2024-06-21T20:28:50.412Z https://www.astrazeneca-us.com/media/press-releases/2023/astrazeneca-will-highlight-momentum-of-practice-changing-cancer-medicines-across-its-robust-pipeline-at-asco-2023-05252023.html 2024-06-21T20:29:36.789Z https://www.astrazeneca-us.com/media/press-releases/2023/imfinzi-durvalumab-plus-lynparza-olaparib-and-imfinzi-alone-both-significantly-improved-progression-free-survival-in-advanced-endometrial-cancer-when-added-to-chemotherapy-05262023.html 2024-06-21T20:30:28.532Z https://www.astrazeneca-us.com/media/press-releases/2023/lynparza-olaparib-plus-abiraterone-approved-in-the-us-for-the-treatment-of-brca-mutated-metastatic-castration-resistant-prostate-cancer.html 2024-06-21T20:31:12.595Z https://www.astrazeneca-us.com/media/press-releases/2023/imfinzi-durvalumab-plus-chemotherapy-significantly-improved-pathologic-complete-response-in-gastric-and-gastroesophageal-junction-cancers-in-matterhorn-phase-iii-trial-06022023.html 2024-06-21T20:31:47.612Z https://www.astrazeneca-us.com/media/press-releases/2023/lynparza-olaparib-and-imfinzi-durvalumab-combination-reduced-risk-of-disease-progression-or-death-by-37-vs-chemotherapy-and-bevacizumab-in-patients-with-advanced-ovarian-cancer-without-tumor-brca-mutations-in-the-duo-o-phase-iii-trial-06032023.html 2024-06-21T20:32:17.595Z https://www.astrazeneca-us.com/media/press-releases/2023/tagrisso-achieved-unprecedented-survival-in-early-stage-egfr-mutated-lung-cancer-with-88-of-patients-alive-at-five-years-in-adaura-phase-iii-trial-06042023.html 2024-06-21T20:32:49.630Z https://www.astrazeneca-us.com/media/press-releases/2023/andexxa-phase-iv-trial-stopped-early-after-achieving-pre-specified-criteria-on-hemostatic-efficacy-versus-usual-care.html 2024-06-21T20:36:34.085Z https://www.astrazeneca-us.com/media/press-releases/2023/enhertu-fam-trastuzumab-deruxtecan-nxki-demonstrated-clinically-meaningful-and-durable-responses-in-patients-across-multiple-her2-expressing-advanced-solid-tumors-06052023.html 2024-06-21T20:37:07.537Z https://www.astrazeneca-us.com/media/press-releases/2023/datopotamab-deruxtecan-combinations-showed-encouraging-tumor-responses-in-patients-with-advanced-non-small-cell-lung-cancer-in-tropion-lung02-phase-ib-trial-06052023.html 2024-06-21T20:37:33.247Z https://www.astrazeneca-us.com/media/press-releases/2023/capivasertib-in-combination-with-faslodex-fulvestrant-granted-priority-review-in-the-us-for-patients-with-advanced-hr-positive-breast-cancer-06122023.html 2024-06-21T20:38:03.614Z https://www.astrazeneca-us.com/media/press-releases/2023/astrazeneca-announces-innovative-partnership-with-vanguard-renewables-to-decarbonize-its-united-states-sites.html 2024-06-21T20:38:40.795Z https://www.astrazeneca-us.com/media/press-releases/2023/ipr-pharmaceuticals-first-pharmaceutical-company-in-puerto-rico-to-use-renewable-liquefied-natural-gas-to-power-its-cogenerator.html 2024-06-21T20:39:11.597Z https://www.astrazeneca-us.com/media/press-releases/2023/imfinzi-durvalumab-plus-imjudo-tremelimumab-actl-demonstrated-sustained-overall-survival-benefit-in-advanced-liver-cancer-with-an-unprecedented-one-in-four-patients-alive-at-four-years-in-himalaya-phase-iii-trial-06292023.html 2024-06-21T20:39:44.676Z https://www.astrazeneca-us.com/media/press-releases/2023/datopotamab-deruxtecan-met-dual-primary-endpoint-of-progression-free-survival-in-patients-with-advanced-non-small-cell-lung-cancer-in-tropion-lung01-phase-iii-trial.html 2024-06-21T20:41:43.836Z https://www.astrazeneca-us.com/media/press-releases/2023/enhertu-fam-trastuzumab-deruxtecan-nxki-demonstrated-clinically-meaningful-progression-free-survival-and-overall-survival-across-multiple-her2-expressing-advanced-solid-tumors-in-destiny-pantumor02-phase-ii-trial-07272023.html 2024-06-21T20:42:19.611Z https://www.astrazeneca-us.com/media/press-releases/2023/astrazeneca-data-at-wclc-advance-ambition-to-have-an-astrazeneca-medicine-for-more-than-half-of-all-patients-treated-for-lung-cancer-by-2030-08162023.html 2024-06-21T20:42:51.669Z https://www.astrazeneca-us.com/media/press-releases/2023/astrazeneca-urges-reexamination-of-unintended-consequences-of-inflation-reduction-act-on-american-cancer-and-rare-disease-patients-08232023.html 2024-06-21T20:44:06.477Z https://www.astrazeneca-us.com/media/press-releases/2023/astrazeneca-data-at-ers-2023-demonstrate-leadership-in-transforming-care-across-a-broad-respiratory-portfolio-of-inhaled-and-biologic-medicines.html 2024-06-21T20:44:48.243Z https://www.astrazeneca-us.com/media/press-releases/2023/flumist-quadrivalent-influenza-vaccine-live-intranasal-vaccine-now-available-in-the-us-for-2023-2024-flu-season.html 2024-06-21T20:45:23.271Z https://www.astrazeneca-us.com/media/press-releases/2023/update-on-us-regulatory-review-of-ultomiris-in-nmosd.html 2024-06-21T20:46:18.818Z https://www.astrazeneca-us.com/media/press-releases/2023/enhertu-fam-trastuzumab-deruxtecan-nxki-demonstrated-strong-and-durable-tumor-responses-in-previously-treated-her2-mutant-advanced-lung-cancer-in-destiny-lung02-phase-ii-trial-09112023.html 2024-06-21T20:47:49.256Z https://www.astrazeneca-us.com/media/press-releases/2023/tagrisso-osimertinib-plus-chemotherapy-extended-median-progression-free-survival-by-nearly-9-months-in-egfr-mutated-advanced-lung-cancer-in-flaura2-phase-iii-trial-09112023.html 2024-06-21T20:48:16.481Z https://www.astrazeneca-us.com/media/press-releases/2023/fasenra-met-the-primary-endpoint-in-the-mandara-phase-iii-trial-in-eosinophilic-granulomatosis-with-polyangiitis-egpa.html 2024-06-21T20:49:00.591Z https://www.astrazeneca-us.com/media/press-releases/2023/datopotamab-deruxtecan-demonstrated-statistically-significant-and-clinically-meaningful-progression-free-survival-benefit-in-patients-with-HR-positive-HER2-low-or-negative-breast-cancer-in-TROPION-Breast01-Phase-III-trial-09222023.html 2024-06-21T20:51:00.218Z https://www.astrazeneca-us.com/media/press-releases/2023/eplontersen-phase-iii-results-published-in-jama-showing-consistent-and-sustained-benefit-at-35-66-and-85-week-analyses.html 2024-06-21T20:52:08.801Z https://www.astrazeneca-us.com/media/press-releases/2023/astrazeneca-advances-scientific-leadership-across-multiple-cancers-with-first-data-from-four-pivotal-phase-iii-trials-at-esmo-10112023.html 2024-06-21T20:52:43.188Z https://www.astrazeneca-us.com/media/press-releases/2023/astrazeneca-announces-winners-of-the-fifth-annual-cancer-community-awards-10132023.html 2024-06-21T21:06:53.271Z https://www.astrazeneca-us.com/media/press-releases/2023/astrazeneca-foundation-awards-12-nonprofit-organizations-more-than-2m-to-advance-health-equity-10122023.html 2024-06-21T21:07:28.131Z https://www.astrazeneca-us.com/media/press-releases/2023/tagrisso-plus-chemotherapy-granted-priority-review-in-the-us-for-patients-with-egfr-mutated-advanced-lung-cancer-10162023.html 2024-06-21T21:08:24.548Z https://www.astrazeneca-us.com/media/press-releases/2023/imfinzi-plus-chemotherapy-more-than-doubled-pathologic-complete-response-rate-in-resectable-early-stage-gastric-and-gastroesophageal-junction-cancers-versus-chemotherapy-alone.html 2024-06-21T21:08:48.870Z https://www.astrazeneca-us.com/media/press-releases/2023/astrazeneca-reinforces-commitment-to-protecting-the-most-vulnerable-from-serious-infectious-diseases-at-idweek-2023.html 2024-06-21T21:09:49.335Z https://www.astrazeneca-us.com/media/press-releases/2023/large-real-world-evidence-studies-reveal-disproportionate-burden-of-coivd-19-on-the-immunocompromised.html 2024-06-21T21:10:34.104Z https://www.astrazeneca-us.com/media/press-releases/2023/tagrisso-osimertinib-plus-chemotherapy-reduced-the-risk-of-disease-progression-in-the-brain-by-42-percent-in-patients-with-egfr-mutated-advanced-lung-cancer-and-brain-metastases-at-baseline-10212023.html 2024-06-21T21:11:23.784Z https://www.astrazeneca-us.com/media/press-releases/2023/imfinz-durvalumab-plus-lynparza-olaparib-reduced-the-risk-of-disease-progression-or-death-by-45-vs-chemotherapy-in-advanced-or-recurrent-endometrial-cancer.html 2024-06-21T21:11:48.435Z https://www.astrazeneca-us.com/media/press-releases/2023/datopotamab-deruxtecan-plus-imfinzi-durvalumab-demonstrated-robust-and-durable-tumor-responses-in-1st-line-treatment-of-patients-with-metastatic-triple-negative-breast-cancer-in-begonia-phase-ib-ii-trial-10222023.html 2024-06-21T21:12:15.581Z https://www.astrazeneca-us.com/media/press-releases/2023/datopotamab-deruxtecan-significantly-extended-progression-free-survival-vs-chemotherapy-in-patients-with-hr-positive-her2-low-or-negative-breast-cancer-in-tropion-breast01-phase-iii-trial.html 2024-06-21T21:12:59.287Z https://www.astrazeneca-us.com/media/press-releases/2023/datopotamab-deruxtecan-improved-progression-free-survival-vs-chemotherapy-in-patients-with-previously-treated-non-small-cell-lung-cancer-in-tropion-lung01-phase-iii-trial-10232023.html 2024-06-21T21:13:25.889Z https://www.astrazeneca-us.com/media/press-releases/2023/enhertu-fam-trastuzumab-deruxtecan-nxki-demonstrated-clinically-meaningful-survival-across-multiple-her2-expressing-advanced-solid-tumors-in-destiny-pantumor02-phase-ii-trial.html 2024-06-21T21:14:02.404Z https://www.astrazeneca-us.com/media/press-releases/2023/us-food-and-drug-administration-accepts-for-review-astrazenecas-supplemental-biologics-license-application-for-self-administration-of-flumist-quadrivalent-influenza-vaccine-live-intranasal.html 2024-06-21T21:14:48.983Z https://www.astrazeneca-us.com/media/press-releases/2023/astrazeneca-announces-multi-year-partnership-with-nhl-and-nhlpa-hockey-fights-cancer-initiative-11022023.html 2024-06-21T21:15:30.508Z https://www.astrazeneca-us.com/media/press-releases/2023/zora-real-world-evidence-demonstrates-that-lokelma-substantially-increases-cardiorenal-patients-chances-of-maintaining-lifesaving-raasi-therapy.html 2024-06-21T21:16:17.106Z https://www.astrazeneca-us.com/media/press-releases/2023/zibotentan-dapagliflozin-combination-demonstrated-significant-albuminuria-reduction-in-patients-with-chronic-kidney-disease-and-proteinuria-in-zenith-ckd-phase-IIb-trial.html 2024-06-21T21:16:54.223Z https://www.astrazeneca-us.com/media/press-releases/2023/astrazeneca-to-leverage-its-global-industrial-scale-manufacturing-and-digital-capabilities-to-boost-us-renewable-natural-gas-productivity.html 2024-06-21T21:17:47.581Z https://www.astrazeneca-us.com/media/press-releases/2023/imfinzi-durvalumab-plus-bevacizumab-met-primary-endpoint-for-progression-free-survival-in-liver-cancer-eligible-for-embolization-in-emerald-1-phase-iii-trial-11092023.html 2024-06-21T21:18:31.143Z https://www.astrazeneca-us.com/media/press-releases/2023/truqap-capivasertib-plus-fulvestrant-approved-in-the-us-for-patients-with-advanced-hr-positive-breast-cancer-11172023.html 2024-06-21T21:18:56.287Z https://www.astrazeneca-us.com/media/press-releases/2023/astrazeneca-advances-scientific-leadership-in-hematology-at-ash-2023-11292023.html 2024-06-21T21:19:31.834Z https://www.astrazeneca-us.com/media/press-releases/2023/long-term-alpha-phase-iii-trial-data-showed-danicopan-as-add-on-to-ultomiris-or-soliris-sustained-sustained-clinical-improvements-in-subset-of-patients-with-phn-experiencing-clinically-significant-extravascular-hemolysis.html 2024-06-21T21:20:00.049Z https://www.astrazeneca-us.com/media/press-releases/2023/wainua-eplontersen-granted-first-ever-regulatory-approval-in-the-us-for-the-treatment-of-adults-with-polyneuropathy-of-hereditary-transthyretin-mediated-amyloidosis.html 2024-06-21T21:20:25.396Z https://www.astrazeneca-us.com/media/press-releases/2024.html 2024-01-12T17:02:07.515Z https://www.astrazeneca-us.com/media/press-releases/2024/airsupra-albuterol-budesonide-now-available-as-the-first-and-only-fda-approved-anti-inflammatory-rescue-option-for-asthma.html 2024-06-24T15:31:22.251Z https://www.astrazeneca-us.com/media/press-releases/2024/imfinzi-durvalumab-plus-transarterial-chemoembolization-tace-and-bevacizumab-reduced-the-risk-of-disease-progression-or-death-by-23-vs-tace-in-liver-cancer-eligible-for-embolization-01192024.html 2024-06-24T15:30:05.504Z https://www.astrazeneca-us.com/media/press-releases/2024/enhertu-fam-trastuzumab-deruxtecan-nxki-granted-priority-review-in-the-us-for-patients-with-metastatic-her2-positive-solid-tumors-01292024.html 2024-06-24T15:29:40.826Z https://www.astrazeneca-us.com/media/press-releases/2024/astrazeneca-expands-us-manufacturing-footprint-to-accelerate-ambitions-in-next-generation-cell-therapy-discovery-and-development.html 2024-06-24T15:29:17.263Z https://www.astrazeneca-us.com/media/press-releases/2024/tagrisso-osimertinib-with-the-addition-of-chemotherapy-approved-in-the-us-for-patients-with-egfr-mutated-advanced-lung-cancer.html 2024-06-24T15:28:29.714Z https://www.astrazeneca-us.com/media/press-releases/2024/datopotamab-deruxtecan-biologics-license-application-accepted-in-the-us-for-patients-with-previously-treated-advanced-nonsquamous-non-small-cell-lung-cancer.html 2024-06-24T15:28:07.364Z https://www.astrazeneca-us.com/media/press-releases/2024/tagrisso-osimertinib-demonstrated-overwhelming-efficacy-benefit-for-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer-in-laura-phase-iii-trial.html 2024-06-24T15:27:40.521Z https://www.astrazeneca-us.com/media/press-releases/2024/astrazeneca-awards-3-3m-for-nonprofit-health-equity-programming.html 2024-06-24T15:26:28.549Z https://www.astrazeneca-us.com/media/press-releases/2024/mandara-phase-iii-data-published-in-new-england-journal-of-medicine-show-remission-is-an-achievable-goal-in-eosinophilic-granulomatosis-with-polyangiitis-egpa-with-fasenra.html 2024-06-24T15:26:54.909Z https://www.astrazeneca-us.com/media/press-releases/2024/astrazeneca-announces-initiation-of-tharros-a-phase-iii-clinical-trial-investigating-the-potential-of-breztri-to-improve-cardiopulmonary-outcomes-in-people-with-copd.html 2024-06-24T15:27:20.438Z https://www.astrazeneca-us.com/media/press-releases/2024/astrazeneca-caps-patient-out-of-pocket-costs-at-35-per-month-for-its-us-inhaled-respiratory-portfolio.html 2024-06-24T15:26:03.339Z https://www.astrazeneca-us.com/media/press-releases/2024/lynparza-olaparib-and-imfinzi-durvalumab-demonstrated-strong-clinical-benefit-and-more-than-doubled-median-duration-of-response-vs-chemotherapy-in-patients-with-mismatch-repair-proficient-advanced-or-recurrent-endometrial-cancer.html 2024-06-24T15:02:58.061Z https://www.astrazeneca-us.com/media/press-releases/2024/tagrisso-osimertinib-with-the-addition-of-chemotherapy-showed-favorable-trend-in-overall-survival-in-egfr-mutated-advanced-lung-cancer-with-further-follow-up-in-flaura2-phase-iii-trial.html 2024-06-24T15:02:39.199Z https://www.astrazeneca-us.com/media/press-releases/2024/saphnelo-demonstrates-higher-rates-of-remission-in-patients-with-systemic-lupus-erythematosus-compared-to-standard-therapy-alone-over-4-year-period.html 2024-06-24T15:02:18.227Z https://www.astrazeneca-us.com/media/press-releases/2024/ultomiris-approved-in-the-us-for-the-treatment-of-adults-with-neuromyelitis-optica-spectrum-disorder.html 2024-06-24T15:01:51.256Z https://www.astrazeneca-us.com/media/press-releases/2024/voydeya-approved-in-the-us-as-add-on-therapy-to-ravulizumab-or-eculizumab-for-treatment-of-extravascular-hemolysis-in-adults-with-the-rare-disease-phn.html 2024-06-24T15:01:26.746Z https://www.astrazeneca-us.com/media/press-releases/2024/datopotamab-deruxtecan-biologics-license-application-accepted-in-the-us-for-patients-with-previously-treated-metastatic-hr-positive-her2-negative-breast-cancer.html 2024-06-24T15:00:41.596Z https://www.astrazeneca-us.com/media/press-releases/2024/imfinzi-significantly-improved-overall-survival-and-progression-free-survival-for-patients-with-limited-stage-small-cell-lung-cancer-in-adriatic-phase-III-trial.html 2024-06-24T14:59:22.888Z https://www.astrazeneca-us.com/media/press-releases/2024/enhertu-approved-in-the-us-as-first-tumor-agnostic-her2-directed-therapy-for-previously-treated-patients-with-metastatic-her2-positive-solid-tumors.html 2024-06-24T14:56:11.742Z https://www.astrazeneca-us.com/media/press-releases/2024/alexion-data-at-aan-2024-demonstrate-how-ultomiris-and-soliris-can-transform-outcomes-for-rare-neurological-diseases.html 2024-06-24T14:55:50.896Z https://www.astrazeneca-us.com/media/press-releases/2024/fasenra-approved-for-treatment-of-children-aged-6-to-11-with-severe-asthma.html 2024-06-24T14:50:28.364Z https://www.astrazeneca-us.com/media/press-releases/2024/imfinzi-durvalumab-plus-chemotherapy-doubled-overall-survival-rate-at-three-years-for-patients-with-advanced-biliary-tract-cancer-in-topaz-1-phase-iii-trial.html 2024-06-24T14:49:13.400Z https://www.astrazeneca-us.com/media/press-releases/2024/real-world-evidence-at-eccmid-2024-further-substantiates-the-continued-significant-and-disproportionate-risk-of-severe-covid-19-facing-immunocompromised-individuals.html 2024-06-24T14:37:50.870Z https://www.astrazeneca-us.com/media/press-releases/2024/enhertu-improved-pfs-in-her2-low-and-ultralow.html 2024-06-24T14:37:28.981Z https://www.astrazeneca-us.com/media/press-releases/2024/astrazeneca-unveils-latest-research-across-key-respiratory-and-immune-mediated-diseases-at-ats-2024-showcasing-strength-of-its-broad-pipeline-and-portfolio.html 2024-06-24T14:36:58.631Z https://www.astrazeneca-us.com/media/press-releases/2024/calquence-combination-regimen-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-in-1st-line-mantle-cell-lymphoma-in-echo-phase-iii-trial.html 2024-06-24T14:36:38.946Z https://www.astrazeneca-us.com/media/press-releases/2024/supernova-phase-iii-trial-of-sipavibart-long-acting-antibody-met-primary-endpoints-in-preventing-covid-19-in-immunocompromised-patient-population.html 2024-06-24T14:36:04.401Z https://www.astrazeneca-us.com/media/press-releases/2024/new-data-presented-at-ats-2024-show-the-potential-of-tezspire-to-play-a-role-in-the-future-treatment-of-chronic-obstructive-pulmonary-disease.html 2024-06-24T14:35:35.470Z https://www.astrazeneca-us.com/media/press-releases/2024/astrazeneca-furthers-ambition-to-transform-outcomes-in-early-lung-cancer-and-redefine-metastatic-breast-cancer-treatment-at-asco-2024.html 2024-06-24T14:34:53.608Z https://www.astrazeneca-us.com/media/press-releases/2024/astrazeneca-demonstrates-commitment-to-patients-living-with-amyloidosis-at-the-2024-international-symposium-on-amyloidosis.html 2024-06-24T14:34:02.626Z https://www.astrazeneca-us.com/media/press-releases/2024/datopotamab-deruxtecan-showed-clinically-meaningful-overall-survival-improvement-vs-chemotherapy-in-patients-with-advanced-nonsquamous-non-small-cell-lung-cancer-in-tropion-lung01-phase-iii-trial.html 2024-06-24T14:29:37.345Z https://www.astrazeneca-us.com/media/press-releases/2024/enhertu-fam-trastuzumab-deruxtecan-nxki-demonstrated-a-median-progression-free-survival-of-13-2-months-in-hr-positive-her2-low-and-her2-ultralow-metastatic-breast-cancer-following-one-or-more-lines-of-endocrine-therapy.html 2024-06-24T14:29:11.136Z https://www.astrazeneca-us.com/media/press-releases/2024/imfinzi-durvalumab-is-the-first-and-only-immunotherapy-to-show-survival-benefit-in-limited-stage-small-cell-lung-cancer-in-global-phase-iii-trial-reducing-the-risk-of-death-by-27-percent-vs-placebo.html 2024-06-24T14:28:43.492Z https://www.astrazeneca-us.com/media/press-releases/2024/tagrisso-osimertinib-reduced-the-risk-of-disease-progression-or-death-by-84-percent-in-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer-vs-placebo-in-laura-phase-iii-trial.html 2024-06-24T14:28:19.241Z https://www.astrazeneca-us.com/media/press-releases/2024/tagrisso-osimertinib-granted-priority-review-in-the-us-for-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer.html 2024-06-24T14:27:56.990Z https://www.astrazeneca-us.com/media/press-releases/2024/farxiga-approved-in-the-us-for-the-treatment-of-pediatric-type-two-diabetes.html 2024-06-24T14:27:29.779Z https://www.astrazeneca-us.com/media/press-releases/2024/calquence-acalabrutinib-plus-chemoimmunotherapy-reduced-the-risk-of-disease-progression-or-death-by-27-percentage-vs-standard-of-care-in-patients-with-untreated-mantle-cell-lymphoma-in-echo-phase-iii-trial.html 2024-06-24T14:27:02.014Z https://www.astrazeneca-us.com/media/press-releases/2024/imfinzi-durvalumab-plus-chemotherapy-approved-in-the-us-for-mismatch-repair-deficient-advanced-or-recurrent-endometrial-cancer.html 2024-06-24T14:26:34.638Z https://www.astrazeneca-us.com/media/press-releases/2024/update-on-the-capitello-290-phase-iii-trial-for-truqap-capivasertib-plus-chemotherapy-in-advanced-or-metastatic-triple-negative-breast-cancer.html 2024-06-24T14:24:54.912Z https://www.astrazeneca-us.com/media/press-releases/2024/imfinzi-durvalumab-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-event-free-survival-and-overall-survival-for-muscle-invasive-bladder-cancer-in-niagara-phase-iii-trial.html 2024-06-25T10:54:07.753Z https://www.astrazeneca-us.com/media/press-releases/2024/fda-advisory-committee-reviewed-imfinzi-durvalumab-for-treatment-of-resectable-non-small-cell-lung-cancer-based-on-aegean-phase-iii-trial-results.html 2024-07-25T20:19:56.779Z https://www.astrazeneca-us.com/media/press-releases/2024/fixed-duration-calquence-acalabrutinib-plus-venetoclax-with-or-without-obinutuzumab-significantly-improved-progression-free-survival-in-first-line-chronic-lymphocytic-leukemia-in-amplify-phase-iii-trial.html 2024-07-29T00:26:39.170Z https://www.astrazeneca-us.com/media/press-releases/2024/astrazeneca-responds-to-white-house-prepare-call-to-action-to-bolster-community-and-health-system-resilience-to-climate-change.html 2024-07-30T20:57:09.422Z https://www.astrazeneca-us.com/media/press-releases/2024/imfinzi-durvalumab-granted-priority-review-and-breakthrough-therapy-designation-for-patients-with-limited-stage-small-cell-lung-cancer-in-the-us.html 2024-08-15T20:40:59.985Z https://www.astrazeneca-us.com/media/press-releases/2024/imfinzir-durvalumab-approved-in-the-us-for-the-treatment-of-resectable-non-small-cell-lung-cancer-before-and-after-surgery.html 2024-08-16T11:03:24.632Z https://www.astrazeneca-us.com/media/press-releases/2024/astrazeneca-advances-ambition-to-improve-standards-of-care-in-multiple-cancer-types-at-wclc-and-esmo-2024.html 2024-09-03T10:48:37.195Z https://www.astrazeneca-us.com/media/press-releases/2024/novel-computational-pathology-based-trop2-biomarker-for-dato-dxd-was-predictive-of-clinical-outcomes-in-patients-with-nsclc-in-tropion-lung01-phase-iii-trial.html 2024-09-08T16:05:43.268Z https://www.astrazeneca-us.com/media/press-releases/2024/dato-dxd-showed-median-overall-survival-of-146-months-in-patients-with-advanced-nsclc-in-tropion-lung01-phase-iii-trial.html 2024-09-09T21:16:32.344Z https://www.astrazeneca-us.com/media/press-releases/2024/enhertur-fam-trastuzumab-deruxtecan-nxki-showed-substantial-clinical-activity-in-patients-with-her2-positive-metastatic-breast-cancer-and-brain-metastases.html 2024-09-13T12:18:56.718Z https://www.astrazeneca-us.com/media/press-releases/2024/imfinzi-perioperative-regimen-reduced-risk-recurrence-by-32-risk-death-by-25-vs-neoadjuvant-chemotherapy-alone-in-mibc-niagara-phase-iii-trial.html 2024-09-15T14:11:39.532Z https://www.astrazeneca-us.com/media/press-releases/2024/imfinzi-plus-imjudo-demonstrated-unprecedented-overall-survival-alc-with-one-in-five-patients-surviving-five-years-himalaya-phase-iii-trial.html 2024-09-16T04:57:46.818Z https://www.astrazeneca-us.com/media/press-releases/2024/fasenra-approved-in-the-us-for-eosinophilic-granulomatosis-with-polyangiitis.html 2025-05-14T22:36:23.029Z https://www.astrazeneca-us.com/media/press-releases/2024/astrazeneca-announces-start-of-recruitment-in-2-new-phase-iii-trials-evaluating-saphnelo-in-cle-and-in-iim.html 2024-09-19T04:55:12.765Z https://www.astrazeneca-us.com/media/press-releases/2024/flumist-approved-for-self-administration-in-the-us.html 2024-09-20T19:46:34.895Z https://www.astrazeneca-us.com/media/press-releases/2024/datopotamab-deruxtecan-final-overall-survival-results-reported-in-patients-with-metastatic-hr-positive-her2-low-or-negative-breast-cancer-in-tropion-breast01-phase-iii-trial.html 2024-09-23T10:15:50.508Z https://www.astrazeneca-us.com/media/press-releases/2024/tagrisso-osimertinib-approved-in-the-us-for-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer.html 2024-09-30T19:49:07.494Z https://www.astrazeneca-us.com/media/press-releases/2024/enhertu-granted-priority-review-us-for-patients-her2-low-or-her2-ultralow-metastatic-breast-cancer-who-have-received-at-least-1-line-endocrine-therapy.html 2024-10-01T04:39:48.267Z https://www.astrazeneca-us.com/media/press-releases/2024/calquence-granted-priority-review-in-the-us-for-patients-with-untreated-mantle-cell-lymphoma.html 2024-10-02T22:29:15.480Z https://www.astrazeneca-us.com/media/press-releases/2024/airsupra-positive-results-phase-iii-batura-trial.html 2025-05-14T22:43:38.758Z https://www.astrazeneca-us.com/media/press-releases/2024/astrazeneca-showcases-strength-of-hematology-portfolio-and-pipeline-at-ash-2024.html 2024-11-07T06:30:26.358Z https://www.astrazeneca-us.com/media/press-releases/2024/tezspire-met-both-co-primary-endpoints-in-the-Phase-iii-waypoint-trial-in-patients-with-chronic-rhinosinusitis-with-nasal-polyps.html 2025-05-14T22:39:00.318Z https://www.astrazeneca-us.com/media/press-releases/2024/datopotamab-deruxtecan-new-bla-submitted-for-accelerated-approval-in-the-us-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer.html 2024-11-12T09:04:53.213Z https://www.astrazeneca-us.com/media/press-releases/2024/astrazeneca-awards-35m-for-projects-to-improve-access-to-healthcare-for-patients-across-the-us.html 2024-11-20T02:06:18.431Z https://www.astrazeneca-us.com/media/press-releases/2024/truqap-combination-in-pten-deficient-metastatic-hormone-sensitive-prostate-cancer-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-radiographic-progression-free-survival-in-capitello-281-phase-iii-trial.html 2024-11-25T05:29:34.440Z https://www.astrazeneca-us.com/media/press-releases/2024/astrazeneca-foundation-awards-six-nonprofit-organizations-more-than-1-4m-in-second-year-funding-to-help-advance-health-equity-and-increase-access-to-healthcare.html 2024-11-25T15:48:57.350Z https://www.astrazeneca-us.com/media/press-releases/2024/imfinzi-durvalumab-approved-us-first-immunotherapy-regimen-patients-limited-stage-small-cell-lung-cancer.html 2024-12-05T12:07:18.141Z https://www.astrazeneca-us.com/media/press-releases/2024/imfinzi-durvalumab-granted-priority-review-in-the-us-for-patients-with-muscle-invasive-bladder-cancer.html 2024-12-06T07:19:43.900Z https://www.astrazeneca-us.com/media/press-releases/2024/fixed-duration-calquence-plus-venetoclax-demonstrated-superior-pfs-vs-standard-care-previously-untreated-cll-with-77-of-patients-progression-free-3-years-amplify-phase-iii-trial.html 2024-12-13T14:46:45.087Z https://www.astrazeneca-us.com/media/press-releases/2024/datopotamab-deruxtecan-granted-breakthrough-therapy-designation-in-US-for-patients-with-previously-treated-advanced-EGFR-mutated-non-small-cell-lung-cancer.html 2024-12-09T12:10:30.312Z https://www.astrazeneca-us.com/media/press-releases/2024/lynparza-demonstrated-clinically-meaningful-prolonged-survival-benefit-in-early-breast-cancer-in-olympia-phase-iii-trial.html 2024-12-11T13:12:02.722Z https://www.astrazeneca-us.com/media/press-releases/2025.html 2025-02-26T10:48:55.668Z https://www.astrazeneca-us.com/media/press-releases/2025/calquence-acalabrutinib-plus-chemoimmunotherapy-approved-in-the-us-for-patients-with-previously-untreated-mantle-cell-lymphoma.html 2025-01-17T10:48:09.975Z https://www.astrazeneca-us.com/media/press-releases/2025/datroway-datopotamab-deruxtecan-dlnk-approved-in-the-us-for-patients-with-previously-treated-metastatic-hr-positive-her2-negative-breast-cancer.html 2025-01-28T00:18:34.284Z https://www.astrazeneca-us.com/media/press-releases/2025/enhertu-fam-trastuzumab-deruxtecan-nxki-approved-in-the-us-as-first-her2-directed-therapy-for-patients-with-her2-low-or-her2-ultralow-metastatic-breast-cancer-following-disease-progression-after-one-or-more-endocrine-therapies.html 2025-05-21T11:40:27.903Z https://www.astrazeneca-us.com/media/press-releases/2025/imfinzi-durvalumab-perioperative-regimen-improved-event-free-survival-and-overall-survival-across-muscle-invasive-bladder-cancer-patients-regardless-of-complete-pathology-response-status-in-post-hoc-exploratory-analysis-of-niagara-phase-III-trial.html 2025-02-14T16:10:53.751Z https://www.astrazeneca-us.com/media/press-releases/2025/datopotamab-deruxtecan-granted-priority-review-in-the-us-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer.html 2025-02-26T10:48:55.668Z https://www.astrazeneca-us.com/media/press-releases/2025/Camizestrant-demonstrated-highly-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-in-1st-line-advanced-HR-positive-breast-cancer-with-an-emergent-ESR1-tumor-mutation-in-SERENA-6-Phase-III-trial.html 2025-02-26T12:23:21.475Z https://www.astrazeneca-us.com/media/press-releases/2025/Positive-results-from-the-TEZSPIRE-Phase-III-WAYPOINT-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps.html 2025-05-14T22:45:14.657Z https://www.astrazeneca-us.com/media/press-releases/2025/IMFINZI-durvalumab-based-regimen-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-event-free-survival-in-resectable-early-stage-gastric-and-gastroesophageal-junction-cancers.html 2025-03-07T11:55:04.860Z https://www.astrazeneca-us.com/media/press-releases/2025/AstraZeneca-and-Erin-Andrews-team-up-to-inspire-fans-to-Get-Body-Checked-Against-Cancer.html 2025-03-14T14:19:27.115Z https://www.astrazeneca-us.com/media/press-releases/2025/Eneboparatide-met-primary-endpoint-of-normalizing-serum-calcium-in-adults-with-hypoparathyroidism-at-24-weeks-in-CALYPSO-Phase-III-trial.html 2025-03-17T11:06:57.167Z https://www.astrazeneca-us.com/media/press-releases/2025/New-study-results-reinforce-TAGRISSO-osimertinib-as-the-backbone-therapy-for-EGFR-mutated-lung-cancer-across-stages-and-settings.html 2025-03-31T10:37:19.962Z https://www.astrazeneca-us.com/media/press-releases/2025/Alexion-data-presented-at-the-2025-AAN-Annual-Meeting-highlight-advancements-in-improving-care-for-rare-neurological-diseases.html 2025-03-28T22:58:09.478Z https://www.astrazeneca-us.com/media/press-releases/2025/IMFINZI-durvalumab-approved-in-the-US-as-first-and-only-perioperative-immunotherapy-for-patients-with-muscle-invasive-bladder-cancer.html 2025-03-31T11:02:22.114Z https://www.astrazeneca-us.com/media/press-releases/2025/AZD0780-a-novel-oral-PCSK9-inhibitor-demonstrated-significant-LDL-cholesterol-LDL-C-reduction-in-PURSUIT-Phase-IIb-trial.html 2025-03-31T14:03:31.898Z https://www.astrazeneca-us.com/media/press-releases/2025/ENHERTU-fam-trastuzumab-deruxtecan-nxki-plus-pertuzumab-demonstrated-highly-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-THP-as-1st-line-therapy-for-patients-with-HER2-positive-metastatic-breast-cancer.html 2025-04-21T11:18:47.577Z https://www.astrazeneca-us.com/media/press-releases/2025/iPR-Pharmaceuticals-Earns-its-1st-EPAs-ENERGY-STAR-Certification-for-Superior-Energy-Efficiency.html 2025-04-22T18:22:36.010Z https://www.astrazeneca-us.com/media/press-releases/2025/Update-on-CAPItello-280-Phase-III-trial-of-TRUQAP-capivasertib-in-metastatic-castration-resistant-prostate-cancer.html 2025-04-29T11:12:52.984Z https://www.astrazeneca-us.com/media/press-releases/2025/Breztri-met-primary-endpoints-in-kalos-and-logos-phase-III-trials-in-asthma.html 2025-05-14T22:46:31.831Z https://www.astrazeneca-us.com/media/press-releases/2025/enhertu-fam-trastuzumab-deruxtecan-nxki-improved-pcr-in-early-stage-breast-cancer.html 2025-05-07T10:25:49.267Z https://www.astrazeneca-us.com/media/press-releases/2025/IMFINZI-durvalumab-regimen-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-disease-free-survival-for-high-risk-non-muscle-invasive-bladder-cancer-in-POTOMAC-Phase-III-trial.html 2025-05-09T10:51:35.806Z https://www.astrazeneca-us.com/media/press-releases/2025/astrazeneca-to-showcase-latest-research-on-comprehensive-portfolio-and-pipeline-aimed-at-transforming-respiratory-diseases-at-ATS-2025.html 2025-05-14T22:47:52.150Z https://www.astrazeneca-us.com/media/press-releases/2025/Statistically-significant-and-clinically-meaningful-BATURA-Phase-III-trial-results-provide-new-evidence-for-AIRSUPRA-as-standard-of-care-for-as-needed-rescue-treatment-in-asthma.html 2026-05-01T20:35:18.220Z https://www.astrazeneca-us.com/media/press-releases/2025/AstraZenecas-record-seventh-year-of-plenary-data-at-ASCO-furthers-ambition-to-redefine-breast-cancer-care-and-transform-outcomes-in-gastric-cancer.html 2025-05-21T11:22:04.173Z https://www.astrazeneca-us.com/media/press-releases/2025/IMFINZI-durvalumab-regimen-reduced-risk-of-progression-recurrence-or-death-by-29-percent-in-early-stage-gastric-cancer-vs-chemotherapy-alone-in-MATTERHORN-Phase-III-trial.html 2025-06-01T12:08:17.056Z https://www.astrazeneca-us.com/media/press-releases/2025/Camizestrant-reduced-the-risk-of-disease-progression-or-death-by-56-in-patients-with-advanced-HR-positive-breast-cancer-with-an-emergent-ESR1-tumor-mutation-in-SERENA-6-Phase-III-trial.html 2025-06-01T12:39:47.890Z https://www.astrazeneca-us.com/media/press-releases/2025/ENHERTU-fam-trastuzumab-deruxtecan-nxki-plus-pertuzumab-reduced-the-risk-of-disease-progression-or-death-by-44-percent-vs-THP-as-1st-line-therapy-in-patients-with-HER2-positive-metastatic-breast-cancer-in-DESTINY-Breast09-Phase-III-trial.html 2025-06-02T11:08:59.330Z https://www.astrazeneca-us.com/media/press-releases/2025/astrazenecas-mount-vernon-ndiana-supply-site-earns-its-first-epa-energy-star-certification-for-superior-energy-efficiency.html 2025-06-06T16:14:18.415Z https://www.astrazeneca-us.com/media/press-releases/2025/Datroway-approved-in-the-US-for-patients-with-previously-treated-advanced-EGFR-mutated-non-small-cell-lung-cancer.html 2025-06-24T10:02:09.045Z https://www.astrazeneca-us.com/media/press-releases/2025/baxdrostat-met-the-primary-and-all-secondary-endpoints-in-BaxHTN-Phase-III-trial-in-patients-with-uncontrolled-or-treatment-resistant-hypertension.html 2025-07-14T11:41:49.491Z https://www.astrazeneca-us.com/media/press-releases/2025/Update-on-CARES-Phase-III-clinical-program-of-anselamimab-in-light-chain-amyloidosis.html 2025-07-16T14:37:51.390Z https://www.astrazeneca-us.com/media/press-releases/2025/TAGRISSO-osimertinib-plus-chemotherapy-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-in-EGFR-mutated-advanced-lung-cancer.html 2025-07-21T10:30:47.838Z https://www.astrazeneca-us.com/media/press-releases/2025/AstraZeneca-plans-to-invest-50-billion-in-America-for-medicines-manufacturing-and-R-and-D.html 2025-07-21T18:11:54.916Z https://www.astrazeneca-us.com/media/press-releases/2025/Update-on-CARES-Phase-III-clinical-program-of-anselamimab-in-light-chain-amyloidosis1.html 2025-07-24T15:30:18.801Z https://www.astrazeneca-us.com/media/press-releases/2025/IMFINZI-durvalumab-granted-priority-review-and-breakthrough-therapy-designation-in-the-US-for-patients-with-resectable-early-stage-gastric-and-gastroesophageal-junction-cancers.html 2025-07-28T10:28:16.179Z https://www.astrazeneca-us.com/media/press-releases/2025/FLUMIST-the-nations-only-nasal-spray-flu-vaccine-now-available-for-home-delivery.html 2026-05-01T20:40:43.083Z https://www.astrazeneca-us.com/media/press-releases/2025/Baxdrostat-demonstrated-statistically-significant-and-clinically-meaningful-reduction-in-systolic-blood-pressure-in-patients-with-hard-to-control-hypertension-in-the-BaxHTN-Phase-III-trial.html 2025-08-30T11:59:47.104Z https://www.astrazeneca-us.com/media/press-releases/2025/TAGRISSO-osimertinib-plus-chemotherapy-demonstrated-a-median-overall-survival-of-nearly-four-years-the-longest-benefit-ever-reported-in-a-global-Phase-III-trial-in-EGFR-mutated-advanced-lung-cancer.html 2025-09-07T10:51:18.698Z https://www.astrazeneca-us.com/media/press-releases/2025/SAPHNELO-self-administration-TULIP-SC-Phase-III-trial-meets-primary-endpoint-in-patients-with-systemic-lupus-erythematosus-based-on-an-interim-analysis.html 2026-05-01T20:44:49.633Z https://www.astrazeneca-us.com/media/press-releases/2025/Update-on-the-RESOLUTE-Phase-III-trial-for-FASENRA-in-chronic-obstructive-pulmonary-disease.html 2026-05-01T20:41:34.468Z https://www.astrazeneca-us.com/media/press-releases/2025/AIRSUPRA-albuterol-budesonide-US-prescribing-information-updated-to-reflect-the-statistically-significant-severe-exacerbation-risk-reduction-in-patients-with-mild-asthma-compared-with-albuterol.html 2026-05-01T20:43:38.951Z https://www.astrazeneca-us.com/media/press-releases/2025/ENHERTU-fam-trastuzumab-deruxtecan-nxki-plus-pertuzumab-granted-Priority-Review-in-the-US-as-1st-line-treatment-for-patients-with-HER2-positive-metastatic-breast-cancer.html 2025-09-23T22:10:47.889Z https://www.astrazeneca-us.com/media/press-releases/2025/AstraZeneca-launches-direct-to-consumer-platform-to-expand-access-to-medications-for-US-patients-including-those-living-with-chronic-conditions.html 2025-09-26T13:08:29.616Z https://www.astrazeneca-us.com/media/press-releases/2025/enhertu-fam-trastuzumab-deruxtecan-nxki-improved-idfs-in-early-ebc-in-db-05.html 2025-09-29T06:46:39.165Z https://www.astrazeneca-us.com/media/press-releases/2025/datroway-datopotomab-deruxtecan-dlnk-improved-os-and-pfs-in-tb-02.html 2025-10-05T23:58:33.889Z https://www.astrazeneca-us.com/media/press-releases/2025/Baxdrostat-met-the-primary-endpoint-in-Bax24-Phase-III-trial-in-patients-with-resistant-hypertension.html 2025-10-07T11:03:26.760Z https://www.astrazeneca-us.com/media/press-releases/2025/astrazeneca-plans-to-increase-investment-and-scope-of-its-virginia-manufacturing-facility-to-four-point-five-billion-creating-thirty-six-hundred-new-jobs.html 2025-10-10T19:16:30.515Z https://www.astrazeneca-us.com/media/press-releases/2025/astrazeneca-announces-historic-agreement-with-us-government-to-lower-the-cost-of-medicines-for-american-patients.html 2025-10-10T21:58:36.411Z https://www.astrazeneca-us.com/media/press-releases/2025/AstraZeneca-furthers-ambition-to-redefine-cancer-care-with-first-data-from-four-major-pivotal-trials-at-ESMO.html 2025-10-13T06:58:38.808Z https://www.astrazeneca-us.com/media/press-releases/2025/AstraZeneca-opens-expanded-manufacturing-facility-in-Texas.html 2025-10-15T11:57:59.379Z https://www.astrazeneca-us.com/media/press-releases/2025/IMFINZI-durvalumab-regimen-reduced-the-risk-of-disease-recurrence-or-death-by-32-percent-in-high-risk-non-muscle-invasive-bladder-cancer-in-the-POTOMAC-Phase-III-trial.html 2025-10-17T11:40:58.662Z https://www.astrazeneca-us.com/media/press-releases/2025/TEZSPIRE-approved-in-the-US-for-chronic-rhinosinusitis-with-nasal-polyps.html 2026-05-01T20:45:40.028Z https://www.astrazeneca-us.com/media/press-releases/2025/IMFINZI-durvalumab-based-regimen-reduced-the-risk-of-death-by-22-percent-in-early-gastric-cancer-vs-chemotherapy-alone-in-MATTERHORN-Phase-III-trial.html 2025-10-17T12:00:45.343Z https://www.astrazeneca-us.com/media/press-releases/2025/ENHERTU-fam-trastuzumab-deruxtecan-nxki-reduced-the-risk-of-disease-recurrence-or-death-by-53-percent-vs-T-DM1-in-patients-with-high-risk-HER2-positive-early-breast-cancer-following-neoadjuvant-therapy-in-DESTINY-Breast05-Phase-III-trial.html 2025-10-28T15:55:19.079Z https://www.astrazeneca-us.com/media/press-releases/2025/ENHERTU-fam-trastuzumab-deruxtecan-nxki-followed-by-THP-before-surgery-resulted-in-a-pathologic-complete-response-in-67-percent-of-patients-with-high-risk-HER2-positive-early-stage-breast-cancer-in-DESTINY-Breast11-Phase-III-trial.html 2025-10-28T17:51:32.484Z https://www.astrazeneca-us.com/media/press-releases/2025/datroway-datopotamab-deruxtecan-dlnk-improved-median-OS-in-TB-02.html 2025-10-19T16:53:23.416Z https://www.astrazeneca-us.com/media/press-releases/2025/astrazeneca-foundation-awards-over-1-4-m-in-third-year-grants-to-advance-healthcare-access-announces-2026-call-for-applications.html 2025-10-21T20:57:24.745Z https://www.astrazeneca-us.com/media/press-releases/2025/Alexion-data-presented-at-2025-AANEM-Annual-Meeting-and-MGFA-Scientific-Session-underscores-pioneering-C5-inhibition-leadership-in-gMG.html 2025-10-29T16:29:31.268Z https://www.astrazeneca-us.com/media/press-releases/2025/gefurulimab-nanobody-met-phase-iii-endpoints.html 2025-10-30T14:34:09.370Z https://www.astrazeneca-us.com/media/press-releases/2025/statistically-significant-NATRON-Phase-III-trial-results-for-hypereosinophilic-syndrome-show-FASENRA-delayed-time-to-first-flare-or-worsening-of-disease.html 2026-05-01T20:46:19.946Z https://www.astrazeneca-us.com/media/press-releases/2025/Baxdrostat-demonstrated-a-statistically-significant-and-highly-clinically-meaningful-placebo-adjusted-reduction-of-14-mmHg-in-24-hour-ambulatory-systolic-blood-pressure-in-patients-with-resistant-hypertension-in-the-Bax24-Phase-III-trial.html 2025-11-09T21:23:30.273Z https://www.astrazeneca-us.com/media/press-releases/2025/KOSELUGO-selumetinib-approved-in-the-US-for-adults-with-neurofibromatosis-type-1.html 2025-11-20T14:59:49.775Z https://www.astrazeneca-us.com/media/press-releases/2025/AstraZeneca-plans-2-billion-manufacturing-investment-in-Maryland-supporting-2600-jobs-and-catalyzing-economic-growth.html 2025-11-21T20:14:47.214Z https://www.astrazeneca-us.com/media/press-releases/2025/IMFINZI-approved-in-the-US-as-first-and-only-perioperative-immunotherapy-for-patients-with-early-gastric-and-gastroesophageal-cancers.html 2025-11-25T23:31:10.675Z https://www.astrazeneca-us.com/media/press-releases/2025/Baxdrostat-New-Drug-Application-accepted-under-FDA-Priority-Review-in-the-US-for-patients-with-hard-to-control-hypertension.html 2025-12-02T14:22:08.631Z https://www.astrazeneca-us.com/media/press-releases/2025/AstraZeneca-advances-hematology-and-cell-therapy-ambition-with-largest-ever-presence-at-ASH.html 2025-12-04T11:56:55.386Z https://www.astrazeneca-us.com/media/press-releases/2025/ENHERTU-fam-trastuzumab-deruxtecan-nxki-plus-pertuzumab-approved-in-the-US-as-first-new-treatment-in-a-decade-for-the-1st-line-treatment-of-patients-with-HER2-positive-metastatic-breast-cancer.html 2025-12-15T21:44:13.421Z https://www.astrazeneca-us.com/media/press-releases/2025/ENHERTU-fam-trastuzumab-deruxtecan-nxki-granted-Breakthrough-Therapy-Designation-in-the-US-as-post-neoadjuvant-therapy-for-patients-with-HER2-positive-early-breast-cancer.html 2025-12-21T21:41:30.518Z https://www.astrazeneca-us.com/media/press-releases/2025/Update-on-LATIFY-Phase-III-trial-of-ceralasertib-plus-IMFINZ-durvalumab-in-previously-treated-advanced-non-small-cell-lung-cancer.html 2025-12-22T20:39:08.969Z https://www.astrazeneca-us.com/media/press-releases/2026.html 2026-01-07T15:56:37.267Z https://www.astrazeneca-us.com/media/press-releases/2026/Rick-R-Suarez-appointed-US-President-and-Head-of-US-BioPharmaceuticals-Business-Unit.html 2026-01-08T12:04:26.891Z https://www.astrazeneca-us.com/media/press-releases/2026/AstraZeneca-begins-trading-on-the-New-York-Stock-Exchange.html 2026-02-02T11:01:20.601Z https://www.astrazeneca-us.com/media/press-releases/2026/DATROWAY-datopotamab-deruxtecan-dlnk-granted-Priority-Review-in-the-US-as-1st-line-treatment-for-patients-with-metastatic-triple-negative-breast-cancer-who-are-not-candidates-for-immunotherapy.html 2026-02-03T11:46:33.137Z https://www.astrazeneca-us.com/media/press-releases/2026/AstraZeneca-awards-3-4-million-for-programs-to-improve-access-to-healthcare-for-patients-across-the-US.html 2026-06-09T20:09:12.858Z https://www.astrazeneca-us.com/media/press-releases/2026/Positive-and-clinically-meaningful-results-from-the-Phase-III-KALOS-and-LOGOS-trials-for-BREZTRI-in-patients-with-uncontrolled-asthma-published-in-The-Lancet-Respiratory-Medicine.html 2026-05-01T20:47:28.088Z https://www.astrazeneca-us.com/media/press-releases/2026/CALQUENCE-plus-venetoclax-approved-in-the-US-as-first-all-oral-fixed-duration-combination-for-patients-with-chronic-lymphocytic-leukemia-in-the-1st-line-setting.html 2026-02-20T14:20:00.232Z https://www.astrazeneca-us.com/media/press-releases/2026/ENHERTU-fam-trastuzumab-deruxtecan-nxki-granted-Priority-Review-in-the-US-as-post-neoadjuvant-treatment-for-patients-with-HER2-positive-early-breast-cancer.html 2026-03-30T16:18:51Z https://www.astrazeneca-us.com/media/press-releases/2026/AstraZeneca-and-Joshua-Jackson-partner-to-encourage-fans-to-Get-Body-Checked-Against-Cancer.html 2026-03-10T12:34:55Z https://www.astrazeneca-us.com/media/press-releases/2026/Tozorakimab-met-primary-endpoint-in-both-OBERON-and-TITANIA-Phase-III-trials-in-patients-with-COPD.html 2026-05-01T20:47:51.198Z https://www.astrazeneca-us.com/media/press-releases/2026/Efzimfotase-alfa-demonstrated-positive-results-from-global-Phase-III-clinical-program-in-hypophosphatasia.html 2026-03-31T10:36:07Z https://www.astrazeneca-us.com/media/press-releases/2026/IMFINZI-plus-IMJUDO-combined-with-lenvatinib-and-transarterial-chemoembolization-TACE-showed-trend-toward-improved-overall-survival.html 2026-04-02T10:35:08Z https://www.astrazeneca-us.com/media/press-releases/2026/Alexion-data-at-2026-AAN-Annual-Meeting-reflects-industry-leading-portfolio-and-commitment-to-enhancing-care-across-rare-diseases.html 2026-04-10T18:11:32Z https://www.astrazeneca-us.com/media/press-releases/2026/Tozorakimab-met-primary-endpoint-in-Phase-III-MIRANDA-trial-in-patients-with-COPD.html 2026-05-01T20:48:07.013Z https://www.astrazeneca-us.com/media/press-releases/2026/ULTOMIRIS-ravulizumab-cwvz-demonstrated-statistically-significant-and-clinically-meaningful-reduction-of-proteinuria-in-adults-with-immunoglobulin-A-nephropathy-in-I-CAN-Phase-III-trial.html 2026-04-23T18:03:08.226Z https://www.astrazeneca-us.com/media/press-releases/2026/SAPHNELO-approved-in-the-US-for-subcutaneous-self-administration-as-a-new-autoinjector-for-the-treatment-of-systemic-lupus-erythematosus.html 2026-05-01T20:48:40.889Z https://www.astrazeneca-us.com/media/press-releases/2026/BREZTRI-approved-in-the-US-for-asthma-as-first-and-only-triple-therapy-for-patients-12-years-of-age-and-older.html 2026-05-01T20:49:07.973Z https://www.astrazeneca-us.com/media/press-releases/2026/Update-on-FDA-Advisory-Committee-vote-on-camizestrant-in-combination-with-a-CDK-4-6-inhibitor-for-advanced-HR-positive-breast-cancer.html 2026-04-30T22:35:43.832Z https://www.astrazeneca-us.com/media/press-releases/2026/TRUQAP-capivasertib-recommended-by-FDA-Advisory-Committee-for-PTEN-deficient-metastatic-hormone-sensitive-prostate-cancer.html 2026-05-01T01:08:44.289Z https://www.astrazeneca-us.com/media/press-releases/2026/Eneboparatide-normalized-serum-calcium-and-achieved-independence-from-active-vitamin-D-and-oral-calcium-supplements-in-31-point-1-percent-of-adults-with-hypoparathyroidism-at-week-24-in-CALYPSO-Phase-III-trial.html 2026-05-12T11:24:47.572Z https://www.astrazeneca-us.com/media/press-releases/2026/Perioperative-IMFINZI-durvalumab-plus-neoadjuvant-EV-showed-statistically-significant-and-clinically-meaningful-improvements-in-event-free-survival-and-overall-survival-in-muscle-invasive-bladder-cancer-in-the-Phase-III-VOLGA-trial.html 2026-05-14T10:22:28.796Z https://www.astrazeneca-us.com/media/press-releases/2026/IMFINZI-durvalumab-regimen-reduced-early-disease-recurrence-among-high-risk-non-muscle-invasive-bladder-cancer-patients-in-POTOMAC-Phase-III-trial-exploratory-analyses.html 2026-05-16T00:22:17.827Z https://www.astrazeneca-us.com/media/press-releases/2026/ENHERTU-fam-trastuzumab-deruxtecan-nxki-approved-in-the-US-for-two-new-indications-for-patients-with-HER2-positive-early-breast-cancer.html 2026-05-18T09:41:16.042Z https://www.astrazeneca-us.com/media/press-releases/2026/BAXFENDY-approved-in-the-US-as-the-first-and-only-aldosterone-synthase-inhibitor-treatment-for-adults-with-hypertension.html 2026-05-18T10:43:27.060Z https://www.astrazeneca-us.com/media/press-releases/2026/AstraZeneca-to-showcase-Phase-III-data-in-liver-breast-and-bladder-cancers-and-potential-first-in-class-rare-disease-therapy-at-ASCO-2026.html 2026-05-22T02:55:50.591Z https://www.astrazeneca-us.com/media/press-releases/2026/DATROWAY-datopotamab-deruxtecan-dlnk-approved-in-the-US-as-first-TROP2-directed-antibody-drug-conjugate-for-1st-line-treatment-of-patients-with-metastatic-triple-negative-breast-cancer-who-are-not-PD-1-PD-L1-inhibitor-candidates.html 2026-05-22T14:17:28.800Z https://www.astrazeneca-us.com/media/press-releases/2026/US-FDA-decision-date-extended-for-SERENA-6-filing-of-camizestrant-to-enable-review-of-additional-data.html 2026-05-27T08:46:26.848Z https://www.astrazeneca-us.com/media/press-releases/2026/cares-phase-iii-clinical-program-demonstrated-anselamimab-as-potential-first-anti-fibril-therapy-in-kappa-light-chain-amyloidosis.html 2026-05-29T10:57:13.900Z https://www.astrazeneca-us.com/media/press-releases/2026/imfinzi-durvalumab-approved-in-the-us-in-only-immunotherapy-combination-for-patients-with-bcg-naive-high-risk-non-muscle-invasive-bladder-cancer.html 2026-05-29T01:29:00.225Z https://www.astrazeneca-us.com/media/press-releases/2026/imfinzi-plus-imjudo-combined-with-lenvatinib-and-trace-reduced-the-risk-of-disease-progression-or-death-by-30-percent.html 2026-06-01T12:08:31.813Z https://www.astrazeneca-us.com/media/press-releases/2026/Camizestrant-combination-delayed-time-to-first-progression-by-55-percent-and-to-second-progression-by-37-percent-in-patients-with-advanced-HR-positive-breast-cancer-with-an-emergent-ESR1-tumor-mutation-in-SERENA-6-trial.html 2026-06-02T13:06:41.241Z https://www.astrazeneca-us.com/media/press-releases/2026/ULTOMIRIS-ravulizumab-cwvz-demonstrated-43-point-4-percent-reduction-in-proteinuria-vs-placebo-in-adults-with-immunoglobulin-A-nephropathy-at-34-weeks-in-I-CAN-Phase-III-trial.html 2026-06-06T11:09:40.132Z https://www.astrazeneca-us.com/media/press-releases/2026/TRUQAP-capivasertib-combination-approved-in-the-US-as-first-and-only-targeted-treatment-for-PTEN-deficient-metastatic-hormone-sensitive-prostate-cancer.html 2026-06-12T21:26:15.845Z https://www.astrazeneca-us.com/media/press-releases/2026/ULTOMIRIS-ravulizumab-cwvz-granted-Priority-Review-in-the-US-as-treatment-for-adults-with-immunoglobulin-A-nephropathy.html 2026-06-15T10:30:42.891Z https://www.astrazeneca-us.com/media/press-releases/2026/AstraZeneca-and-YMCA-of-the-USA-Announce-Landmark-Partnership-Aimed-to-Address-Gaps-in-Cancer-Care.html 2026-06-24T10:43:27.624Z https://www.astrazeneca-us.com/media/press-releases/2026/Efzimfotase-alfa-demonstrated-improvements-in-bone-health-in-treatment-naive-pediatric-patients-with-hypophosphatasia-achieving-median-difference-of-1-point-67-vs-placebo-in-RGI-C-Score-at-week-25-in-MULBERRY-Phase-III-trial.html 2026-06-28T13:36:36.927Z https://www.astrazeneca-us.com/media/press-releases/2026/Sonesitatug-vedotin-demonstrated-a-statistically-significant-and-highly-clinically-meaningful-improvement-in-overall-survival-in-2nd-and-later-line-CLDN18-2-positive-advanced-gastric-gej-cancers.html 2026-07-27T10:39:42.720Z https://www.astrazeneca-us.com/media/press-releases/2026/Update-on-Phase-III-trial-of-ULTOMIRIS-ravulizumab-cwvz-in-adults-and-adolescents-with-thrombotic-microangiopathy-after-hematopoietic-stem-cell-transplant.html 2026-07-27T10:37:26.617Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog.html 2024-04-15T22:43:22.375Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016.html 2016-03-24T14:27:32.745Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/5-ways-fit2me-can-help-you-make-lifestyle-changes-in-2016-01062016.html 2016-12-20T14:10:47.632Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/three-companies-collaborate-to-end-coronary-heart-disease-for-good-01262016.html 2016-12-20T13:54:20.966Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/nonprofit-funding-opportunities-from-astrazeneca-now-open-for-a-limited-time-01272016.html 2016-12-20T13:53:20.731Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/millions-in-prescription-assistance-provided-to-patients-in-2015-03032016.html 2016-12-20T13:48:56.388Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/dr-phils-6-rules-to-help-manage-type-2-diabetes-03102016.html 2016-09-21T14:56:05.174Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/from-the-head-to-the-heart-key-learnings-to-improve-cardiovascular-health-03112016.html 2016-12-20T14:07:36.281Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/how-were-making-medicine-personal-03142016.html 2016-09-21T14:54:37.210Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/why-people-with-type-2-diabetes-should-start-a-walking-program-04052016.html 2016-09-21T14:54:15.467Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/bringing-medical-meetings-to-everyone-via-social-media-05022016.html 2016-09-21T14:53:38.321Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/i-had-no-idea-that-there-were-other-forms-of-constipation-a-patients-oic-story-05022016.html 2016-09-21T14:53:06.908Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/asking-congress-to-get-on-it-for-diabetes-05042016.html 2016-09-21T14:52:35.876Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/science-of-novel-drug-delivery-in-respiratory-medicine-04262016.html 2026-07-20T19:08:04.469Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/a-patients-perspective-during-oral-head-and-neck-cancer-awareness-04152016.html 2016-09-21T14:49:17.801Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/perspectives-on-cardiovascular-disease-a-multi-faceted-03312016.html 2016-12-20T14:06:31.154Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/making-medicine-personal-in-respiratory-health-05132016.html 2016-09-21T14:46:04.559Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/purposeful-collaboration-teaming-up-to-increase-community-impact24052016.html 2016-12-20T13:54:55.478Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/harnessing-the-immune-system-to-potentially-revolutionize-cancer-treatment-for-patients-06012016.html 2016-09-21T14:44:09.623Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/Patient-influencers-bring-medical-meetings-to-life-online-08062016.html 2016-09-21T14:42:53.208Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/mobile-savings-and-support-app-offers-patients-new-ways-to-manage-health-14062016.html 2016-09-21T14:42:31.385Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/interactive-teaching-model-engages-students-in-stem-27062016.html 2016-12-20T13:57:02.583Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/making-medicine-personal-in-cardiovascular-and-metabolic-health-210620161.html 2016-10-06T18:29:42.411Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/Making-Medicine-Personal-in-Cancer-Treatments.html 2016-10-06T18:30:35.549Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/connecting-the-dots-of-hereditary-cancer-1092016.html 2016-12-20T14:05:03.432Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/power-of-diversity-celebrated-at-astrazenecas-5th-annual-womens-summit-09212016.html 2018-10-09T16:12:19.923Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/new-resource-offers-24-7-support-for-those-with-mental-illness-092620161.html 2016-12-20T13:56:27.948Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/18-years-strong-living-with-metastatic-breast-cancer-10032016.html 2016-12-20T14:04:24.387Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/one-brave-idea-75-million-research-award-for-coronary-heart-disease-winner-announced-10052016.html 2016-12-20T14:03:41.973Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/navigating-cancer-clinical-trials-where-to-start-10182016.html 2016-10-18T16:43:52.586Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/protecting-your-childs-lungs-this-rsv-season-10312016.html 2016-12-20T14:02:53.433Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/astrazeneca-gives-back-advancing-respiratory-health-beyond-the-medicine-11032016.html 2016-12-20T13:55:26.424Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/how-the-type-2-diabetes-patient-community-is-unifying-their-voice-online-11112016.html 2016-11-11T17:09:41.783Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/what-getting-on-it-means-to-me-for-american-diabetes-month-11162016.html 2016-12-20T14:01:15.965Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/personalized-healthcare-what-it-means-and-why-it-matters-11282016.html 2016-11-22T19:32:44.620Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/what-does-the-new-cancerlinq-discovery-initiative-mean-for-the-future-of-patient-care-11302016.html 2016-12-20T13:58:46.595Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/stigma-genetics-and-hope-11-years-with-lung-cancer-12022016.html 2016-12-20T14:00:13.132Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2016/our-favorites-from-2016-highlights-of-the-az-you-blog-12202016.html 2016-12-20T15:38:41.453Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2015.html 2016-03-24T14:27:51.335Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2014.html 2016-03-24T14:28:13.665Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2013.html 2016-03-24T14:28:27.999Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017.html 2017-01-06T14:58:05.334Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/the-power-of-us-employees-community-impact-in-2016-01062017.html 2017-01-06T16:19:35.556Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/a-new-approach-to-reducing-lung-cancer-deaths-and-extending-lives-03232017.html 2017-03-23T12:46:12.824Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/knowing-your-options-when-facing-advanced-bladder-cancer-05012017-old.html 2018-05-03T19:42:31.367Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/supporting-patients-and-communities-our-2016-corporate-responsibility-at-a-glance-04212017.html 2017-04-21T19:40:13.669Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/advancing-science-and-accelerating-innovation-in-the-biohealth-capital-region-04272017.html 2017-04-27T19:03:36.332Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/knowing-your-options-when-facing-advanced-bladder-cancer-05012017.html 2018-05-03T19:44:28.001Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/more-than-4-million-patients-assisted-over-ten-years-05152017.html 2017-05-04T19:40:43.497Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/how-the-chest-foundation-is-addressing-the-needs-of-severe-asthma-patients-05192017.html 2017-05-19T19:41:46.338Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/making-science-understandable-and-accessible-for-cancer-patients-05302017.html 2017-05-25T00:45:21.683Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/personalizing-lung-cancer-why-testing-matters-06032017.html 2017-08-25T12:29:54.334Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/employees-donate-their-time-to-support-communities-during-power-of-us-week-06202017.html 2017-06-20T16:19:27.111Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/astrazeneca-supports-hurricane-harvey-relief-efforts-08302017.html 2018-06-28T20:17:40.657Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/expanding-treatment-options-to-address-unmet-need-in-blood-cancer-09052017.html 2018-01-22T17:21:48.355Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/5-important-things-to-know-about-lung-cancer-09072017.html 2017-09-08T19:32:55.091Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/6th-annual-womens-summit-looks-forward-boldly-bravely-fearlessly-09282017.html 2018-10-09T16:07:41.650Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/living-with-metastatic-breast-cancer-swimmer-raises-awareness-and-research-funding-10022017.html 2017-10-03T17:09:17.069Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/a-mothers-strategy-to-protect-against-rsv-10042017.html 2017-10-03T17:08:32.440Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/from-scanxiety-to-living-life-fully-roberts-stage-iii-lung-cancer-story-11102017.html 2017-11-10T17:33:15.383Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/why-were-talking-about-cvmd-11092017.html 2017-11-15T21:57:18.658Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/more-than-a-tagline-delivering-value-to-patients-11142017.html 2017-11-14T22:04:54.320Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/understanding-if-your-asthma-is-severe-11202017.html 2017-11-20T17:08:48.212Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/advancing-stem-through-the-health-science-innovation-challenge-11282017.html 2021-01-28T21:24:09.439Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/stories-of-hope-from-people-with-lymphoma-12042017.html 2018-01-22T17:21:15.886Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2017/employees-give-back-to-those-affected-by-natural-disasters-in-2017-12192017.html 2017-12-19T20:02:19.663Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018.html 2018-01-10T12:31:49.263Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/moving-forward-as-a-heart-attack-survivor-01162018.html 2018-01-31T20:37:00.048Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/community-programs-help-improve-heart-health-and-share-lessons-learned-01182018.html 2018-01-18T14:23:04.262Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/a-years-worth-of-giving-our-2017-power-of-us-impact-01222018.html 2018-01-18T19:40:51.490Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/heres-what-metastatic-breast-cancer-patients-want-you-to-know-02222018.html 2018-02-22T16:29:29.428Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/meet-the-survivors-have-heart-essay-contest-winners-03012018.html 2018-03-02T18:53:45.531Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/understanding-asthma-resources-and-the-patient-perspective-03022018.html 2018-03-02T15:40:33.179Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/bob-harper-on-connecting-with-fellow-heart-attack-survivors-04062018.html 2018-04-06T14:03:00.526Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/lung-cancer-treatment-today-earlier-and-more-precise-04132018.html 2018-04-17T19:24:11.289Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/making-some-sense-of-lung-cancer-04182018.html 2018-04-19T00:01:59.954Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/patient-advocacy-leader-shares-advice-for-people-living-with-bladder-cancer-05032018.html 2018-05-03T19:02:59.196Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/reducing-the-burden-of-diabetes-3-takeaways-from-the-adas-recent-report-05212018.html 2018-05-21T16:45:37.184Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/what-were-watching-during-asco-2018-05292018.html 2018-05-30T00:32:55.570Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/5-ways-were-fighting-cancer-in-the-us-05292018.html 2018-05-30T00:34:29.331Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/4-big-ways-employees-gave-back-during-power-of-us-week-05312018.html 2018-05-31T18:16:55.700Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/celebrating-inclusion-and-diversity-during-lgbtqa-pride-month-06052018.html 2018-10-09T16:05:43.054Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/this-is-the-future-immuno-oncology-is-redefining-cancer-treatment-07172018.html 2018-07-18T14:46:29.621Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/highlights-from-our-inclusion-diversity-conference-07312018.html 2018-10-09T16:06:16.525Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/3-ways-were-supporting-the-blood-cancer-community-08312018.html 2018-09-04T12:50:41.453Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/the-future-of-asthma-management-with-geisinger-09052018.html 2018-09-05T17:48:02.230Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/7th-annual-womens-summit-challenges-employees-to-believe-lead-change-09182018.html 2018-10-09T16:06:45.106Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/clinical-trial-endpoints-in-cancer-research-four-terms-you-should-know-09242018.html 2018-09-24T18:00:04.148Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/whats-changed-during-17-years-with-metastatic-breast-cancer-10012018.html 2018-10-01T17:32:47.509Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/vanessa-lachey-on-rsv-and-protecting-your-little-ones-lungs-this-season-10222018.html 2018-10-22T15:04:03.359Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/astrazenecas-commitment-to-improving-the-lives-of-patients-with-renal-cardio-disease-10262018.html 2019-01-11T13:44:30.613Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/caring-for-a-loved-one-with-copd-11192018.html 2018-11-19T17:26:18.573Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/being-an-advocate-helps-me-thrive-11272018.html 2018-11-27T18:37:01.802Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2018/metastatic-egfrm-non-small-cell-lung-cancer-in-the-era-of-personalized-medicine-12052018.html 2018-12-05T20:16:39.633Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2019.html 2018-12-10T18:28:44.264Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2019/the-critical-need-for-understanding-the-complexities-of-chronic-kidney-disease-01112019.html 2019-01-10T16:23:41.771Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2019/employees-lead-the-way-through-volunteerism-and-giving-011719.html 2019-01-17T17:57:29.645Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2019/nonprofits-innovate-to-solve-health-challenges-and-stem-shortages-021219.html 2019-02-12T18:24:59.134Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2019/important-discoveries-in-asthma-022219.html 2019-02-22T18:26:03.467Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2019/the-path-forward-evolving-the-current-healthcare-system-02282019.html 2019-02-28T19:47:00.648Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2019/survivors-have-heart-one-year-later-and-beyond-02282019.html 2019-02-28T19:41:54.191Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2019/bob-harper-and-astrazeneca-take-survivors-have-heart-on-the-road-06032019.html 2019-06-03T17:05:00.961Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2019/understanding-the-unexpected-connections-between-diabetes-and-kidney-disease-06052019.html 2019-06-05T20:07:50.080Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2019/project-seed-supporting-a-dynamic-stem-education-experience-06182019.html 2019-06-20T18:25:15.982Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2019/the-lung-ambition-alliance-a-global-partnership-with-a-goal-to-eliminate-lung-cancer-as-a-cause-of-death-08122019.html 2019-08-12T20:28:15.900Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2019/astrazenecas-empowerment-summit-emphasizes-importance-of-courage-action-change-10212019.html 2019-10-21T15:17:23.160Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2019/high-hopes-how-a-rising-star-basketball-players-story-is-bringing-light-to-the-darkness-of-cancer-10242019.html 2019-11-12T17:23:27.525Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2019/a-decade-of-making-a-difference-in-improving-heart-health-11082019.html 2020-01-22T16:09:58.364Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020.html 2020-01-22T16:07:29.455Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/2019-a-year-to-volunteer-02272020.html 2020-02-26T19:03:38.987Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/covid-19-resources-for-patients-and-caregivers-managing-chronic-conditions-04132020.html 2020-04-14T15:19:42.033Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/its-been-a-journey-patient-with-heart-failure-shares-her-story-05132020.html 2020-05-15T21:01:03.303Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/our-hearts-are-open-our-commitment-to-the-cardiovascular-disease-chronic-kidney-disease-and-diabetes-communities-during-covid-19-05192020.html 2020-06-04T21:46:27.769Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/a-lupus-awareness-month-well-never-forget-05222020.html 2020-05-22T17:48:54.302Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/astrazenecas-commitment-to-patients-healthcare-workers-amidst-covid-19-05282020.html 2020-06-25T20:44:26.499Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/raising-awareness-and-the-importance-of-advocacy-in-bladder-cancer-05292020.html 2020-05-29T21:25:24.395Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/a-patients-call-to-action-raising-awareness-about-small-cell-lung-cancer-06222020.html 2020-06-23T14:17:28.875Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/survive-today-reminding-heart-attack-victims-about-the-importance-of-calling-9-1-1-for-medical-attention-even-during-covid-19-07132020.html 2020-07-10T16:17:07.520Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/giving-voice-to-the-patient-experience-in-cancer-clinical-trials-06262020.html 2020-07-13T21:24:07.847Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/second-chances-how-im-advocating-for-and-connecting-heart-attack-survivors-virtually-07152020.html 2020-07-14T21:00:10.733Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/life-with-copd-patient-shares-his-story-of-positivity-and-perseverance-07242020.html 2020-07-23T19:25:08.481Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/for-funnyman-tony-hale-asthma-is-no-laughing-matter-08112020.html 2020-08-05T21:16:53.063Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/a-new-hope-for-chronic-kidney-disease-starts-today-9022020.html 2020-11-11T21:47:09.208Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/new-normal-same-cancer-our-commitment-to-the-cancer-community-during-the-pandemic-10012020.html 2020-10-01T14:19:09.030Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/from-the-experts-navigating-a-different-kind-of-flu-season-10122020.html 2020-10-13T15:28:26.338Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/metastatic-breast-cancer-and-pink-tutus-linda-and-bob-careys-journey-of-laughter-and-hope-10132020.html 2021-01-07T16:13:04.805Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/finding-hope-in-the-treatment-outlook-for-small-cell-lung-cancer-11062020.html 2020-11-11T21:54:29.110Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/pancreatic-cancer-awareness-month-addressing-the-unmet-needs-of-the-pancreatic-cancer-community-11182020.html 2020-11-20T19:41:34.169Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/partnering-to-support-caregivers-in-blood-cancer-11302020.html 2020-11-30T15:18:08.209Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2020/meet-our-2020-power-of-us-award-winners-12172020.html 2021-01-07T16:11:45.046Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021.html 2020-12-03T11:05:55.395Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/nina-parker-on-breaking-the-cycle-of-asthma.html 2021-11-12T18:36:37.216Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/tackling-rare-uplifting-athletes-highlights-genetic-disorder-at-rare-disease-focused-conference-for-student-athletes-01252021.html 2021-12-01T17:19:23.624Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/fighting-fear-with-facts-taking-action-to-make-a-difference-in-lung-cancer-01282021.html 2021-01-28T23:40:25.696Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/taking-advanced-ovarian-cancer-treatment-further-than-before-with-genetic-tumor-biomarker-testing-03222021.html 2021-03-22T13:09:34.315Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/national-kidney-month-celebrating-the-kidney-community-03182021.html 2021-03-22T21:26:43.191Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/national-high-potassium-awareness-day--spreading-the-word-about-05042021.html 2021-04-30T08:28:09.947Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/reimagining-the-future-of-asthma-and-lupus-this-may.html 2021-05-12T13:59:47.649Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/from-little-sister-to-caretaker-she-uprooted-her-life-to-help-her-brother-recover-from-a-stroke.html 2021-05-19T14:01:11.608Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/its-time-to-talk-about-lung-cancer.html 2021-05-24T04:36:17.843Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/nf-awareness-month--an-opportunity-to-educate-and-support-famili-05262021.html 2021-05-25T05:37:53.830Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/astrazeneca-us-and-health-equity-today-and-tomorrow-06142021.html 2026-07-20T18:10:49.749Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/no-one-missed-the-importance-of-comprehensive-biomarker-testing-in-non-small-cell-lung-cancer.html 2021-06-18T13:41:27.491Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/multidisciplinary-care-teams-and-patient-centricity-in-small-cell-lung-cancer-07192021.html 2021-07-15T05:40:52.875Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/innovation-partnership-and-advocacy-how-astrazeneca-is-working-to-improve-life-07252021.html 2021-07-26T16:19:59.107Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/living-with-lupus--the-unique--unpredictable-journey-08032021.html 2021-08-03T13:41:45.592Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/leading-a-revolution-in-oncology-by-starting-with-one.html 2021-08-09T13:21:19.098Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/going-green-blazing-a-trail-in-sustainability.html 2021-09-15T15:33:54.062Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/a-sense-of-comfort-providing-housing-to-patients-and-their-families-during-treatment-09222021.html 2021-09-22T14:57:41.030Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/prostate-cancer-awareness-month-an-opportunity-to-educate-09282021.html 2021-09-29T13:33:21.897Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/never-heard-of-eosinophilic-asthma-tony-hale-s-got-a-lung-story-10012021.html 2021-10-01T15:45:15.548Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/breast-cancer-awareness-month-a-renewed-commitment-to-all-patients-10132021.html 2021-10-13T14:08:22.254Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/from-the-experts-taking-control-of-flu-season.html 2021-10-26T06:05:25.714Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/advancing-health-equity-through-community-based-contributions-announcing-the-act-on-health-equity-community-solutions-challenge-recipients.html 2026-05-01T13:43:48.484Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/from-diagnosis-to-late-stage-astrazenecas-commitment-to-patients-with-chronic-kidney-disease-11052021.html 2021-11-12T18:27:23.014Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2021/portraits-of-lung-cancer-11232021.html 2021-11-22T21:17:24.125Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022.html 2022-02-08T21:48:46.674Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022/meet-our-2021-power-of-us-award-winners-02092022.html 2022-02-09T19:29:16.235Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022/5-ways-to-celebrate-caregivers-on-national-caregivers-day-02162022.html 2022-02-16T20:26:06.704Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022/national-kidney-month-speaking-with-your-doctor-about-ckd.html 2023-03-01T15:01:17.726Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022/harnessing-the-power-of-community-the-act-on-health-equity-community-solutions-challenge-is-back-04062022.html 2022-04-08T12:06:54.649Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022/communication-is-key-with-copd-the-importance-of-patient-and-provider-conversations.html 2022-04-29T18:28:18.847Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022/conversations-on-severe-asthma-realities-from-the-patient-advocacy-community.html 2022-05-03T19:00:34.711Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022/reimagining-the-life-sciences-to-be-patient-centric-05172022.html 2022-05-18T14:45:57.545Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022/national-stroke-awareness-month-key-facts-you-should-know.html 2022-05-27T15:42:56.474Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022/extra-layer-of-protection-06022022.html 2022-06-14T17:19:52.086Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022/chronic-kidney-disease-common-but-misunderstood-and-severely-underdiagnosed-080122.html 2022-08-03T20:37:53.576Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022/introducing-up-the-antibodies-helping-the-immunocompromised-community-get-back-to-what-they-love.html 2022-09-15T16:09:46.479Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022/world-heart-day-astrazeneca-continues-commitment-to-saving-hearts-and-lives-through-survivors-have-heart.html 2022-09-23T14:59:19.183Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022/from-the-experts-this-is-not-the-season-to-skip-flu-vaccination.html 2022-09-22T20:24:20.716Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022/an-ovarian-cancer-survivors-guide-to-the-disease-09282022.html 2022-09-29T01:43:50.621Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022/prostate-cancer-awareness-month-a-conversation-with-reggie-tucker-seeley-ma-scm-scd-09302022.html 2022-09-29T15:56:51.066Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022/genetic-and-biomarker-testing-may-provide-powerful-information-to-help-combat-breast-cancer-10212022.html 2023-10-05T17:02:27.712Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022/advancing-access-and-heart-health-a-decade-of-community-impact-10252022.html 2022-10-21T18:26:07.374Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022/world-amyloidosis-day-raising-awareness-of-attr-102622.html 2023-01-31T17:31:25.967Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022/act-on-health-equity-contributions-recipient-announcement.html 2022-12-13T16:55:02.184Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2022/addressing-chronic-kidney-disease-through-prevention-detection-and-management.html 2022-12-13T19:18:43.100Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2023.html 2023-02-07T16:52:24.503Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2023/our-commitment-to-transforming-care-in-cardiovascular-disease.html 2025-05-28T19:49:47.624Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2023/lets-talk-about-cholangiocarcinoma-awareness-month-02272023.html 2025-05-28T19:50:45.146Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2023/astrazeneca-foundation-whats-at-the-heart-of-our-new-health-equity-program-04192023.html 2026-07-20T18:20:56.112Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2023/our-work-in-r-and-i-inspired-by-our-people-and-the-patients-we-impact.html 2025-05-28T19:56:33.942Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2023/the-importance-of-partnering-with-a-doctor-to-manage-heart-failure-05082023.html 2025-05-28T19:51:52.570Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2023/what-the-end-of-the-covid-19-public-health-emergency-means-for-immunocompromised-communities-05112023.html 2025-05-28T19:52:16.991Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2023/elevating-community-based-programs-to-advance-health-equity-06152023.html 2025-05-28T19:52:38.256Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2023/emergency-medicine-day-how-hospitals-can-prepare-for-life-threatening-bleeding.html 2025-05-28T19:53:01.751Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2023/prostate-cancer-awareness-month.html 2025-05-28T19:53:21.374Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2023/celebrating-30-years-of-history-with-2m-in-grants-to-advance-health-equity-10042023.html 2025-05-28T19:54:43.049Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2023/transforming-the-delivery-of-ckd-education-and-care.html 2026-07-20T18:02:44.127Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2023/understanding-patient-perspectives-during-liver-cancer-awareness-month.html 2025-05-28T19:55:58.694Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2023/understanding-attr-the-challenges-of-amyloidosis.html 2025-05-28T19:57:56.041Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2023/veterans-day-spotlight-navy-veteran-discusses-his-dance-with-prostate-cancer.html 2025-05-28T19:58:32.858Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2023/copd-awareness-month-breathing-new-life-into-proactive-copd-management.html 2025-05-28T19:59:04.784Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2023/outside-the-four-walls-of-the-oklahoma-city-indian-clinic-a-conversation-on-addressing-health-equity-12072023.html 2025-05-28T19:59:52.063Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2024.html 2024-02-20T16:22:56.408Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2024/advancing-our-health-equity-ambition-2023-2024-act-on-health-equity-community-investments-02222024.html 2025-05-28T19:23:10.563Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2024/a-conversation-with-sharsheret.html 2025-05-28T19:23:33.091Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2024/the-crucial-role-of-genetic-testing-in-amyloidosis.html 2025-05-28T19:23:56.461Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2024/the-importance-of-treating-hyperkalemia-with-a-timely-and-long-term-approach.html 2025-11-18T20:00:37.717Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2024/taking-the-wheel-in-diverse-clinical-trial-recruitment-introducing-az-aire-mobile-unit.html 2025-05-28T19:24:56.747Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2024/the-impact-of-high-blood-pressure-important-things-to-know.html 2025-05-28T19:25:24.172Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2024/collective-action-to-advance-health-equity.html 2025-05-28T19:26:41.951Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2024/empowering-action-in-asthma-care-this-peak-week.html 2025-10-01T13:32:39.838Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2024/shining-light-on-the-importance-of-genetic-testing-during-prostate-cancer-awareness-month.html 2025-05-28T19:29:13.512Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2024/transthyretin-amyloidosis-the-importance-and-need-for-early-diagnosis.html 2025-05-28T19:39:59.954Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2024/liver-cancer-awareness-month-reimagining-whats-possible-for-patients-with-uhcc.html 2025-05-28T19:39:21.186Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2024/veterans-day-empowering-heroes-in-the-fight-against-prostate-cancer.html 2025-05-28T20:01:01.237Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2024/act-on-health-equity-contributions-recipient-announcement.html 2025-05-28T19:35:26.545Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2024/breathing-easier-astrazenecas-ongoing-commitment-to-lung-health.html 2025-05-28T19:37:07.827Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2025.html 2025-02-20T16:14:19.298Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2025/Under-Pressure-Hypertension-and-the-Heart.html 2026-02-24T18:56:43.748Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2025/Hyperkalemia-Barbs-Journey-Living-With-High-Potassium.html 2025-05-28T19:11:01.912Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2025/bladder-cancer-awareness-month-shifting-the-paradigm-for-patients-with-muscle-invasive-bladder-cancer.html 2025-05-28T19:10:36.122Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2025/bladder-cancer-awareness-month-shifting-the-paradigm-for-patients-with-muscle-invasive-bladder-cancer1.html 2025-05-28T19:09:22.916Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2025/redefining-lupus-care-the-path-to-health-equity-and-innovation.html 2025-05-28T19:09:50.758Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2025/innovating-for-every-breath-our-bold-approach-to-respiratory-care.html 2025-05-29T19:19:07.396Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2025/gastric-and-gastroesophageal-junction-cancers-in-focus-understanding-potential-symptoms-risks-and-treatment-options.html 2025-08-14T18:08:24.936Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2025/celebrating-national-nonprofit-day-partnerships-that-transform-healthcare-access.html 2025-08-15T15:08:34.624Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2025/a-new-era-in-understanding-chronic-rhinosinusitis-with-nasal-polyps.html 2025-10-15T14:25:05.399Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2025/beyond-philanthropy-the-power-of-cross-sector-collaborations-that-advance-access-to-care.html 2025-11-13T16:04:46.605Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2025/spotlight-on-HER2-positive-gastric-cancer-using-biomarker-testing-to-inform-treatment-decisions.html 2026-02-17T19:40:33.071Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2025/building-pathways-to-better-lung-health-partnering-with-american-lung-association-to-drive-early-detection-and-timely-diagnosis-for-lung-cancer-and-copd.html 2026-02-17T19:26:51.856Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2026.html 2026-02-10T22:05:35.816Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2026/ACT-on-Health-Equity-Contributions-Recipient-Announcement.html 2026-02-17T19:39:25.882Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2026/Diagnosi-Delays-in-Amyloidosis-What-Patients-Experience-and-What-We-Can-Change-Together.html 2026-03-10T18:26:16Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2026/Donnas-Journey-Living-with-Chronic-Kidney-Disease-and-High-Potassium.html 2026-03-19T16:03:18Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2026/Advancing-Care-in-Asthma-and-Lupus-Putting-Patients-First.html 2026-06-03T22:26:35.318Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2026/Advancing-Sustainable-Respiratory-Care-Solutions-for-a-Healthier-Future.html 2026-05-08T18:56:15.655Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2026/Self-Advocating-Helped-Change-Moniques-Bladder-Cancer-Treatment-Trajectory.html 2026-05-20T21:02:49.870Z https://www.astrazeneca-us.com/media/astrazeneca-us-blog/2026/Cancer-Impacts-Many-of-Us-Understanding-Treatment-Options.html 2026-06-26T18:59:22.566Z https://www.astrazeneca-us.com/media/personified.html 2024-06-21T17:46:06.646Z https://www.astrazeneca-us.com/media/personified/our-employees.html 2024-06-21T17:46:51.676Z https://www.astrazeneca-us.com/media/personified/our-employees/personified-michele-funiciello.html 2025-06-17T19:38:50.556Z https://www.astrazeneca-us.com/media/personified/our-employees/personified-colby-flint.html 2024-06-21T17:49:08.790Z https://www.astrazeneca-us.com/media/personified/our-employees/personified-mike-philpot.html 2024-06-21T17:49:34.880Z https://www.astrazeneca-us.com/media/personified/our-employees/personified-alex-bowditch.html 2024-06-21T17:51:10.637Z https://www.astrazeneca-us.com/media/personified/our-employees/personified-heather-vanderploeg.html 2024-06-21T17:51:28.954Z https://www.astrazeneca-us.com/media/personified/our-employees/personified-brandon-jones.html 2024-06-21T17:51:51.866Z https://www.astrazeneca-us.com/media/personified/our-employees/personified-bridget-therriault.html 2024-07-17T15:04:08.372Z https://www.astrazeneca-us.com/media/personified/our-employees/personified-jay-harper.html 2024-07-31T17:09:48.256Z https://www.astrazeneca-us.com/media/personified/our-employees/personified-interns.html 2025-06-17T20:26:34.621Z https://www.astrazeneca-us.com/media/personified/our-employees/personified-interns-2025.html 2025-07-31T20:49:34.906Z https://www.astrazeneca-us.com/media/personified/our-employees/az-apprentices.html 2026-04-27T17:38:32.671Z https://www.astrazeneca-us.com/media/personified/our-employees/haley-boyker.html 2026-07-07T17:36:04.486Z https://www.astrazeneca-us.com/media/personified/our-leadership-team.html 2024-06-21T17:47:18.607Z https://www.astrazeneca-us.com/media/thats-understandable-podcast.html 2025-12-18T18:16:38.116Z https://www.astrazeneca-us.com/search-results.html 2017-01-19T16:50:14.229Z https://www.astrazeneca-us.com/500.html 2016-01-19T15:05:46.232Z https://www.astrazeneca-us.com/503.html 2016-01-19T15:05:46.274Z https://www.astrazeneca-us.com/404.html 2017-07-07T13:04:09.064Z https://www.astrazeneca-us.com/privacy-notice.html 2018-04-19T19:04:49.278Z https://www.astrazeneca-us.com/legal-notice.html 2016-10-19T14:41:07.443Z https://www.astrazeneca-us.com/copyright.html 2016-04-15T19:51:38.790Z https://www.astrazeneca-us.com/household-generated-sharps-management-plan.html 2025-07-01T20:20:08.425Z https://www.astrazeneca-us.com/california-supply-chains-disclosure.html 2020-03-03T09:35:50.353Z https://www.astrazeneca-us.com/pharmaceutical-marketer-price-disclosure-vermont.html 2026-07-10T19:07:30.010Z https://www.astrazeneca-us.com/astrazeneca-purchasing-general-terms-and-conditions.html 2016-05-24T09:13:59.816Z https://www.astrazeneca-us.com/medicines.html 2024-06-21T17:44:59.255Z https://www.astrazeneca-us.com/medicines/astrazeneca-medications.html 2026-05-22T16:04:39.886Z https://www.astrazeneca-us.com/medicines/Affordability.html 2025-07-31T14:18:44.077Z https://www.astrazeneca-us.com/medicines/astrazeneca-direct.html 2024-06-21T17:39:33.716Z https://www.astrazeneca-us.com/medicines/product-counterfeiting.html 2024-06-21T17:40:38.569Z https://www.astrazeneca-us.com/medicines/Medical-information-healthcare-providers.html 2024-06-21T17:41:18.774Z https://www.astrazeneca-us.com/medicines/transparency-in-coverage-machine-readable-files1.html 2024-06-21T17:42:24.607Z https://www.astrazeneca-us.com/contact-us.html 2021-07-22T12:36:33.925Z https://www.astrazeneca-us.com/contact-us/product-information.html 2024-07-16T09:27:14.834Z https://www.astrazeneca-us.com/contact-us/educational-items.html 2026-04-21T09:57:15.543Z https://www.astrazeneca-us.com/contact-us/hcp-request-for-pharmaceutical-samples.html 2025-10-27T08:50:59.216Z https://www.astrazeneca-us.com/contact-us/other-requests.html 2024-07-16T09:31:38.587Z https://www.astrazeneca-us.com/contact-us/thank-you.html 2016-04-27T12:32:05.339Z https://www.astrazeneca-us.com/sitemap.html 2022-10-25T16:09:15.435Z https://www.astrazeneca-us.com/facebook-community-guidelines.html 2017-07-11T19:59:42.569Z https://www.astrazeneca-us.com/Bladder-Cancer-Resources.html 2024-06-21T17:35:54.814Z https://www.astrazeneca-us.com/respiratory-inhaler-affordability.html 2024-12-13T18:31:10.364Z https://www.astrazeneca-us.com/our-leadership.html 2026-08-07T15:22:58.987Z https://www.astrazeneca-us.com/astrazeneca-impact-in-the-us.html 2026-08-07T14:14:22.867Z https://www.astrazeneca-us.com/astrazeneca-impact-in-the-us/economic-impact.html 2026-08-07T14:14:22.866Z https://www.astrazeneca-us.com/astrazeneca-impact-in-the-us/research-development.html 2026-08-07T14:14:22.867Z https://www.astrazeneca-us.com/astrazeneca-impact-in-the-us/community-engagement.html 2026-08-07T14:14:22.867Z https://www.astrazeneca-us.com/astrazeneca-impact-in-the-us/sustainability.html 2026-08-07T14:14:22.867Z https://www.astrazeneca-us.com/astrazeneca-impact-in-the-us/workforce-development.html 2026-08-07T14:14:22.867Z https://www.astrazeneca-us.com/astrazeneca-impact-in-the-us/exports.html 2026-08-07T14:14:22.866Z https://www.astrazeneca-us.com/astrazeneca-impact-in-the-us/overview.html 2026-08-07T14:14:22.867Z https://www.astrazeneca-us.com/pdf.html 2026-08-05T12:53:04.536Z